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Abstract 
 
Fibrosis is characterised by the excessive accumulation of extracellular matrix 
(ECM) proteins, resulting in a loss of tissue architecture and function. Central 
in liver fibrosis development is the transdifferentiation of hepatic stellate cells 
(HSCs) to a myofibroblast phenotype, responsible for increased deposition of 
ECM. Presently there are no treatments available for fibrosis. Critical to the 
discovery of novel anti-fibrotics is the development of a non-invasive imaging 
modality to accurately diagnose fibrosis severity. 
The hepatic myofibroblast specific single chain antibody (scAb) C1-3 was 
conjugated with a fluorophore and administered to mice with liver fibrosis prior 
to IVIS imaging to diagnose fibrosis severity. The expression of C1-3’s target 
antigen (synaptophysin) was confirmed by quantitative real-time PCR (qRT-
PCR) and immunocytochemistry (ICC) in both quiescent and activated HSCs. 
The anti-inflammatory effects of PXR agonists were investigated utilising an in 
vivo model of liver fibrosis. Finally the pro-inflammatory properties of hepatic 
myofibroblasts were studied in vitro and in vivo. 
There was a statistically significant increase in fluorescence detected ex vivo 
in fibrotic livers versus the controls. qRT-PCR confirmed that quiescent HSCs 
(qHSCs) and hepatic myofibroblasts express similar levels of synaptophysin. 
The PXR agonist PCN significantly reduced the level of liver inflammation 
(NF-κB activity) following liver injury in vivo, 24 hours after its administration. 
The data presented indicates hepatic myofibroblasts release a pro-
inflammatory soluble factor and induce NF-κB activity when injected in vivo. 
These findings suggest that hepatic myofibroblast number is an indicator of 
fibrosis severity. Hepatic myofibroblasts possess pro-inflammatory 
characteristics, which may contribute to fibrosis development. Finally PXR 
agonists exhibited anti-inflammatory properties that may be beneficial in the 
treatment of liver fibrosis. 
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1.1 The liver  
 
1.1.1 General liver anatomy and physiology 
 
The liver is the largest visceral organ, located within the upper right quadrant 
of the abdominal cavity weighing approximately 1.5kg (up to 2.5% of the total 
body weight in an average human adult). In man the liver is composed of two 
main anatomical lobes; the larger right lobe is separated from the left by the 
falciform ligament (a fold in the peritoneum). The smaller caudate and 
quadrate lobes are attached to the posterior inferior surface of the right lobe 
(Figure 1.1). The fibrous capsule of Glisson encases the entire liver, except 
one posterior region, where it is in direct contact with the diaphragm. The 
capsule of Glisson serves to reduce friction against the surrounding organs, 
whilst also protecting the hepatic blood vessels and bile duct. 
 
Figure 1.1 General liver anatomy (Image taken from [1]) 
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The liver has a unique dual blood supply, arriving from the portal vein and 
hepatic artery, receiving approximately 75% and 25% from each respectively 
[2]. The blood from the portal vein is only partially oxygenated, but is rich in 
nutrients from the digestive tract, spleen, pancreas and gall bladder. 
Oxygenated blood arriving from the hepatic artery supplies the liver cells with 
the necessary oxygen for aerobic respiration and energy production. The two 
blood supplies mix at the edge of the portal tract before draining into the 
hepatic sinusoids. 
Hepatic sinusoids are specialized blood vessels running between rows of 
hepatocytes, carrying blood from the portal tract to the central vein (before 
recirculation of the deoxygenated blood via the inferior vena cava). Bile 
produced by the hepatocytes is also transported to the bile duct via the 
sinusoids (Figure 1.2). Specialized fenestrated endothelial cells are found 
lining the hepatic sinusoid adapted to control the flow of macromolecules 
across the perisinusoidal area (Space of Dissé) to the hepatocytes. 
 
Figure 1.2 Architecture of the hepatic sinusoids and location of specific hepatic cell types (Image 
taken from [3]). Hepatic sinusoids are effectively the liver’s capillaries and are found running between 
rows of hepatocytes. They are lined by specialized fenestrated endothelial cells to control the flow of 
materials between the sinusoids to the Space of Disse and hepatocytes. The space of Disse is where 
hepatic stellate cells (HSCs) are located; these cells are central in fibrosis development.  
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1.1.2 Functional units 
 
The structure of the liver has been well documented since Weppler’s initial 
description of liver lobules in 1665. The liver is known to be composed of tens 
of thousands of repeating functional units that are uniformly distributed around 
the portal tract (blood enters) and central vein (blood exits) [3, 4]. Many 
models have been proposed for these functional units, primarily due to the 
lack of a structural barrier between each functional unit making it difficult to 
define. The two most widely accepted are the liver lobule and liver acinus 
proposed by Kiernan [5] and Rappaport [6] respectively (Figure 1.3). 
The hepatic lobule is based on a hexagonal unit with hepatocytes and 
sinusoids radiating out in branches [2, 5]. The central vein is found at the 
centre of the lobule and the portal triads (containing the bile canaliculi, portal 
venules and hepatic arterioles) are found at each corner of the hexagon 
defining the periphery of the lobule. The acinus of Rappaport is a smaller 
functional unit, consisting of an irregular shaped mass of hepatocytes aligned 
around the terminal afferent vessels (hepatic arterioles and distributing portal 
venules) just as they branch into the sinusoids [2, 6]. The blood flow from 
these branches is unidirectional as it flows along the sinusoids from the 
periportal to the centrilobular hepatocytes. The acinus can be divided into 
three functional zones (zone (1) periportal, (2) mediolobular, (3) centrilobular) 
governed by the difference in oxygen content in these areas decreasing from 
zone 1 – zone 3. Histopathologists favour the acinar model as it explains 
many pathological lesions in the liver. Another point of interest is the 
heterogeneous expression of genes along hepatic sinusoids, resulting in 
metabolic zonation across the lobule. Coupling the high expression of 
metabolic enzymes and the low levels of oxygen present, hepatocytes in zone 
3 are most susceptible to both ischeamic and drug-induced injury [7]. 
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Figure 1.3 Schematic diagrams of Kiernan’s lobule (top) and Rappaport’s acinus (bottom) 
(Figure taken from [3]). The acinus has been overlaid onto the lobule schematic to aid in their 
comparison. In the lobule the portal tract (PT), which contains the periportal arteriole (PA – red dot), 
bile duct (BD – yellow dot) and periportal venule (PV – blue dot) mark the periphery of individual 
lobules and blood can flow in all directions including into surrounding lobules draining into the central 
vein (CV). However in the acinar model all blood entering from the portal tact is believed to stay in the 
acinus and the oxygen/ nutrient levels decrease as the blood diffuses from zone 1 – zone 3.  
 
1.1.3 Liver functions  
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The major function of the liver is in intermediary metabolism and the 
metabolism/ clearance of xenobiotics absorbed from the environment and 
diet. It also performs a number of other critical roles essential in maintaining 
homeostasis throughout the body (including albumin production critical in 
maintenance of the blood volume and osmotic pressure). The bulk of these 
functions are carried out by the hepatocytes including [3, 8] : - 
 Glycogenolysis and gluconeogenesis. 
 Fatty acid metabolism. 
 Amino acid metabolism and blood protein synthesis (e.g. coagulation 
and fibrinolysis factors, transport proteins and protease inhibitors). 
 Ammonia metabolism and urea synthesis. 
 Plasma lipid and lipoprotein metabolism (cholesterol, triglyceride and 
phospholipid homeostasis). 
 Metabolism of bilirubin and bile acids prior to bile formation. 
 Storage of metals (e.g. iron). 
 
1.1.4 Hepatic cell types and their specific functions 
 
There are six major types of cell in the liver, each with an individual role 
critical to maintaining a healthy functional liver. 
Hepatocytes account for over 60% of the total cell population of the liver and 
80% of the liver volume [9]. They are highly specialized, containing a high 
number of mitochondria to provide the necessary ATP for the majority of the 
aforementioned functions (section 1.1.3). The hepatocyte’s major function is 
intermediary metabolism and the metabolism of xenobiotics and compounds 
absorbed into the blood. They are specifically adapted for this by the 
presence of microvilli on the membrane in contact with the Space of Dissé, 
increasing the surface area available for uptake [2, 8].The Space of Dissé 
(perisinusoidal space) represents a space between the sinusoidal endothelial 
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cells and hepatocytes which allows blood plasma to come into direct contact 
with the hepatocytes and improve absorption from the plasma. 
Kupffer cells are liver resident macrophages, located in close proximity to the 
fenestrated endothelial cells lining the sinusoids. Their major function is to 
help remove any bacteria and cell debris from the blood as it flows along the 
sinusoids before reaching the central vein. When liver damage occurs, they 
are responsible for the release of a multitude of pro-inflammatory factors 
including cytokines interleukin-6 (IL-6), IL-1β and tumour necrosis factor alpha 
(TNFα), interferons and reactive oxygen species (ROS) such as nitric oxide 
(NO) and superoxide [10]. If sufficiently high levels of these pro-inflammatory 
factors are released, circulating monocytes and macrophages in the blood 
can be activated, secreting their own pro-inflammatory cytokines. This results 
in an amplification of  the inflammatory signal and increased fibrogenesis, 
although the different subsets of macrophages make it difficult to determine 
their exact function [11, 12]. Studies have also indicated these cytokines play 
a role in liver regeneration via priming hepatocytes for mitosis [13]. 
Hepatic stellate cells (HSCs) are the major storage location for retinoids and 
vitamin A in the body, residing within the Space of Disse (Figure 1.4). 
However, following liver damage, they lose their quiescent retinoid storing 
phenotype, becoming ‘activated’ and transdifferentiating to a myofibroblast-
like phenotype characterised by the expression of alpha smooth muscle actin 
(αSMA) [2, 14]. There are a range of inflammatory mediators associated with 
the activation of HSCs, the most common being transforming growth factor β 
(TGF-β) [15]. When activated to a hepatic myofibroblast phenotype they are 
the major fibrogenic cell in the liver, responsible for promoting the deposition 
of high levels of extracellular matrix (ECM) proteins including collagens by 
hepatic myofibroblasts (e.g. collagen type I), which are the main constituent of 
the fibrotic scars [14]. These scars are associated with a loss of tissue 
architecture and subsequent reduction in overall liver function. HSC 
transdifferentation also affects other properties of the cells, including changes 
in their contractility, which contributes to the development of portal 
hypertension [16]. 
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Endothelial cells line the liver sinusoid and are highly specialized for their 
function by the presence of fenestrae measuring 150 - 175nm in diameter, 
allowing macromolecules, solutes and water to reach the hepatocytes [17]. 
They have also been shown to endocytose a range of compounds via a 
membrane mediated method. This highlights their important role as a 
scavenger system, clearing macromolecular waste products, produced 
throughout the body in other tissues [18]. When inflammatory molecules are 
present in the blood, the endothelial cells upregulate adhesion molecules 
expression, which leads to the recruitment of neutrophils into the liver [19, 20]. 
Neutrophils are the hallmark cell in the acute inflammation response and their 
recruitment leads to further amplification of the inflammatory signal, often 
preceding liver damage. 
Oval cells are bipotent progenitor cells located in the periportal regions of the 
liver, acting as a potential source of both hepatocytes and bile duct epithelial 
cells [21]. When hepatocytes fail to undergo mitosis after serious tissue 
damage, oval cells can migrate through the liver and repopulate hepatocytes 
[21, 22]. 
Bile duct epithelial cells (cholangiocytes) line the bile ducts and are 
important in the excretion of bile, dynamically controlling its excretion by 
alterations in their cellular electrolyte concentrations. They are also known to 
release a range of inflammatory mediators (e.g. TGF-β, platelet derived 
growth factor (PDGF) and connective tissue growth factor (CTGF)) during 
liver injury, which prolongs the fibrotic response [23]. 
 
1.2 Liver disease 
 
1.2.1 Epidemiology & background 
 
The incidence of liver disease in the UK (and many other Western countries) 
has been rising for the past 50 years, shown by increasing liver cirrhosis 
mortality rates [24]. Liver disease is now one of the top five causes of death in 
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the UK, and is consequently an increasing burden on the healthcare system. 
Liver fibrosis and cirrhosis (end stage of liver fibrosis) represent the final 
pathway of nearly all major chronic liver insults/ diseases. The most common 
global cause of liver disease and fibrosis is viral infections (particularly 
hepatitis B and C viral infections) [25, 26]. 
In the Western world the increasing consumption of alcohol has led to a huge 
increase in alcoholic liver disease (ALD). Coupled with a more sedentary 
lifestyle and poor diet there has also been an increase in non-alcoholic forms 
of liver disease, including non-alcoholic fatty liver disease (NAFLD) and non-
alcoholic steatohepatitis (NASH) [27, 28]. A range of autoimmune conditions 
exist, including autoimmune hepatitis and primary biliary cirrhosis (PBC), 
where autoimmune destruction of liver cells precedes fibrosis development 
[29]. There are also rarer genetic conditions that predispose fibrosis 
development, including haemachromatosis and Wilson’s disease (which 
cause defective iron and copper metabolism respectively) leading to hepatic 
toxicity [30, 31]. 
 
1.2.2 Liver fibrosis pathogenesis 
 
Liver fibrosis is defined as the excessive accumulation of ECM, rich in fibrillar 
collagens [32, 33]. It is a classical wound healing/ scarring response seen 
after acute liver injury, arising from multiple aetiologies including viral 
infections, adverse drug reactions and excessive alcohol consumption. 
Following an acute injury, hepatocytes are able to regenerate and replace the 
apoptotic and necrotic cells. The liver’s remarkable regenerative properties 
are highlighted by its ability to return to its normal size and functioning 
capacity even after losing 70% of its parenchymal cells [21]. 
In chronic situations with continued insult there is repeated inflammation and 
ECM accumulation, leading to the increased replacement of the hepatic 
parenchyma with fibrotic scars, in an attempt to encapsulate the injury. Left 
untreated this culminates in liver fibrosis and eventually cirrhosis 
development, characterised by a disruption of liver architecture and 
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subsequent reduction in liver function [32, 34, 35]. Figure 1.4 illustrates the 
major cellular changes that occur as a result of liver fibrosis, including the 
accumulation of collagen scars and subsequent loss of hepatocyte microvilli 
and endothelial cell fenestrae reducing liver function. 
 
 
Figure 1.4 Major cellular morphological changes that occur during fibrosis development (Figure 
taken from [32]). Major cellular changes that occur as a result of HSC activation and liver fibrosis 
development include the accumulation of collagen scars, hepatocyte apoptosis and subsequent loss of 
hepatocyte microvilli and endothelial cell fenestrae.  
 
1.2.3 HSCs and hepatic myofibroblast 
 
The major fibrogenic cell in the liver is the hepatic myofibroblast, which is 
predominantly derived from the HSC. Hepatic myofibroblasts may also be 
derived from bone marrow mesenchymal cell progenitors [36], circulating 
fibrocytes and via an epithelial to mesenchymal transition route [37]. HSCs 
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are perisiunsoidal cells located within the Space of Disse. In their quiescent 
state their major function is to store retinoids (e.g. Vitamin A) absorbed from 
the diet [38]. 
The activation of HSCs to hepatic myofibroblasts is divided into two major 
phases, firstly initiation, which describes the early changes in the gene 
expression of HSCs. Most prominent in this stage are the loss of Vitamin A 
and the increased expression of αSMA from undetectable levels. There is 
coupled with increased expression of PDGF and TGF-β receptors rendering 
HSCs more responsive to fibrogenic stimuli [14, 39]. 
Initiation is primarily induced by paracrine stimuli, such as fibrogenic ROS and 
pro-inflammatory cytokines including TGF-β and IL-6 released by the 
neighbouring hepatic cells (hepatocytes, sinusoidal endothelial cells and 
Kupffer cells) when injury has occurred [40]. Hepatocyte apoptosis can also 
lead to the release of apoptotic fragments, which when phagocytosed by 
Kupffer cells leads to the expression of Fas and death ligands further 
perpetuating hepatocyte apoptosis and fibrosis development [41]. Endothelial 
cells are also known to produce a splice variant of fibronectin that plays a 
critical role in hepatic myofibroblast formation [42]. 
The second phase, perpetuation, results from the initiating stimuli and 
autocrine signals, which maintain the activated hepatic myofibroblast 
phenotype. Perpetuation is characterised by six changes in the cellular 
phenotype responsible for the increased deposition of ECM and subsequent 
loss of tissue architecture and liver function. 
Proliferation – As outlined during initiation, increased levels of autocrine 
PDGF and the increased expression of PDGF receptors early in the activation 
process increases the HSCs responsiveness to the mitogen PDGF [43, 44]. 
There are also a range of other mitogens identified and known to promote 
myofibroblast proliferation including epidermal growth factor (EGF), thrombin 
and vascular endothelial growth factor (VEGF) [45]. 
Chemotaxis – Hepatic myofibroblasts migrate when exposed to cytokine 
chemoattractants, shown by their ability to align themselves in regions of 
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inflammation [46]. The major cytokines involved in chemotaxis are PDGF and 
monocyte chemotactic protein-1 (MCP-1) [47]. 
Fibrogenesis – Fibrosis generation is accomplished by both an increase in 
hepatic myofibroblast number but also an increase in ECM production per 
individual cell [48]. The major component of hepatic scars is collagen type I, 
and the major stimulus for its production is TGF-β arriving through both 
paracrine (activated Kupffer cells) and autocrine routes [49, 50]. A number of 
other signals are known to also contribute to fibrogenesis including lipid 
peroxide products and CTGF [51, 52]. 
Contractility – the increased levels of αSMA bestow the cells with greater 
contractility properties [53]. This can result in increases in portal resistance, 
causing reduced blood flow along individual sinusoids. It is especially severe 
when cirrhosis develops and is a contributing factor in the development of 
portal hypertension [54]. 
Matrix degradation – Fibrosis development is significantly influenced by the 
relative activities of matrix metalloproteinases (MMPs) and tissue inhibitors of 
matrix metalloproteinases (TIMPs) [55]. Early alterations to basal MMP 
activity results in increased removal of ECM, therefore allowing its 
replacement with scar matrix. Hepatic myofibroblasts are known to express 
both MMPs (e.g. MMP-2) and TIMPs (e.g. TIMP-1, which is known to be anti-
apoptotic to hepatic myofibroblasts) [56, 57]. 
Retinoid loss – Activation of HSCs is associated with the loss of the Vitamin 
A droplets. It is still not known whether this retinoid loss is necessary for HSC 
activation [33]. 
 
1.2.4 In vitro/ vivo models of liver fibrosis 
 
The most common in vitro model of liver fibrosis is the isolation of quiescent 
HSCs following collagenase and pronase digestion of liver tissue [53, 58]. 
When cultured on plastic in serum containing media the quiescent HSCs 
undergo a transdifferentiation to a myofibroblast phenotype cell type similar to 
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that seen in the liver during chronic injury. The cells can be sub-cultured by 
trypsinisation for approximately 5-6 passages, but often senesce around this 
passage number (varies between different species). An issue with their use is 
the different isolation protocols used between laboratories affecting the purity 
of HSCs isolated. They are a useful tool to assess potential anti-fibrotics for 
preventing initial HSC transdifferentiation. 
Other important in vitro tools are the LX-1 and LX-2 cell lines. Both are human 
hepatic myofibroblast like cell lines derived by transfection and 
immortalisation with SV40 T antigen (LX-2s were further cultured in low serum 
conditions) [59]. Both cell lines express low levels of αSMA and a number of 
receptors known to regulate fibrogenesis including the β-PDGF receptor. 
Microarray analysis confirmed similar gene expression to that of primary 
human HSCs (hHSCs) and LX-2 cells have the advantage of also being highly 
transfectable. The limited availability of human HSCs to investigate gene 
targets for anti-fibrotics makes the LX-1 and LX-2 cell lines a precious tool for 
advancements in hepatic fibrosis research [59]. 
In vivo models of liver fibrosis are invaluable in the search for novel anti-
fibrotic agents, containing all the complex intracellular pathways present in the 
liver and extrahepatic sources that may contribute to liver fibrosis. The most 
common modes of inducing liver fibrosis in vivo are shown below: - 
Carbon tetrachloride (CCl4) administration – The most commonly studied 
model, normally by intraperitoneal (i.p.) injection (1ml/kg body weight twice 
weekly for 4-12 weeks) [12]. CCl4 hepatotoxicity results from the bioactivation 
of CCl4 to a trichloromethyl radical by CYP2E1 metabolism; this radical reacts 
with oxygen forming the highly toxic trichloromethyl peroxy radical. This free 
radical is highly reactive and attacks polyunsaturated fatty acids commonly 
found in membrane lipids culminating in lipid peroxidation [60] (see Figure 
1.5). The subsequent loss of membrane structure results in centrilobular 
hepatocyte death, with chronic administration leading to bridging fibrosis as 
fibrosis radiates out from the central veins. 
Dimethylnitrosamine (DMN) – Most commonly induced by 10mg/kg i.p. 
injection for 3 consecutive days/ week for up to 4 weeks [61]. As with CCl4 
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CYP2E1 is responsible for metabolism of DMN [62], culminating in the 
production of formaldehyde and methanol. Alkylating intermediates are able to 
methylate nucleic acids and proteins of the hepatocytes, leading to severe 
hepatocyte necrosis [63]. In chronic treatments there is also destruction of 
sinusoidal endothelial cells in the centrilobular regions with increased 
coagulation [64, 65]. Induced macrophage activity can result in elevated iron 
concentrations and subsequent oxidative stress promoting fibrosis 
development [61]. 
Bile duct ligation (BDL) – A surgical procedure in which the bile duct is 
ligated with 2 pieces of suture for up to 3-4 weeks [66, 67]. Increased levels of 
bile acids in the liver result in hepatocyte apoptosis and at higher levels 
hepatocyte necrosis. The bile duct is located within the portal tract so fibrosis 
bridges out from the periportal regions [68]. 
 
Figure 1.5 Schematic illustrating CCl4 hepatotoxicity mode of action (modified from [60]). CCl4 
hepatotoxicity is a result of its metabolism by CYP2E1 to a trichloromethyl free radical. This radical 
reacts with oxygen to produce a highly reactive peroxytrichloromethyl free radical that culminates with 
a series of lipid peroxidation reactions and subsequent hepatotoxicity.  
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There are a number of other models available including the intragastric 
enteral feeding model of alcohol induced fibrosis and other alternative drug 
induced models (e.g. thioacetamide). Generally any potential anti-fibrotic 
agent should be tested in at least two of these models. It must be appreciated 
that all of these models exhibit some significant pathological differences to the 
severity of fibrosis seen in humans. Most notably the severity of fibrotic bands 
that develop in these models are not as severe as in humans and models do 
not exhibit the same alterations in vasculature that contribute to complications 
associated to fibrosis and cirrhosis in man [3]. 
 
1.3 Treatments of liver disease 
 
Despite enormous strides made over the past 30 years establishing the 
importance of the HSC in liver fibrosis and the multitude of signalling 
pathways involved in its initiation and perpetuation, an effective treatment 
regimen for liver fibrosis still eludes us. With the exception of transplantation, 
there is no recognised treatment; the increasing incidence of liver fibrosis 
coupled with the finite number of donors available reinforces the need for 
novel anti-fibrotic treatments. At present the most effective anti-fibrotic therapy 
is to treat the underlying cause of the disease, the most prominent example 
being the anti-viral (e.g. pegylated α-interferon) treatment of hepatitis viral 
infections [69]. Alternatively in cases of NASH, educating the population so 
they know the severity of liver disease and encouraging weight loss is a good 
preventative measure. 
There are a number of potential drug target sites/ pathways where anti-fibrotic 
agents are currently being targeted including: 
 
1.3.1 Reducing the initial immune response/ inflammation to avoid HSC 
activation.  
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Treatment of hepatitis C patients with a combination of ribavirin and pegylated 
α-interferon has been able to reduce fibrosis severity as diagnosed by liver 
biopsy samples [69, 70]. It is believed their improvement is a result of viral 
clearance, but pegylated α-interferon has also been shown to have anti-
fibrotic benefits in biliary fibrosis suggesting it may have direct anti-fibrotic 
properties as well [71]. Corticosteroids have been employed in the treatment 
of numerous inflammatory diseases for decades (e.g. arthritis and irritable 
bowel syndrome). They also exhibit beneficial properties in autoimmune 
hepatitis with a reduction or abolition of fibrosis development when 
administered [72]. Other anti-inflammatory agents that may be beneficial in 
preventing initial HSC activation are inhibitors of the renin-angiotensin system 
[73]. This is a viable route as oxidative stress is known to be increased by this 
system. Finally novel compounds such as ‘mimics’ of hepatocyte growth 
factor (HGF) may decrease TGF-β signalling and subsequent collagen 
deposition [74]. 
 
1.3.2 Directly prevent HSC activation. 
 
Activation of HSCs is the critical step in fibrosis development, therefore 
reducing the transdifferentiation of quiescent HSCs to hepatic myofibroblasts 
is an attractive anti-fibrotic route to pursue. Oxidative stress is one of the first 
stimuli to initiate HSC activation; experiments utilising the anti-oxidant α-
tocopherol have been successful in some animal models of liver fibrosis 
(specifically iron overload induced fibrosis) [75]. Peroxisome proliferator-
activated receptor gamma (PPARγ) is highly expressed in HSCs and 
synthetic PPARγ agonists reduced HSC activation in vitro [76]. These initial 
findings suggest anti-diabetic treatments such as thiazolidinediones may be 
an effective drug to treat liver fibrosis, which was later reinforced both in vitro 
and vivo by Galli et al [77]. Another anti-fibrotic target is leptin which is known 
to be released by HSCs and to be pro-inflammatory. When both leptin 
knockout and wildtype mice received liver insults the level of fibrosis 
development was significantly reduced in the knockout mice when compared 
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to the wildtype mice [78]. Therefore it is believed treatment of fibrosis with 
adiponectin, an important regulator of leptin, may reduce inflammation and 
HSC activation [79]. 
 
1.3.3 Neutralise the proliferative, fibrogenic, contractile and pro-
inflammatory responses of HSCs. 
 
The continued increase in knowledge of the growth factors (e.g. PDGF and 
TGF-β) involved in HSC initiation and perpetuation, including their intracellular 
signalling pathways and target receptors provide an array of anti-fibrotic 
targets. These intracellular signalling pathways are common to other disease 
states (e.g. chronic myeloid leukaemia (CML) and gastrointestinal stromal 
tumours) [80, 81], therefore a number of inhibitors are available and being 
tested in fibrosis models including Gleevec (a tyrosine kinase antagonist) 
used in leukaemia [82] and pentoxyphylline (an inhibitor of PDGF signalling). 
Another major target is TGF-β signalling, as this cytokine is prominent in 
fibrogenesis.  A number of antagonists to TGF-β have displayed the potential 
of this treatment route [83-85]. They are beneficial as they inhibit both matrix 
deposition whilst also simultaneously increasing its degradation [86]. There 
are also a number of other potential targets including relaxin [87], endothelin-1 
and regulators of wound healing/ contraction whose antagonism is anti-fibrotic 
[88]. 
 
1.3.4 Induction of hepatic myofibroblast apoptosis. 
 
Important work by the Iredale group ascertained that, following the removal of 
the causative stimuli, liver fibrosis naturally regresses, enforced by the 
increased apoptosis of hepatic myofibroblasts [89]. This discovery prompted 
the development of a number of targeted therapies, including gliotoxin (GTX) 
which was shown to induce HSC apoptosis in vivo and significantly reduce 
fibrosis severity [90]. A similar method to this was the inhibition of Iĸĸ, an 
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important factor in regulating NF-ĸB activation, responsible for preventing 
hepatic myofibroblast apoptosis and promoting fibrosis development [91]. A 
number of other apoptotic factors are expressed in hepatic myofibroblasts 
including nerve growth factor (NGF) [92], Fas ligands and Bcl providing 
alternative routes to induce hepatic myofibroblast apoptosis. 
 
1.3.5 Increase MMP activity and fibrotic scar degradation. 
 
Matrix resorption and degradation are both essential in the resolution of liver 
fibrosis. Work by Issa et al [93] highlighted the importance of MMPs in fibrosis 
resolution, as mice expressing a mutated form of collagen type I were unable 
to resolve fibrosis. TIMP-1 is dramatically upregulated by several pro-
inflammatory cytokines, including TNFα [94], and TGF-β [95] inhibiting MMP 
activity and preventing collagen degradation. Novel methods to inhibit TIMP 
activity and restore MMP activity are ongoing. Examples include utilizing a 
mutant MMP-9 peptide to retain TIMP-1 bound in an inactive state [96], or 
alternatively antibodies antagonizing TIMP-1 result in a reduction in fibrosis 
severity in a rodent model of liver fibrosis [97]. 
 
1.4 Targeting hepatic myofibroblasts 
 
The major issue with potential treatments such as the fungal metabolite GTX 
is their lack of specificity to hepatic myofibroblasts. Although it preferentially 
induced the apoptosis of hepatic myofibroblasts, there was also increased 
apoptosis/ necrosis of Kupffer cells [90, 98]. The presence of Kupffer cells is 
known to be of benefit in both the development and the reversal of fibrosis 
from work carried out by Duffield et al [12], which shows they are required for 
successful degradation of the excess ECM. Also under inflammatory 
conditions hepatocytes may be more vulnerable to cell death if NF-κB has 
already been inhibited [90, 98]. It is well known that GTX has 
immunosuppressive effects, abrogating B and T cell stimulation and causing 
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leucocyte apoptosis [99]. These findings highlight the advantages in both 
efficacy and specificity of targeting apoptotic agents directly to hepatic 
myofibroblasts. 
Initial research focused on identifying a target that was only present on 
hepatic myofibroblasts, it was discovered that the mannose 6 phosphate/ 
insulin like growth factor II receptor (M6P/IGF-II) was highly expressed on the 
surface of hepatic myofibroblasts [100]. Further work involved the modification 
of human serum albumin (HSA) bound with M6P to target hepatic 
myofibroblasts directly [101]. When its functioning had been confirmed, it was 
conjugated with a range of anti-fibrotic agents including pentoxiffylline, 
losartan, GTX and doxorubicin [102-105]. When administered to animal 
models of liver fibrosis they all showed a significant anti-fibrotic effect (e.g. 
decreased number of αSMA positive cells). 
 
1.4.1 Synaptophysin expression in the liver and the heterogeneity of 
hepatic myofibroblasts 
 
Synaptophysin is a transmembrane glycoprotein found within the presynaptic 
vesicles of neurons of the brain, spinal cord, and at neuromuscular junctions 
[106]. It is primarily involved in controlling neurotransmitter release and 
exocytosis at the nerve terminal although its specific function is yet to be 
established [107]. IHC analysis by Cassiman et al [108] revealed that 
synaptophysin is also expressed on the surface of quiescent and activated 
HSCs. Synaptophysin’s external cellular location and cycling to internal 
locations made it an ideal target for anti-fibrotic therapeutics. 
It is difficult to determine the origin of hepatic myofibroblasts due to the 
various populations (e.g. periportal fibroblasts and centrilobular 
myofibroblasts) [109], with a heterogeneous expression of various markers. 
As well as synaptophysin, quiescent HSCs and hepatic myofibroblasts 
express a range of other neural markers including glial fibrillary acidic protein 
(GFAP) and nestin [110]. This suggests that a proportion of hepatic 
myofibroblasts may derive from the neural crest, and would explain 
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synaptophysin’s expression on hepatic myofibroblasts. However tests utilising 
transgenic mice encoded with fluorescent proteins (specific to neural crest 
cells) revealed that desmin-positive perisinusoidal cells of the liver did not 
express any fluorescent protein [111]. Further studies have highlighted 
alternative routes that may contribute to hepatic myofibroblast development 
including bone marrow derived HSCs [112, 113] and also directly from 
hepatocytes via an ‘epithelial to mesenchymal’ route during fibrosis [114]. 
 
1.4.2 C1-3 a recombinant human single chain antibody fragment (scAb) 
and synaptophysin 
 
Phage display screening was used to generate a recombinant single chain 
antibody (scAb) specific to a conserved peptide sequence present on an 
extracellular domain of synaptophysin [115]. The scAb isolated could be 
rapidly produced in E-coli and subsequently purified via its terminal His tag; it 
was termed C1-3 and binds specifically to peptide sequence 2 of the 
synaptophysin protein (see Figure 1.6). Further in vitro work incubating 
fluorescently labelled C1-3 with both human hepatocytes and HSCs 
highlighted its specificity for HSCs [115]. The use of monensin to block scAb 
uptake and conjugation of the toxin tributylin to test whether the scAb is taken 
up through the delivery of the toxin and subsequent cell death confirmed that 
the scAb is taken up intracellularly. 
Work by Douglass et al [116] coupled the apoptosis inducing effects of GTX 
with the hepatic myofibroblast specificity of C1-3 in a CCl4 model of liver 
fibrosis. This form of the scAb was named C1-3-GTX and shown to reduce 
the number of αSMA positive hepatic myofibroblasts by up to 60%, and 
consequently fibrosis severity was significantly reduced [116]. In addition 
there was no effect on Kupffer cell numbers and no serious extrahepatic side 
effects associated with the administration of free GTX. 
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Figure 1.6 Outline of human synaptophysin protein (taken from [115]).  Human synaptophysin is 
believed to span the plasma membrane as outlined; C1-3 is specific to the synaptophysin peptide region 
2.  
 
1.5 Diagnosis of liver fibrosis 
 
Accurately assessing the severity of liver fibrosis is essential to determine the 
prognosis of the disease and ascertain whether a treatment may be beneficial 
for a specific patient, and also to determine the success of any treatment. 
 
1.5.1 Liver biopsy 
 
For fifty years since Menghini advocated the use of the percutaneous needle 
biopsy [117], it has been the ‘gold standard’ in the diagnosis of liver fibrosis. 
Histochemical analysis of the removed liver sample is in most instances 
achieved by staining with hematoxylin and eosin (H&E) and is graded by a 
pathologist, using the Ishak, METAVIR or Scheur scales [118-120] (Table 
1.1). 
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Scoring system Grade Staging criteria 
METAVIR F0 No fibrosis 
 F1 Fibrous portal expansion (stellate 
enlargement) but no septae formation 
 F2 Enlargement portal tract with rare septae 
formation 
 F3 Numerous septae without cirrhosis 
 F4 Cirrhosis 
Ishak 0 Normal (no fibrosis) 
 1 Fibrous expansion of some portal areas, 
with or without short fibrous septa 
 2 Fibrous expansion of most portal areas, 
with or without short fibrous septa 
 3 Fibrous expansion of most portal areas, 
with or without portal-portal bridging 
 4 Fibrous expansion of  portal areas, with 
marked bridging (portal-portal and 
portal-central) 
 5 Marked bridging (portal-portal &/or 
portal-central) with occasional nodules 
(incomplete cirrhosis) 
 6 Cirrhosis, probable or definite 
Scheur 0 None 
 1 Enlarged, fibrotic portal tracts 
 2 Periportal or portal-portal septa but intact 
architecture 
 3 Fibrosis with architectural distortion but 
no obvious cirrhosis 
 4 Probable or definite cirrhosis 
Table 1.1 – Major liver biopsy scores 
 
The limitations of the liver biopsy have become clear though; it is a highly 
invasive procedure. With significant medical complications ranging from 
excessive bleeding and pain (resulting in prolonged hospital admission in 1 - 
5% of patients) to mortality (in 1 in 1000 – 10000 patients) [121]. Other 
potential complications include significant sampling variability due to the fact 
that on average, the size of the biopsy sample is approximately 1/50000th the 
total size of the liver. Regev et al [122] highlighted the sampling error 
associated with biopsies with a difference of at least one fibrosis stage 
recorded between the two major liver lobes. Interobserver variation is another 
issue due to the subjective nature of assessing fibrosis severity from liver 
biopsy samples, coupled with the number of scoring systems available 
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making it difficult to make comparisons between different studies as well 
[119]. 
 
1.5.2 Serum markers  
 
A range of common serum markers are used to assess the level of liver 
damage and they can be divided into two classes. An ideal serum marker 
should be specific to the liver, not impaired by biliary and urinary excretion, 
whilst being simple to assay and detectable in all classes of liver disease [34]. 
Class I (direct) biomarkers are generally derived from the increased ECM 
turnover seen during HSC activation or a mediator involved in fibrogenesis 
(e.g. TGF-β). Therefore many structural glycoproteins, pro-collagens and 
collagen fragments are used as biomarkers as well as MMPs and TIMPs, with 
N-terminal propeptide of type III procollagen (P III NP) being used in some 
clinical settings [123]. Hyaluronic acid (an essential component of ECM found 
at increased levels in fibrotic livers) [124] is currently considered the best 
class I biomarker due to its high sensitivity and specificity in a recent study of 
NAFLD [125] and its ability to exclude late fibrosis and cirrhosis. 
Class II biomarkers are indirect markers estimating the degree of fibrosis, 
which do not necessarily involve ECM and fibrogenic cellular changes. They 
have however been statistically proven to be associated with fibrosis levels. 
They are composed of different ‘biomarker panels’ that are programmed into 
mathematical algorithms to stage fibrosis severity [126]. Parameters used in 
these tests include the Aspartate aminotransferase/ Alanine aminotransferase 
(AST/ ALT) ratio, with increased AST levels in the serum after liver injury. 
Another common parameter is the platelet count; thrombopoitein (the major 
enzyme responsible for platelet production) is produced in the liver and 
therefore its relative level is directly related to liver function [127]. To improve 
the accuracy of this test it can be combined with the AST levels to form the 
AST to platelet ratio index (APRI); this simple index is relatively easy to carry 
out and can potentially differentiate between individuals with severe fibrosis/ 
cirrhosis and those without [128]. 
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There are over twenty scores that are currently used to stage fibrosis severity 
(the most widely employed are shown in table 1.2), the two most common 
being the Fibrotest™ (Fibro-Score) and the ActiTest™. The Fibrotest™ was 
developed by Imbert-Bismut et al [129]; it involves the detection of 
haptoglobin, α2-macroglobulin, apolipoprotein A1, bilirubin and γ-
glutamyltransferase (GGT). The results of the Fibrotest™ are used to produce 
three categories of fibrosis – mild (METAVIR F0-F1), significant (METAVIR 
F2-F4) and indeterminate (removed from clinical reporting by making fibrosis 
score linear) [130]. The Actitest™ incorporates the same diagnostic criteria as 
the Fibrotest™ but also includes ALT, to reflect necro-inflammatory activity as 
well as fibrosis. Numerous studies have been performed to validate the 
accuracy of both these tests to suggest they could be used as an alternative 
to the liver biopsy in numerous models of liver disease preceding fibrosis 
development [131-133]. 
 
Non 
invasive 
fibrosis test 
Components Theory Pros Cons 
Actitest™ α2-macroglobulin 
Haptoglobin 
Apolipoprotein 
A1 
Bilirubin 
GGT 
ALT 
Identical to the 
Fibrotest™ but also 
assesses the necro-
inflammatory 
activity. 
Addition of 
ALT to criteria 
aids diagnosis of 
later stage 
fibrosis when 
there is 
increased 
necrosis and 
inflammation. 
Only validated 
in HCV [132]. 
APRI ALT 
Platelet count 
Statistically 
significant +ve 
correlation between 
fibrosis severity & 
AST level, -ve 
correlation with 
platelet count. 
Distinguishes 
between 
individuals with 
or without 
significant 
fibrosis [128]. 
Unable to 
differentiate 
between specific 
fibrosis stages 
[127, 128].  
Fibrotest™ α2-macroglobulin 
Haptoglobin 
Apolipoprotein 
A1 
Bilirubin 
GGT 
Mathematical 
formula combining 
5 indirect markers 
of liver fibrosis that 
gives a fibrosis 
score. 
Can distinguish 
between all 
stages of liver 
fibrosis [129, 
134].  
Discordant 
results with liver 
biopsy in HCV 
patients. False 
positives can 
result due to 
treatment 
regimens 
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affecting 
bilirubin levels. 
Forns Index 
 
Platelet count 
GGT 
Age 
Cholesterol 
4 variables 
developed in an 
attempt to 
differentiate 
between clinically 
significant fibrosis 
and less severe 
early stages. 
Good at 
predicting early 
stage fibrosis 
[135]. 
Can't detect 
severe fibrosis, 
cholesterol 
parameter is a 
weakness and 
can vary 
according to 
HCV genotype. 
Only validated 
in HCV. 
Hepascore Bilirubin 
GGT 
Age 
Sex 
α2-macroglobulin 
Hyaluronic acid 
Bilirubin levels 
increase due to 
decreased liver 
function associated 
with fibrosis 
development, 
whilst hyaluronic 
acid and α2-
macroglobulin both 
increase as a result 
of HSC activation 
and fibrosis 
presence. 
Use of 
hyaluronic acid 
improves the 
detection of 
significant and 
advanced 
fibrosis/ 
cirrhosis [136, 
137].  
Is not an 
effective model 
to determine 
early fibrosis 
stages. 
Table 1.2 – Common non-invasive serum biomarker panels 
 
1.5.3 Non-invasive imaging modalities  
 
Radiologic assessment of hepatic fibrosis including ultrasonography and 
computed tomography has been trialled. However, they are limited to the 
detection of cirrhosis and complications associated with it (i.e. portal 
hypertension and ascites) [138]. These techniques are not sensitive enough 
to detect fibrosis during its developmental and early stages, which is a major 
limitation to their use when coupled with their high costs. Transient 
elastography (FibroScan) is a novel non-invasive imaging technique, 
incorporating a transducer which transmits vibrations through the liver 
producing a shear wave. Pulse-echo ultrasounds can detect the speed and 
velocity of the shear wave as it travels through the liver tissue. The velocity of 
the wave is directly proportional to the stiffness of the liver tissue, therefore as 
fibrosis and ECM deposition increase the relative stiffness of the liver also 
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increases. Consequently the velocity of a shear wave will be higher in a 
fibrotic liver when compared to a healthy liver [139]. The benefits of this 
technique focus on the fact it is non-invasive, whilst also being relatively 
cheap and having high reproducibility. Also it is able to measure a much 
larger region of the liver in comparison to a liver biopsy; normally a region of 
1cm diameter and 5cm in length is measured in transient elastography over 
one hundred times that measured in a typical liver biopsy [140]. The major 
limitation of transient elastography is that it is not effective in determining liver 
stiffness in obese patients and those suffering with ascites. The presence of a 
fatty thoracic band attenuates the elastic wave and ultrasound waves making 
diagnosis impossible [141]. Transient elastography has been evaluated in a 
range of liver diseases including NAFLD, ALD and hepatitis B and C viral 
infections. Reproducibility of transient elastography is another important factor 
in its use in clinical practice; the level of inter-observer discrepancies is 
significantly reduced when compared to the liver biopsy. Fraquelli et al [142] 
amongst others have shown that its reproducibility is excellent for cirrhosis 
and severe fibrosis (>F2) but significantly reduced in milder forms of fibrosis 
(F0-F1). Continued research to develop probes that can penetrate thoracic fat 
and determine uniform cut-off points for all studies to improve the diagnosis of 
earlier types of fibrosis are ongoing [143]. 
Magnetic resonance imaging (MRI) has been investigated retrospectively by 
Aguirre et al [144] in over 100 patients using a double contrast agent to 
improve MRI resolution. It was found that this method could be used to detect 
severe fibrosis (F>3 using METAVIR scale) with a sensitivity/ specificity above 
90%. 
A major fundamental issue in diagnosing liver fibrosis is the fact that the liver 
biopsy, which is the ‘gold standard’ and reference for all novel hepatic imaging 
techniques has been shown to be limited (Section 1.5.1). Perhaps the most 
effective method to diagnose liver fibrosis as highlighted by numerous studies 
[145, 146] is the combination of multiple non invasive techniques (including 
more than one fibrosis test and/ or transient elastography). This non-invasive 
approach removes the need for liver biopsy unless absolutely necessary, 
whilst also reducing the incidence of misdiagnosis and subsequent treatment. 
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It is important to acknowledge the advancements being made with the use of 
imaging modalities in other diseases (e.g. positron emission tomography 
(PET) and MRI) that may be beneficial in non-invasively diagnosing hepatic 
fibrosis. 
 
1.6 The pregnane X receptor (PXR) 
 
The PXR is an orphan nuclear receptor (~50 kDa in size) and a member of 
the nuclear receptor superfamily (NRS) of ligand activated transcription 
factors. It is named the PXR due to its activation by both natural and synthetic 
pregnanes (e.g. cortisone and progesterone). Other members of the NRS 
include the steroid, thyroid and retinoid hormone receptors [147-149]. The 
PXR is constitutively expressed at high levels in both the liver and intestines 
and has been shown to regulate drug and corticosteroid induction of important 
drug metabolising enzymes. This includes the glutathione-S-transferases 
(GST’s) [150, 151], UDP-glucuronosyltransferases [152, 153] and numerous 
cytochrome P450 (CYP450) isoforms, including CYP3A4 [154]. This is of high 
significance as the CYP3A4 isoform is responsible for metabolising over 50% 
of clinically administered drugs [155, 156]. The PXR also mediates the 
expression of a number of drug efflux pumps and transporters, including the 
multidrug resistance 1 (MDR1) and organic anion transporter polypeptide-2 
(OATP2) [157]. It is referred to as a ‘xenosensor’ [158], due to this wide 
variety of transcriptional impacts on the different processes central to the 
clearance and removal of drugs and toxins from the body. 
 
1.6.1 The PXR pathway  
 
The PXR protein, like all NRS members, is composed of a central DNA 
binding domain (DBD) containing two highly conserved zinc fingers, a variable 
amino-terminal domain and a carboxy-terminal ligand binding domain (LBD). 
In most cases there are two transcriptional activation domains, activation 
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function 1 (AF-1) located in the N-terminal domain and AF-2 found in the C-
terminal region of the LBD [147, 159] (Figure 1.7A). Upon ligand binding to 
the LBD there is a conformational change in AF-2 resulting in disruption of the 
interactions normally seen with transcriptional co-repressor proteins such as 
N-CoR and SMRT. This now allows transcriptional co-activator proteins 
including SRC-1 and TIF-2 to bind to the AF-2 domain facilitating heterodimer 
formation with the 9-cis retinoic acid receptor (RXR) [160]. This PXR/ RXR 
heterodimer is able to bind to DNA response elements found in the promoter 
regions of target genes, stimulating their expression i.e. CYP3A4. 
The PXR has been identified in other species including the mouse, rat, rabbit 
and dog with there being very close homology between the orthologues. The 
mammalian PXR shares approximately 95% homology in the DBD, but there 
is more variation with regards to the LBD (see Figure 1.7B). This may be the 
reason for the differences seen in ligand binding between species to the PXR, 
with pregnenolone-16α-carbonitrile (PCN) demonstrating high affinity for the 
rodent PXR but none for the human PXR [161, 162]. 
 
Figure 1.7 A: Schematic diagram illustrating the domains present in all members of the NRS and 
B: Sequence comparison across species illustrating PXR similarity (taken from [147] and [155] 
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respectively). A/B = variable N-terminal region. C = highly conserved DBD. D = variable hinge region. 
E = conserved LBD. F = variable C-terminal domain. 
 
1.6.2 PXR ligands and drug-drug interactions 
 
What separates the PXR from its counterparts in the NRS is its ability to bind 
such a broad spectrum of xenobiotics. Research utilising X-ray 
crystallography gave a greater insight into the architecture of the LBD region 
of the PXR [155]. It showed that the hydrophobic pocket of the PXR was 
much larger than other members of the NRS, and had a unique smooth 
elliptical shape [155, 163]. 
The hydrophobicity of the ligand binding site means that the receptor is ideal 
for binding lipophilic ligands that are able to diffuse into the cells. Chief 
examples include rifampicin, hyperforin, taxol and ritonavir. The issue 
involving these compounds is their induction of the CYP3A4 isoform and 
potential drug-drug interactions. Consequently if polypharmacy is being 
employed there can be increased CYP3A4 metabolism of the compound, 
sometimes resulting in ineffective treatment outcome or formation of life 
threatening levels toxic metabolites. The detrimental drug-drug interaction 
effects of St. John’s Wort (hyperforin) on the anti-cancer agent irinotecan is a 
recent example [164]. Commonly encountered PXR activators: - 
Rifampicin is a macrocyclic antibiotic used as a component of a multidrug 
regimen to treat tuberculosis, and now commonly used to treat a range of 
bacterial and fungal infections. Extensive research in humans has also 
outlined its immunosuppressive effects in the liver, in some instances 
depressing IgG antibody response [165, 166]. Rifampicin functions by 
inhibiting DNA dependent RNA polymerase in bacterial cells, it binds to the β-
subunit preventing gene transcription and subsequent protein formation. 
St. John’s Wort is an herb derived from the Hypericum perforatum plant used 
to treat mild depression. Normally a prescription is required to obtain St. 
John’s Wort but this is not the case in the USA. The mode of action of St. 
John’s Wort is not fully understood but is believed to be similar to the 
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conventional selective serotonin reuptake inhibitor class of anti-depressants, 
by preventing the reuptake of serotonin. Hyperforin, a major constituent of St. 
John’s Wort was found to be the most active chemical present activating the 
PXR, responsible for numerous drug-drug interactions between St. John Wort, 
and prescription drugs cited in medical literature in the 1990’s in the USA 
[164, 166]. 
 
1.6.3 PXR and inflammation 
 
It has long been known that there is a correlation between increased levels of 
inflammation and infection with decreased hepatic expression of CYP450 
isoforms, yet the mechanism of this CYP downregulation remained unclear 
[167]. Other nuclear receptors, most notably the glucocorticoid receptor (GR) 
have been shown to inhibit the nuclear factor ĸB (NF-ĸB) signalling pathway, 
which is a major pro-inflammatory transcription factor important in the 
inflammation/ apoptosis cascade [168, 169]. 
Work by Zhou et al [166] demonstrated that activation of the PXR by 
rifampicin administration antagonised the activity of NF-ĸB in both in vitro and 
in vivo models of irritable bowel disorder (IBD), suggesting there is an 
important link between xenobiotic metabolism and the immune system. The 
major findings of this report were that PXR agonists (e.g. rifampicin and 
phenytoin) reduce expression of NF-ĸB regulated pro-inflammatory genes 
such as TNFα, and rifampicin inhibits NF-ĸB by a PXR dependent manner not 
via the GR as postulated [166]. 
These findings were reinforced by Shah et al [170], whilst investigating the 
effects of PXR activation on IBD again via NF-ĸB inhibition. They induced IBD 
by administration of dextran sulphate sodium (DSS) in both PXR wildtype and 
PXR null mice. Administration of the rodent PXR activator PCN resulted in 
reduced colitis in PXR wildtype mice, but had no effect on PXR null mice 
indicating that PXR activation reduced the severity of IBD and this effect was 
mediated by the PXR. Relative mRNA levels highlighted that this was 
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mediated by decreased expression of several important NF-ĸB target genes 
(including TNFα) [170]. 
The PXR is constitutively expressed in the liver, in combination with the 
knowledge that the immune and inflammatory cascades are central to liver 
fibrosis development following liver injury. This suggests that PXR activation 
may be a viable route to ameliorate liver fibrosis. 
 
1.6.4 The PXR and liver fibrosis 
 
Rodents - Initial studies within this group focussed on investigating the 
potential of utilising liver regeneration as a method of alleviating liver fibrosis, 
as demonstrated previously by other groups [171]. This was investigated by 
administering PCN to rodents with CCl4 induced liver fibrosis. Administration 
of PCN to rodents treated with CCl4 did not affect the hepatotoxicty of CCl4, 
but did reduce the severity of liver fibrosis that developed, gauged by αSMA 
levels and sirius red IHC [172]. In vitro treatment of quiescent rat HSCs 
(rHSCs) with PCN prevented their transdifferentiation to an activated 
myofibroblast phenotype, suggesting it would be an effective anti-fibrogenic 
agent. PXR mRNA was not detected at significant levels in rHSCs implying 
that PCN’s mode of action was independent of the PXR. Further studies in 
vivo in both PXR wildtype and PXR null mice highlighted that PCN’s anti-
fibrotic action was dependent on the presence of a functional PXR [172]. 
Humans - Further studies from within the group focussed on the effects of 
PXR activation in humans to reinforce the earlier work carried out in rodent 
models of liver fibrosis [172]. Firstly freshly isolated human HSCs (hHSCs) 
were shown to express PXR mRNA at all stages (quiescent to activated HSC 
transdifferentiation), displayed by increased levels of collagen I, TGF-β and an 
induction of αSMA mRNA. Transfection of hHSCs with a PXR responsive 
luciferase construct demonstrated that the PXR was constitutively expressed, 
and treatment with rifampicin (a PXR specific agonist) further increased the 
luciferase response of the reporter construct [173]. GeneChip analysis 
highlighted that rifampicin treatment modulated the expression of TGFβ, a 
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cytokine central to increased ECM deposition in liver fibrosis. Further qRT-
PCR data showed that TIMP-1 expression was also significantly decreased 
following rifampicin treatment and a variety of genes important in the cell cycle 
were also repressed (e.g. cyclins and WNT signalling). This suggests that 
PXR activation could prevent HSC transdifferentiation/ proliferation supporting 
the data from the earlier rodent studies [173, 174]. 
Later work aimed to ascertain whether the anti-fibrogenic effects displayed by 
the PXR were due to inhibition of NF-κB activity [175], trying to build upon the 
work carried out by other groups in similar inflammatory situations (DSS 
induced model of IBD [170]). The importance of NF-κB during the 
development and maintenance of liver fibrosis has been shown; it plays a key 
role in preventing the inhibition of hepatic myofibroblast apoptosis [90, 91, 
176]. The effect of PXR activation on NF-κB activity was investigated using 
the U937-NF-κB cell line (stably transfected with firefly-luciferase gene under 
the control of a concatamer of NF-κB response elements) [175, 177]. 
Treatment of the U937-NF-κB cells with the pro-inflammatory cytokine TNFα 
or bacterial lipopolysaccharide (LPS) induced luciferase expression. Addition 
of the PXR activators rifampicin, hyperforin and metyrapone in turn all 
inhibited this luciferase induction, when induced by LPS but not with TNFα. 
Multiple cell lines (THP-1, HepG2 and LX-2) were transfected with a luciferase 
reporter gene under the control of a TNFα promoter (as U937-NF-κB cells are 
not very amenable to transfection). Administration of PXR activators as above 
inhibited the constitutive luciferase expression seen previously. To verify 
these findings to the conditions seen in liver fibrosis and inflammation, Kupffer 
cells were isolated from human patients (confirmed by their expression of 
CD68 – a recognised monocyte/ macrophage marker). Kupffer cells express 
TNFα in response to LPS treatment, and this response was abrogated upon 
treatment with PXR activators. It was confirmed this was mediated via a PXR 
dependent mode of action by identical studies carried out in Kupffer cells 
isolated from both PXR wild type and null mice [177]. 
 
1.7 Nuclear factor-κB (NF-κB) 
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1.7.1 NF-κB family members and signalling pathway 
 
NF-κB is a family of transcription factors (made up of dimers) central to the 
regulation of the inflammatory, immune, wound healing and cell fate cycles. It 
functions by binding to κB binding domains present in the regulatory regions 
of target genes (e.g. TNFα receptor-associated factor 1 (TRAF1) and pro-
inflammatory cytokines) and inducing their transcription. The NF-κB dimers 
consist of either homodimers or heterodimers. There are five members of the 
NF-κB family in mammalians – p50, p52, p65, RelB and c-Rel. Each member 
has distinct biological activities; consequently all dimers have different effects/ 
targets on gene transcription. NF-κB is known as a ‘rapid-acting’ primary 
transcription factor, as a result of its presence in cells at all times. In resting 
cells NF-κB is held in an inactive state within the cytoplasm by inhibitor of κB 
(IκB) proteins. Upon activation IκB is phosphorylated at specific sites 
ultimately resulting in its ubiquination and degradation (catalysed by IκB 
kinase (IKK)). Following its release the NF-κB dimer is able to cross the 
nuclear membrane and bind to the DNA binding domain of target genes 
initiating their transcription [178] (See figure 1.8). 
 
Figure 1.8 Canonical NF-κB signalling pathway. Illustrates cytoplasmic location of NF-κB 
heterodimer (p50/p65) until IκB degradation by IKK allowing NF-κB translocation to the nucleus and 
subsequent gene transcription. 
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The NF-κB pathway is controlled by two major signal transduction routes 
called the canonical and non-canonical pathways. The canonical pathway 
(Figure 1.8) is activated by a wide range of stimuli including bacterial antigens 
that activate Toll like receptors (TLR) (e.g. LPS) and pro-inflammatory 
cytokines including TNFα and IL-1. It functions as outlined above with IKK 
mediated degradation of the IκB protein allowing NF-κB translocation to the 
nucleus and gene transcription. The non-canonical pathway has a smaller set 
of activating stimuli (e.g. CD40, lymphotoxin β and B-cell activating factor 
(BAFF)), and is involved specifically in activation of p52/ RelB heterodimer 
activation (which is central in B- and T-cell organ development). Upon stimuli 
binding NF-kB-inducing kinase (NIK) is activated, which phosphorylates 
specific serine residues on IKKα. Specific serine residues present on p52’s 
precursor p100 are phosphorylated leading to release of the mature p52/ RelB 
heterodimer and subsequent gene transcription [179]. 
1.7.2 NF-κB and liver fibrosis 
 
As highlighted earlier liver fibrosis development is a result of chronic 
inflammation and the wound healing response, experimental models have 
shown that elevated NF-κB levels are found in a variety of hepatic cell types 
[180, 181]. Kupffer cells exhibit high levels of NF-κB activity in response to 
continued liver insult and as a result secrete a range of pro-inflammatory 
cytokines including TNFα and IL-6 that perpetuate fibrosis development [182]. 
NF-κB activation is also important in HSC transdifferentation to hepatic 
myofibroblasts (central in fibrosis development). Specifically NF-κB is 
associated with promoting hepatic myofibroblast survival and preventing their 
apoptosis [183, 184]. 
 
1.8 Study objectives 
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Research over the previous thirty years has recognised the central role of the 
HSC in hepatic fibrosis development and perpetuation [185, 186]. A number 
of routes and pathways have been identified to target potential anti-fibrotic 
agents to (e.g. inducing hepatic myofibroblast apoptosis and preventing initial 
HSC activation) [72, 76, 90, 93]. A relatively unstudied target except for work 
within this laboratory is the PXR, whose anti-inflammatory potential has been 
highlighted in other chronic diseases including IBD [166, 170]. 
A fundamental issue in the development of a clinically available anti-fibrotic 
agent is the lack of a suitable non-invasive imaging modality to accurately 
quantify hepatic fibrosis at all stages of disease progression. 
Another area of interest is that the stimulus responsible for activation and 
transdifferentation of HSCs remains elusive. This may be due to the complex 
interaction between wound healing and inflammatory pathways after liver 
injury, highlighted by the numerous inflammatory cytokines and mediators 
released after initial liver injury [39, 40]. It has been suggested the stimulus 
may arise from a subset of hepatic myofibroblasts themselves, which I intend 
to investigate further [3]. 
Recognising the central role of hepatic myofibroblasts in the development of 
liver fibrosis, the first hypothesis is that their number is an indicator of fibrosis 
severity. Secondly we hypothesise that hepatic myofibroblasts are pro-
inflammatory and will therefore perpetuate fibrosis development following 
hepatic myofibroblast formation. Finally in addition to their anti-fibrotic traits 
we hypothesise that PXR agonists also possess beneficial anti-inflammatory 
properties decreasing NF-κB activity. 
 
The specific initial aims of this study are to: - 
 
 Determine whether the hepatic myofibroblast specific scAb C1-3 can 
be used as a non-invasive imaging agent for liver fibrosis in vivo when 
conjugated to a fluorescent tag. 
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 Investigate synaptophysin expression of both quiescent and activated 
HSCs and to confirm C1-3’s affinity for synaptophysin expressed on 
their surface. 
 
 Investigate the anti-inflammatory potential of the PXR agonist PCN in 
both an acute and chronic animal model of liver fibrosis. 
 
 Determine whether hepatic myofibroblasts are pro-inflammatory in vitro 
by co-culturing them with a NF-κB luciferase responsive monocyte cell 
line. Secondly in vivo, inject hepatic myofibroblasts directly into NF-κB 
luciferase mice and calculate their inflammatory properties from the 
optical images. 
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2.1 Materials  
 
Materials were purchased from Sigma-Aldrich (Poole, Dorset) unless stated 
otherwise. 
 
2.2 Animals 
 
2.2.1 Ethics  
 
All animal work was carried out adhering to Home Office regulations as 
outlined in both the project license (PPL 60/3907) and personal license (PIL 
60/12677). Protocols were individually designed for each study and the senior 
animal technician consulted before the study commenced. 
 
2.2.2 Housing 
 
Rats and mice were housed separately in the Comparative Biology Centre 
(CBC) at Newcastle University. Specifically they were housed in an air 
conditioned environment with a 12 hour light dark cycle, regulated 
temperature (20 oC ± 3 oC) and humidity (50% ± 10%). 
3x-ĸB-luc C57BL/6J x CBA/J (NF-κB luciferase) mice were also housed in 
regulated conditions in the animal unit at the University of Oslo or in the CBC, 
and all experiments were performed according to the national guidelines for 
animal welfare. 
 
2.2.3 C57B1/6 (wildtype) mice 
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Mice were purchased from Charles-River (Margate, UK) and housed as 
outlined in 2.2.2 and cared for as outlined in the Home Office licenses. All 
mice were at least 8 weeks of age before use in any studies. 
 
2.2.4 3x-ĸB-luc C57BL/6J x CBA/J (NF-ĸB luciferase) mice 
 
In the PXR study, NF-ĸB luciferase mice [187] were kindly provided by Dr 
Harald Carlsen (University of Oslo, Norway). In the later C1-3/ C1-3-GTX and 
hepatic myofibroblast studies carried out at the CBC in Newcastle (section  
6.5), NF-ĸB luciferase mice were bred in house after revival and fertilisation of 
zygotes purchased from Charles-River. All mice were a minimum of 8 weeks 
of age before use in any studies. 
 
2.2.5 Sprague-Dawley rats 
 
Male Sprague-Dawley rats were purchased from Charles-River and housed 
as outlined in 2.2.2, rats were approximately 250-300g in bodyweight when 
studies began. 
 
2.2.6 Dosing solutions  
 
The concentration, volumes and administration routes of all compounds 
administered to mice and rats are listed in Table 2.1. 
Solution Concentration Amount dosed Route 
CCl4 1:3 (CCl4: olive oil) 1.5ml/kg 
bodyweight 
i.p. injection 
Olive oil Olive oil only (control) 1.5ml/kg 
bodyweight 
i.p. injection 
PCN 50mg/ml in 1:3 (CCl4: 
olive oil) 
2ml/kg bodyweight i.p. injection 
PCN 50mg/ml in olive oil  2ml/kg bodyweight i.p. injection 
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C1-3 1mg/ml in 1 xPBS 20ml/kg bodyweight i.p. injection 
C1-3-GTX 0.5mg/ml in 1 xPBS 40ml/kg bodyweight i.p. injection 
C1-3-750 1mg/ml in 1 x PBS 20ml/kg bodyweight i.p. & i.v. 
injection 
D-luciferin 15mg/ml in 1 xPBS 10ml/kg bodyweight i.p. injection 
Hepatic 
myofibroblasts 
1 x10
6
 (NF-κB 
luciferase) cells/ml in 1 x 
PBS 
10ml/kg bodyweight i.v. injection 
(tailvein) 
Kidney 
fibroblasts 
1 x10
6
 (NF-κB 
luciferase) cells/ml in 1 x 
PBS 
10ml/kg bodyweight i.v. injection 
(tailvein) 
Latex beads Sigma (1.0µM, L2778) 2.5ml/kg 
bodyweight 
i.v. injection 
(tailvein) 
Table 2.1 – In vivo dosing solutions  
 
2.3 Cell culture 
 
2.3.1 Primary human HSCs (hHSCs) 
 
Cells were isolated from human liver resection tissue samples following a 
collagenase/ pronase digestion method as outlined previously [90, 188]. 
Ethical approval for the use of human tissue was obtained from the Newcastle 
and North Tyneside Local Regional Ethical Committee 2, and was subject to 
informed patient consent. 
Briefly the liver was perfused with calcium free Hanks Balanced Salt Solution 
(HBSS-) (NaCl, 80 g/L; KCl, 4 g/L; glucose, 10 g/L; KH2PO4 600 mg/L; 
Na2HPO4 475 mg/L and phenol red, 170 mg/L) supplemented with 6mM 
Hepes and 0.035% (w/v) NaHCO3 manually to flush blood out of the liver. The 
liver was then perfused with HBSS+ (composed as above but with the 
addition of 1mM CaCl2) supplemented with 235mg of pronase (Roche) and 
30mg of Collagenase B (Roche) until it was malleable to touch. At this point 
the tissue was diced and filtered through 125µm nybolt mesh with HBSS+ 
washes and the flowthrough aliquoted into 50ml falcons. 1mg of DNase was 
added per falcon prior to centrifugation at 2000rpm for 7 minutes. The cell 
pellet was resuspended in 50ml of HBSS+ containing 1mg of DNase and 
washed a further two times in the same way. Following the final wash the cell 
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pellet was resuspended in 13ml of optiprep, 2mg of DNase and 60ml of 
HBSS+. 2ml of HBSS+ was carefully overlaid onto the mixture prior to density 
gradient centrifugation at 4000rpm for 20 minutes. The lipid rich HSC phase 
was visible at the top of the falcon and was removed prior to mixing with an 
excess of HBSS+ (at least 3:1 excess) before centrifugation at 2000rpm for 7 
minutes. The HSC cell pellet was resuspended in HSC media and seeded out 
in 6 well plates as desired. 
HSCs were grown in Dulbecco’s Modified Eagle Media (DMEM) with 4.5g/L 
glucose, 110mg/L sodium pyruvate, and 110mg/L sodium bicarbonate, 
supplemented with 20% (v/v) fetal calf serum (FCS), 10mg/L penicillin/ 
streptomycin and 2mM L-glutamine. Cells were incubated in a humidified 
atmosphere at 37 oC and 5% CO2. 
 
2.3.2 Primary mouse and rat HSCs 
 
Mouse and rat HSCs were isolated by an essentially identical method to that 
used in 2.3.1 for hHSC isolation. The only difference being the scaling down 
of the pronase and collagenase B as necessary, determined on the number of 
mice/ rat livers to be digested. The cells were cultured in identical media and 
conditions to that of hHSCs. 
 
2.3.3 LX-2 cells (human myofibroblast cell line) 
 
LX-2 cells were kindly provided by Professor Scott Friedman (Mount Sinai 
School of Medicine, New York) and were grown in DMEM with 4.5g/L glucose, 
110mg/L sodium pyruvate, and 110mg/L sodium bicarbonate, supplemented 
with 10% (v/v) FCS, 10mg/L penicillin/ streptomycin and 2mM L-glutamine. 
Cells were incubated at 37 oC and 5% CO2. 
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2.3.4 Cos7 cells  
 
Cos7 cells were grown in DMEM with 4.5g/L glucose, 110mg/L sodium 
pyruvate, and 110mg/L sodium bicarbonate, supplemented with 10% (v/v) 
FCS, 10mg/L penicillin/ streptomycin and 2mM L-glutamine. Cells were 
incubated at 37 oC and 5% CO2. 
 
2.3.5 U937-NF-κB cells (human monocytic cell line stably transfected 
with luciferase reporter gene under the control of 3 x NF-ĸB response 
elements) 
 
U937-NF-κB cells  are stably transfected with 3 copies of NF-ĸB response 
elements and were generously donated by Dr Harald Carlsen (University of 
Oslo, Norway) and grown in RPMI-1640 media (25mM Hepes and 25mM 
sodium bicarbonate) (Sigma) supplemented with 10% (v/v) FCS, 10mg/L 
penicillin/ streptomycin, 2mM L-glutamine and 150µg/ml Hygromycin B. 
Incubated at 37 oC with 5% CO2, U937-NF-κB cells are a non-adherent cell 
line so trypsination was not required when passaging. 
Untransfected U937 cells were also purchased from the European Collection 
of Cell Cultures (ECACC). They were cultured in identical media except the 
lack of selective antibiotic Hygromycin B. 
 
2.3.6 Cell passage 
 
All the cell lines cultured with the exception of the U937 and U937-NF-κB cells 
were adherent and were routinely grown as a monolayer to approximately 75-
100% confluence before passaging. Initially the media was aspirated from the 
cells prior to two brief washes in 1 x PBS (approximately 10mls – T75 and 1ml 
per well of a 6 well plate). Cells were then incubated with Trypsin-EDTA 
diluted accordingly (dependent upon cell type) in 1 x PBS (approximately 3mls 
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– T75 and 0.5ml per well of a 6 well plate) in identical conditions listed in 2.3.1 
for between 5-15 minutes. At random intervals during this incubation the 
detachment of the cells from the culture vessel was encouraged by gentle 
tapping. Once detachment was confirmed by light microscopy, Trypsin-EDTA 
activity was inhibited by the addition of an excess of serum containing media. 
The Trypsin-EDTA/ cell mixture was then transferred to a sterile 50ml falcon 
tube prior to centrifugation (typically at 2000rpm for most cell types) for 5 
minutes. The supernatant was aspirated off prior to resuspension of the cell 
pellet in fresh media, before seeding the cells as desired for experiments or 
cell maintenance. 
 
2.3.7 Cell storage 
 
Cell lines were routinely frozen down both in liquid nitrogen (LqN2) and at – 80 
oC when no longer required or for stock lines. Cells were detached as outlined 
in 2.3.6, but the cell pellet was resuspended in a small volume of media 
(typically 1-2ml for a T75 flask). This was then diluted 1:1 with freezing media 
(90% (v/v) FCS/ 10% (v/v) DMSO) before aliquoting into sterile cryovials 
(approximately 1.5ml per cryovial). The cryovials were then placed into a 
Nalgene® Mr. Frosty® Cryo 1°C Freezing Container containing isopropanol 
and left at – 80 oC overnight. This cools the cells at a rate of approximately 1 
oC per hour. The following day some cryovials were placed in LqN2 whilst the 
rest were left at – 80 oC. 
 
2.3.8 Cell revival  
 
Cell lines were removed from the – 80 oC or LqN2 and rapidly thawed at 37 
oC 
in a waterbath, resuspended in 30ml freshly warmed media and centrifuged at 
600rpm for 5 minutes. The supernatant was then discarded and the cell pellet 
resuspended in 5mls of fresh media, which was aliquoted between 2 wells of 
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a 6 well plate. The cells were left to attach overnight and the following 
morning the media was replaced. 
 
2.3.9 Cell viability and number 
 
The viability of cells was determined by their ability to exclude trypan blue. 
This was particularly important for counting the non adherent U937 and U937-
NF-κB cells. Typically a fixed volume of cells (normally 50µl) was added to an 
equal volume of 0.4% (w/v) trypan blue solution. This mixture was then 
pipetted into a haemocytometer and the number of viable live cells was 
determined by those that had not excluded the trypan blue. As the area of the 
haemocytometer and the volume of cell suspension are known, the number 
and percentage of viable cells can be calculated. 
 
2.3.10 U937-NF-κB cells co-culture with LX-2 and hHSCs 
 
hHSCs or LX-2 cells were grown to approximately 50% confluence in 6 well 
plates. The media was then aspirated and the cells washed three times with 1 
x PBS, prior to addition of 1x105 U937-NF-κB cells in 1.5ml of RPMI-1640 
media per well. 1x105 U937-NF-κB cells were also added to wells not 
containing any cells, which acted as controls. At this point any treatments 
were also added (e.g. LPS 300ng/µl, see table 2.2 for a full list of treatments 
and final concentrations). The co-culture was incubated as outlined in 2.3.1 
for 6 hours, before centrifugation of the U937-NF-κB cells at 13,000rpm for 5 
minutes to isolate the cell pellet. Each individual cell pellet was resuspended 
in 100µl of 1 x passive lysis buffer (1 x PLB) (Promega) diluted in distilled 
water, prior to luciferase activity determination. 
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2.3.11 LX-2 and hHSC conditioned media and its treatments 
 
LX-2 cells or hHSCs were washed three times in sterile 1 x PBS before being 
cultured in U937 media (RPMI-1640) for 48 hours, typically the LX-2/ hHSC 
cells were approximately 50% confluent at the start of the 48 hour incubation. 
The media was removed and centrifuged at 2000rpm to remove any cell 
debris and the supernatant was stored at 4 oC short term or -20 oC long term 
before the incubation with U937-NF-κB cells with further treatment when 
required. 
To determine the identity of the soluble factor present in the LX-2/ hHSC 
conditioned media, a number of treatments were performed prior to the 
resuspension of U937-NF-κB cells. A full list of these treatments is shown in 
table 2.3. 
 
Treatment (final concentration) Theory (reference) 
LPS 055:B5 (300ng/µl) Positive control known to induce NF-κB activity 
in U937-NF-κB cells ([175]) 
TNFα (10ng/µl) 
 
Pro-inflammatory cytokine - positive control 
shown to induce NF-κB activity in U937-NF-κB 
cells ([175]) 
IL-6 (10ng/µl) Pro-inflammatory cytokine produced by hepatic 
myofibroblasts ([189] and Table 6.1) 
IL-8 (10ng/µl) 
 
Pro-inflammatory cytokine produced by hepatic 
myofibroblasts (Table 6.1) 
IL-1α (10ng/µl) 
 
Expressed at high levels following liver injury 
and known to be pro-inflammatory ([190, 191])  
IL-1β (10ng/µl) 
 
Expressed at high levels following liver injury 
and known to be pro-inflammatory ([190, 191]) 
IL-1RA (10ng/µl) 
 
Expressed at high levels following liver injury 
and known to be pro-inflammatory ([190, 191]) 
Serotonin (1µM) 
 
hHSCs express serotonin receptors and treatment 
with serotonin antagonists anti-fibrogenic ([192]) 
TIMP-1 (10ng/µl) 
 
Important regulator of ECM deposition & 
prevention of myofibroblast apoptosis ([57, 193]) 
Angiotensin II (10ng/µl) 
 
Known to promote hepatic myofibroblast 
survival by inhibition of NF-κB degradation 
([194]) 
Leptin (1µg/ml) 
 
Leptin expression confined to activated HSCs & 
has a pro-fibrogenic effect ([195, 196]) 
IP-10 (50ng/µl) IP-10 levels correlate with liver inflammation 
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 and fibrosis ([197]) 
MCP-1 (10ng/µl) 
 
MCP-1 important in monocyte recruitment 
during liver fibrosis development ([198, 199]) 
MIP-1α (100ng/µl) 
 
MIP-1α is pro-inflammatory chemokine involved 
in T-cell recruitment and fibrosis progression 
([200]) 
CXCL12 (10ng/µl) 
 
CXCL12 chemokine is up-regulated in regions of 
liver fibrosis in HCV patients ([201]) 
Hydrogen peroxide (10mM - 
1µM) 
Oxidation of fatty acids is a source of ROS 
including H2O2 ([202, 203]) 
Sodium nitroprusside (1mM) 
 
Increased nitric oxide production found during 
hepatic inflammation ([204, 205]) 
OxPAPC (1µg/ml) 
 
TLR4 antagonist to inhibit LPS induced 
inflammation to show LPS isn't being stored and 
re-released by LX-2s ([206]) 
Table 2.2 – U937-NF-κB cells in vitro treatments 
 
Treatment Theory 
 
90 oC incubation Break dipole and Van der Waal bonds - 
disrupting 2
o
/ 3
o
 protein structure 
10 x trypsin-EDTA treatment Protease treatment to hydrolyse proteins 
and peptides present 
Charcoal/ dextran media stripping Adsorb small organic molecules from the 
media (e.g. steroid hormones and 
prostaglandins) 
Separation organic/ aqueous phases Separate organic (e.g. phospholipids, 
lipids) and aqueous phase to see if soluble 
factor is retained specifically in a phase 
pH 1/ 13 incubation Determine the effect of extreme variation 
in pH on soluble factor function 
PD-10 filtration Sepharose gel column so larger molecules 
are eluted earlier as they can't diffuse  
into the column bed 
Table 2.3 – Treatments to 48 hour LX-2 conditioned media  
 
2.4 Cell transfection 
 
2.4.1 Transfection using GeneJuice reagent (Merck) 
 
Cos7 and U937 cells were transfected as outlined in the manufacturers’ 
guidelines, under the standard conditions listed in 2.3.1. Typically adherent 
cells were approximately 60-70% confluent (non adherent cells were seeded 
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at 1x106 cells/ml) to ensure the cells were undergoing cell division at the time 
of transfection. In all instances the cells were suspended in 3ml of serum 
containing media per well, and for each well to be transfected 100µl of serum 
free media was mixed with 3µl of GeneJuice (Merck) and incubated at room 
temperature for 5 minutes. 1µg of plasmid DNA for each well was 
subsequently added and mixed by gentle pipetting, before further incubation 
at room temperature for 15 minutes. The GeneJuice/ DNA mixture 
(approximately 105µl per well) was added dropwise to the centre of the well 
and mixed by gentle rocking. The cell transfection mixture was incubated 
overnight and replaced with fresh media the following morning. The cells were 
left for a further 24 hours before harvesting for analysis or addition of 
antibiotics to select for transfected cells. 
 
2.4.2 Transfection using polyethylenimine (PEI) (Polysciences Inc.) 
 
Cell lines were seeded at the same densities as outlined in 2.4.1, containing a 
total of 1ml of serum containing media per well. For each well of a 6 well 
plate, 10µl of PEI (1mg/ml in 20 mM HEPES, pH 7.5) and 1µg of plasmid DNA 
was added to 1ml of serum free media prior to vortexing and incubation for 30 
minutes at room temperature. The whole mixture (approximately 111µl) was 
then added dropwise to the centre of each well before incubation as outlined 
in 2.4.1 and subsequent harvesting or treatment. 
 
2.4.3 Determination of transfection efficiency 
 
Alongside the transfection of the desired plasmid DNA, control cells were also 
transfected with varying concentrations of enhanced Green Fluorescent 
Protein (eGFP) peGFP-N1 plasmid DNA. The number of GFP positive cells 
was determined by fluorescent microscopy and expressed as a percentage of 
the total number of cells per field of view (normally at least 10 fields of view 
were counted per well). 
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2.5 Plasmid DNA constructs 
 
2.5.1 Transformation of TOP10 competent cells (Invitrogen) 
 
Upon thawing on ice, 2µl of plasmid DNA was added to the TOP10 cells and 
mixed by gentle pipetting. The plasmid cell mixture was left to incubate on ice 
for 30 minutes; following this the cells were heat shocked at 42 oC for thirty 
seconds before a second incubation on ice for five minutes. 250µl of SOC 
media (2% tryptone, 0.5% yeast extract, 10 mM sodium chloride, 2.5 mM 
potassium chloride, 10 mM magnesium chloride, 10 mM magnesium sulphate 
and 20 mM glucose) was added prior to incubation at 37 oC and 250rpm for 
one hour. Finally a small volume (i.e. 10-50µl of each plasmid was streaked 
out on selective agar plates (e.g. 100µg/ml ampicillin) and grown overnight at 
37 oC. 
The following morning a single colony was selected and incubated in 5ml of 
Luria-Bertani media (LB media) (5g/L yeast extract, 10g/L tryptone and 10g/L 
sodium chloride) containing the desired selective antibiotic and grown up at 
37 oC and 250rpm for 8 hours. The culture could then be further used for large 
scale plasmid expression or frozen down for storage as described in 2.5.2. 
 
2.5.2 Storage of DNA plasmids 
 
All constructs were stored long-term as bacterial glycerol stocks by mixing 
500µl of the final culture from 2.5.1 with an equal volume of LB media 
(containing 30% (v/v) glycerol) in a cryovial followed by freezing at – 80 oC. 
The stocks could be streaked out directly onto selective agar plates as 
described in 2.5.1 when further plasmid DNA was required. The plasmid DNA 
could then be purified by either a miniprep (2.5.3) or maxiprep (2.5.4) 
procedure dependent upon the bacterial scale of expression. 
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2.5.3 Miniprep purification of plasmid DNA 
 
The QIAprep® Miniprep system (Qiagen) is designed to rapidly purify plasmid 
DNA in small quantities (up to 20µg of DNA). The principle is based upon the 
alkaline lysis of bacterial cells followed by the adsorption of the DNA onto the 
silica columns at high salt concentrations [207]. 
The manufacturer’s guidelines were followed; briefly the bacterial pellet was 
isolated by centrifugation at 13,000rpm for 5 minutes, this pellet was 
resuspended in 250µl of Buffer P1 (containing RNase) and transferred to an 
RNase free eppendorf. 250µl of Buffer P2 (high salt) was added and mixed by 
inverting the tube six times, 350µl of Buffer N3 was added and again mixed 
immediately by inversion. This solution was centrifuged at 13,000rpm for 10 
minutes; the supernatant is applied to the QIAprep spin column which was 
centrifuged for a further minute. After discarding the flow-through the column 
was washed with 750µl of Buffer PE and centrifuged for one minute, the flow-
through was discarded once more and the column was centrifuged for a 
further minute to remove any residual buffer. Finally the QIAprep spin column 
was placed in an RNase free eppendorf, to elute the plasmid DNA 50µl sterile 
water was added to the column. This was allowed to stand for a minute prior 
to centrifugation for a final minute; the eluted DNA was quantified as outlined 
in 2.6.3. 
 
2.5.4 Maxiprep purification of plasmid DNA 
 
The Qiagen Maxiprep kit purification of plasmid DNA is based upon the same 
principle as that of the Miniprep kit, but is simply manufactured to purify larger 
amounts of plasmid DNA (up to a maximum of 500µg). Initially the bacterial 
cell pellet was isolated by centrifuging the bacterial culture at 3500rpm for 10 
minutes at 4 oC. The cell pellet was resuspended in 10ml of Buffer P1 
(containing RNase) by repeated pipetting, 10ml Buffer P2 was added and 
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mixed by inverting the sealed tube 4-6 times and incubated at room 
temperature for 5 minutes. 10ml of chilled Buffer P3 was subsequently added 
and the whole mixture was mixed by 4-6 vigorous inversions prior to 
incubation on ice for 20 minutes. The mixture was then centrifuged at 
6000rpm and 4 oC for 30 minutes. During the centrifugation step a QIAGEN-
tip 500 was equilibrated by the addition of 10ml Buffer QBT. Upon completion 
of the centrifugation step the supernatant was applied to the column and 
allowed to enter the resin by gravity flow. The column was then washed twice 
in 30ml of Buffer QC; all the flow-through was discarded. The DNA was eluted 
from the column by the addition of 15ml of Buffer QF, which was collected in a 
50ml falcon. The DNA was precipitated by the addition of 0.7 volumes 
(10.5ml) of sterile isopropanol, mixed and centrifuged at 6000rpm for 30 
minutes. The supernatant was discarded and the pellet washed in 5ml of 
sterile 100% ethanol and the DNA pelleted by centrifugation at 6000rpm for 
15 minutes. Finally the ethanol was removed and the pellet dried briefly for 5 
minutes before resuspension of the DNA in a suitable volume of RNase free 
water (dependent upon the size of the pellet). The DNA was quantified as 
outlined in 2.6.3. 
 
2.5.5 3xNF-ĸB response element DNA insert construction 
 
The complementary sequences containing the coding sequence for three 
copies of a NF-ĸB response element were firstly denatured by heating at 95 
oC for 10 minutes. The temperature was then reduced by 1 oC every minute 
from 95 oC down to 50 oC to ensure the complementary sequences annealed 
successfully (see results 3.4.3 for the complete 3xNF-ĸB insert sequence). 
 
2.5.6 Restriction digests of plasmid DNA 
 
Restriction digests were performed following the manufacturers’ guidelines 
(Promega, UK) typically using 1µg (1µl) of plasmid DNA. The reaction mixture 
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was composed of 16.3µl of sterile water, 2µl of 10 x reaction buffer 
(dependent on compatibility with specific restriction enzyme), 0.2µl of 
acetylated BSA (10µg/µl) and 1µl of plasmid DNA (1µg/µl). 0.5µl restriction 
enzyme was added at the last instance and mixed by gentle pipetting before 
incubation at 37 oC for 4 hours. A sample in which no restriction enzyme was 
added was also incubated as a negative control; both samples were run out 
on an agarose gel as described in 2.6.8 to determine if the restriction digest 
had generated DNA fragments of the desired size. 
 
2.5.7 Gel extraction of DNA samples 
 
The DNA fragment of interest was excised from the gel using a clean sharp 
scalpel and placed in a DNase/ RNase free eppendorf. The DNA was purified 
using a gel extraction kit (Qiagen). Firstly the gel fragment was resuspended 
in 3 volumes of Buffer QG (i.e. 100mg gel = 300µl of buffer QG), this was 
heated at 50 oC for 10 minutes until the agarose was fully dissolved. One 
volume of sterile isopropanol was added (100mg gel = 100µl isopropanol). 
The sample was applied to the QIAquick spin column, and centrifuged for one 
minute at 13,000rpm, discarding the flow through. 0.75ml of Buffer PE was 
added to the QIAquick spin column and centrifuged for a further minute to 
wash the bound DNA. The flow through was discarded once more and the 
column centrifuged for another minute to remove any residual Buffer PE. 
Finally the column was placed into a sterile DNase/ RNase free eppendorf 
and the DNA eluted by adding 30µl sterile water to the centre of the QIAquick 
membrane. The column was left to stand for one minute before centrifuging 
for a final minute at 13,000rpm. 
The amount of DNA collected in the eppendorf was quantified as before in 
2.6.3. 
 
2.5.8 T4 DNA ligation of DNA plasmid and insert 
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T4 DNA ligase (Promega) was used to ligate the NF-κB insert (section 2.5.5) 
into the linearised plasmid DNA. The insert encodes the same ‘sticky ends’ 
(restriction site sequences) at its ends as those used to restrict the plasmid 
DNA. A range of molar ratios (1:1, 3:1 and 1:3) of plasmid to insert DNA were 
used in the ligation reaction using 100ng of plasmid DNA. A 10µl reaction 
volume was used composed of 100ng plasmid DNA, a calculated volume of 
insert DNA (dependent on the molar ratio used), 1µl of 10 x ligase buffer, and 
0.5µl of T4 DNA ligase made up to 10µl with sterile water. The reaction was 
incubated at 15 oC for at least 4 hours. 
 
2.6 RNA and DNA isolation/ quantification 
 
2.6.1 RNA isolation 
 
Total RNA was isolated following a guanidium thiocyanate-phenol-chloroform 
extraction protocol using TRIzol reagent (Invitrogen, UK) [208]. A tissue 
sample was resuspended in 1ml of TRIzol and homogenised manually in an 
RNase/ DNase free eppendorf. Alternatively cells were washed in sterile 1 x 
PBS and 1ml of TRIzol was added per well of a 6 well plate and placed on a 
rotating plate mixer at 250rpm for 5 minutes before being transferred to an 
RNase/ DNase free eppendorf. 200µl of chloroform was added to the TRIzol 
and vortexed briefly prior to centrifugation at 13,000rpm and 4 oC for 15 
minutes. The upper aqueous layer containing the RNA was removed and 
transferred to a fresh eppendorf, then 500µl chilled sterile isopropanol was 
added and the mixture incubated on ice for 20 minutes; before centrifugation 
at 13,000rpm and 4 oC for 10 minutes. The supernatant was discarded and 
the RNA pellet washed in 500µl 70% (v/v) ethanol (diluted in sterile water) 
before a final ten minute centrifugation step at 13,000rpm and 4 oC. Finally 
following removal of the 70% ethanol the RNA pellet was resuspended in a 
small volume (typically 10-30µl) of nuclease free water dependent upon the 
pellet size. The purified RNA was quantified as outlined in 2.6.3. 
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2.6.2 DNA isolation  
 
Cells were washed in sterile 1 x PBS, before detachment by scraping into 
sterile 1 x PBS. The cell pellet (typically 5-20 x 106 cells) was isolated by 
centrifugation and the 1 x PBS was discarded and the pellet resuspended in 
200µl of genomic DNA preparation buffer (50mM Tris, 10mM sodium chloride, 
10mM EDTA and 0.5% NP-40,  pH 8). For genotyping, ear notches from mice 
were collected in an RNase/ DNase free eppendorf and resuspended in 200µl 
of genomic DNA preparation buffer as above. 20µl of Proteinase K solution 
(20mg/ml) (Qiagen) was added and the mixture was incubated at 55 oC for a 
minimum of 4 hours – overnight with occasional mixing. The following morning 
50µg of RNase A was added to each sample and incubated at room 
temperature for 20 minutes. 1 volume (200µl) of phenol/ chloroform/ isoamyl 
alcohol (25/24/1 v/v/v) was added, vortexed and centrifuged briefly. The upper 
aqueous phase was carefully removed (~200µl) to a fresh RNase/ DNase free 
eppendorf, prior to the addition 0.1 volumes (20µl) of 3M sodium acetate, pH 
5.2. 2 volumes (500µl) of chilled 100% ethanol was added prior to incubation 
at – 80 oC for one hour; following this, the DNA was isolated by centrifugation 
at 13,000rpm for 10 minutes and 4 oC. The supernatant was discarded and 
the pellet dislodged and washed in 500µl of chilled 70% ethanol before 
incubation at – 80 oC for a further hour. After a final centrifugation step at 
13,000rpm and 4 oC for 10 minutes the supernatant was discarded and the 
pellet air dried briefly before resuspension in a suitable volume of sterile water 
(typically 10-50µl dependent on pellet size). The purified DNA was quantified 
as outlined in 2.6.3. 
 
2.6.3 RNA/ DNA quantification 
 
RNA and DNA were both quantified at 260nm. The relative purity of RNA/ 
DNA was determined by calculating the 260/ 280 ratio. 2µl of RNA/ DNA was 
Chapter 2.0 – Materials and Methods 
54 
 
diluted in 198µl sterile water and transferred to a quartz cuvette, the 
absorbance of samples was measured at both 260 and 280nm, using 200µl of 
sterile water as a control to account for the background absorbance. The DNA 
concentration was calculated knowing an absorbance of 1.0 at 260nm was 
equivalent to a DNA concentration of 20µg/ml; for RNA an absorbance of 1.0 
at 260nm was equivalent to an RNA concentration of 25µg/ml. 
The purity of DNA was assessed with pure DNA having a 260/ 280 ratio of 
approximately 1.80, ratios nearer 1.60 indicate protein contamination whilst 
nearer 2.0 indicate RNA contamination. Pure RNA has a 260/ 280 ratio of 2.1 
so any reading significantly lower than 2.0 suggests DNA and protein 
contamination [209, 210]. 
 
2.6.4 DNase treatment of RNA 
 
RNA was treated with RQ1 (RNA-Qualified) RNase-Free DNase, which is a 
DNase I endonuclease (Promega) that degrades both double-stranded and 
single-stranded DNA whilst not affecting RNA integrity. Typically RNA was 
resuspended in 30-50µl sterile water; if 30µl was used, 0.1 volumes of RQ1 
10x DNase I and 0.1 volumes of DNase I were added to each RNA sample 
(i.e. 3µl of each). The sample was mixed by gentle pipetting and incubated at 
37 oC for 30 minutes; the reaction was terminated by the addition of 0.1 
volumes (3µl) of RQ1 DNase stop solution and incubation at 65 oC for a 
further 10 minutes. An aliquot of the RNA was quantified as outlined in 2.6.3 
to determine sufficient purity for future use. 
 
2.6.5 Reverse transcription 
 
Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) is an 
RNA-dependent DNA polymerase (Promega) that can be used in 
complementary DNA (cDNA) synthesis with long messenger RNA templates. 
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RNA samples were diluted to 200ng/µl with nuclease free water; 1µl of 
50ng/µl Random Primers (Promega) was added to 800ng of RNA (i.e. 4µl of 
200ng/µl RNA) and incubated at 90 oC for three minutes before reducing the 
temperature to 42 oC, and placing the samples on ice. 15µl of reverse 
transcription mastermix was then added to each sample (containing 8µl 
nuclease free water, 2µl 10mM dNTPs, 4µl 5 x M-MLV buffer (50mM Tris-HCl, 
75mM KCl, 3mM MgCl2 and 10mM DTT, pH 8.3) and 1µl M-MLV enzyme). 
The samples were then incubated for a further hour at 42 oC to produce 1st 
strand cDNA and stored at – 20 oC prior to further use. 
 
2.6.6 Polymerase Chain Reaction (PCR) 
 
PCR is a universal technique in molecular biology and is used to amplify 
specific DNA sequences. Generally Go-Taq Green master mix (Promega) 
containing a Taq DNA polymerase was used to amplify DNA; however Pfu 
DNA polymerase (Promega) was also used. Pfu was chosen instead of Go-
Taq in some instances as it has enhanced proofreading capabilities and will 
result in fewer base misinsertions and more accurate DNA amplification. 
PCR reaction conditions were optimised for each individual primer set (see 
table 2.4), always with the same reaction volume, as follows: - 
 
Go-Taq Green – the PCR mastermix was composed of 10µl 2 x Go-Taq 
green master mix, 6µl of nuclease free water and 2µl of each upstream (US) 
and downstream (DS) primer (diluted to 10µM) giving a final concentration of 
1µM per individual sample. 1µl of cDNA was added giving a total volume of 
21µl in each PCR tube. 
 
Pfu – the PCR mastermix was composed of 5µl of 10 x Pfu buffer (200mM 
Tris-HCl, 100mM KCl, 100mM (NH4)2SO4, 20mM MgSO4, 1.0% Triton® X-100 
and 1mg/ml nuclease-free BSA, pH 8.8), 1µl of 10mM dNTPs, 4µl of each US 
and DS primer (10µM), 30.3µl of nuclease free water and finally 0.7µl of Pfu 
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enzyme. 5µl of cDNA was added giving a total volume of 50µl in each 
reaction. 
 
Each PCR reaction was performed using a programmed benchtop 
thermocycler (Px2 Thermal Cycler, Thermo Scientific). 
 
Typically a PCR run consisted of: - 
 
Initial denaturation step at 90 oC for 3 minutes. 
 
35 cycles consisting of 
 
Denature – 90 oC for 1 minute. 
Anneal – X oC for 1 minute. (Optimised for each primer set ~55 oC) 
Elongate – 73 oC for 1 minute 30 seconds. 
 
Final elongation step at 73 oC for 8 minutes. 
 
PCR products were stored at 4 oC for short term periods or – 20 oC long term. 
 
2.6.7 PCR primer design 
 
As shown in table 2.4 multiple primer sequences were designed to specifically 
amplify desired DNA sequences. DNA sequences were obtained from the 
NCBI database (www.ncbi.nlm.nih.gov). The Primer-BLAST program was 
then used to derive the primer sequences specific for the transcript and avoid 
the likelihood of primer dimer formation. The general rules for primer design 
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are that the G & C content of each primer should be similar to ensure the Tm 
values are also similar and that they should contain 40-60% G & C. Primers 
were 18 – 25 bases in length and were not complementary to avoid dimer 
formation. The optimal annealing temperature was determined for each primer 
pair, generally starting around 5 oC below the Tm. 
Oligo ID 5' - 3' sequence 
Annealing 
temperature (
o
C) 
Amplicon 
size (bp) 
LUCIF (US) CCGGAAGCGACCAACGCCTT     
LUCIF (DS) CCGGCGTCATCGTCGGGAAG 58 221 
GAPDH (US) TGACATCAAGAAGGTGGTGAAG 
  GAPDH (DS) TCTTACTCCTTGGAGGCCATGT 42 234 
SYN1 (US) ATGGACGTGGTGAATCAGCTGGT 
  SYN2 (DS) GCCCCCATGGAGTAGAGGAA 62 347 
SYN3 (DS) CATCTGATTGGAGAAGGAGGTGGG   63 924 
SYN4 (DS) GGGTGCATCAAAGTACACTTGG     63 237 
Table 2.4 – DNA oligonucleotide sequences for RT-PCR and PCR genotyping 
 
2.6.8 Agarose gel electrophoresis 
 
This method can be used to separate both DNA and RNA when a charge is 
applied across the gel in an appropriate conducting buffer. The nucleic acids 
will migrate towards the positive electrode due to the negative charge of their 
sugar-phosphate backbone; the distance migrated is governed by the size of 
the fragment, with smaller nucleic acids fragments migrating further. Samples 
were compared against a DNA ladder (New England Biolabs) containing DNA 
fragments of known size, so the size and specificity of bands could be 
determined easily. 
The percentage of agarose used in the gel was dependent on the size of the 
PCR product with a higher percentage gels being used for smaller fragments. 
Typically 1.5% (w/v) agarose in 1 x TAE (Tris acetate EDTA) was heated in 
the microwave until the agarose was fully melted. When it had cooled 
sufficiently, ethidium bromide (EtBr) (2µl EtBr (10mg/ml) per 100ml of 
agarose) was added and mixed. EtBr is an intercalating agent binding to 
nucleic acids, and upon exposure to UV light fluoresces allowing the 
visualisation of both DNA and RNA. The gel was poured into a casting stand 
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with the well comb in the place to form the wells for sample loading. When the 
gel had set it was placed into the gel tank and submerged in 1 x TAE. 10µl of 
each amplified PCR product (diluted 1:0.5 with 6 x loading dye) was loaded 
alongside 6µl of 100bp DNA ladder (New England Biolabs). The gel was 
typically run at 80V for an hour, approximately 4-5V/cm agarose gel, and was 
visualised by UV transillumination using an Alpha Innotech fluorescent 
imaging system and the supplied Fluorchem software. 
 
2.6.9 Quantitative real-time PCR (qRT-PCR) 
 
cDNA samples were diluted 1:4 to 10ng/µl, 1µl was then added to each well of 
a 96 well plate (Applied Biosystems, Warrington, UK), and each sample was 
loaded in triplicate. 12µl of SYBR green mastermix was added to each well in 
turn (consisting of 3.5µl DNase free water, 6.5µl 2x SYBR green mastermix 
and 2µl US and DS primers (250nm)). The plate was run on an Applied 
Biosystems 7500 Fast Real-Time PCR system machine, after the initial 
denaturation step there were 40 cycles consisting of – 
 
 95 oC for 5 seconds 
 62 oC for 30 seconds 
 72 oC for 1 minute 
 
The level of SYBR Green detected was measured during the cycling step of 
each cycle and the cycle threshold (CT) values were calculated by manually 
applying a threshold limit to represent the exponential phase of amplification. 
SYBR Green binds to double stranded DNA (dsDNA) and fluoresces, this was 
detected at the end of each elongation step giving a value to the amount of 
dsDNA present (demonstrated in Figure 2.1). 
Quantitation of gene expression (e.g. synaptophysin) was calculated relative 
to the endogenous control 18s using the comparative CT method as described 
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in the manufacturer’s RT-PCR guide and as validated by Yuan et al [211]. 
Briefly, the mean and standard deviation (SD) of the CT values were 
calculated for 18s and the target gene. The ΔCT was calculated by subtracting 
the 18s CT from the target gene CT. The SD for the ΔCT was calculated as 
follows: SD= (SD1
2 + SD2
2)1/2 where SD1/2 is the SD of 18S and the target 
gene. The ΔΔCT was calculated by subtracting the average ΔCT of the 
designated control (e.g. mouse brain) from the ΔCT of the remaining values. 
The fold change relative to the designated control was calculated using the 
following equation: fold change = 2-ΔΔCT with SD range calculated by SD plus 
= (2-ΔΔCT-SD) – Fold change and SD minus = Fold change - (2-ΔΔCT+SD). 
 
Figure 2.1 Diagram of SYBR Green qRT-PCR reaction. Firstly the DNA was denatured by heating 
at 90 
o
C; the primers were annealed and result in production of complementary dsDNA. SYBR green 
dye binds to freshly produced dsDNA and fluoresces. The level of fluorescence is detected at the end 
of each cycling stage and can be used to calculate variations in the level of target gene present.  
 
2.7 Protein isolation and quantification 
 
2.7.1 Preparation of whole tissue samples 
 
Tissue samples from mice and rats were snap frozen in LqN2, each sample 
was subsequently resuspended in 20% (w/v) TKMS buffer (50mM Tris, 25mM 
potassium chloride, 5mM magnesium chloride and 250mM sucrose). If 
necessary the sample was also sonicated briefly. The homogenised samples 
were aliquoted and stored at -20 oC short term or -80 oC long term. 5µl of 
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protein sample was required for quantification of total protein by the Lowry 
method (2.7.3). 
 
2.7.2 Preparation of cell extracts 
 
Media was aspirated off the cells before two quick washes in 1 x PBS, the 
cells were then scraped into 1ml of 1 x PBS. This 1ml of 1 x PBS was 
transferred from each well of a 6 well plate in turn to maximise the amount of 
protein collected. Once transferred to a clean eppendorf the cell pellet was 
isolated by centrifugation at 13,000rpm for 5 minutes. The supernatant was 
removed and the cell pellet resuspended in a suitable volume of 20mM Tris, 
pH 7.4 (typically 30 – 100µl dependent on pellet size). Samples were stored 
as described in 2.7.1; 5µl of protein sample was required for quantification of 
total protein by the Lowry method (2.7.3). 
 
2.7.3 Lowry protein assay 
 
Protein concentration was determined using a version of Lowry protocol 
originally described by Lowry in 1951 [212]. The principle is that under 
alkaline conditions copper complexes with any protein present; when Folin-
phenol reagent is added this copper-protein complex is reduced. The resultant 
colour change can be measured spectrophotometrically at 750nm to 
determine the protein concentration. Therefore unknown protein 
concentrations can be easily determined when measured in parallel with 
samples of known protein concentration (e.g. bovine serum albumin (BSA)). 
This can be extrapolated on a simple graph of protein concentration versus 
absorbance, utilising the equation y = mx + c. 
BSA protein standards were prepared ranging from 0 - 20µg/ml, Buffer ABC 
was prepared fresh each time, composed of 1 x Lowry A (2% (w/v) Na2CO3/ 
4% (w/v) NaOH), B (2% (w/v) sodium tartrate), C (1% (w/v) copper sulphate) 
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mixed at a ratio of 100:1:1 (v/v/v). 5µl of each BSA standard or unknown 
protein sample was placed into an individually labelled eppendorf and further 
diluted with 50µl of distilled water and 1ml of buffer ABC. After incubation for 
10 minutes at room temperature 100µl of Folins reagent (diluted 1:1 with 
distilled water) was added and incubated for a minimum of 25 minutes to 
allow colour development. Samples were transferred to individual plastic 
cuvettes prior to absorbance determination at 750nm by spectrophotometric 
analysis using the 0µg/ml BSA standard as the background absorbance. A 
calibration curve was generated using the BSA standards. 
 
2.7.4 Sodium-dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
 
SDS-PAGE analysis is an invaluable technique first described by Laemmli in 
1970 [213], for analysing proteins based upon their molecular weight. The 
fundamental principle involves the denaturation of proteins by heating in the 
presence of both DL-Dithiothreitol (DTT) (a thiol reducing agent) and SDS (a 
detergent). The combination of all three ensures that the proteins lose all their 
secondary, tertiary and quaternary structures and are linear, with a negative 
charge. Therefore when loaded onto a gel with fixed pore sizes and a current 
is applied they will migrate towards the positive electrode, governed by their 
molecular weight. When run against markers of known molecular weight 
(Colorburst™, Sigma) the molecular weight of unknown protein sample bands 
could be determined. 
Briefly the acrylamide gels were set between glass plates clamped together 
and sealed at the bottom with Vaseline to prevent leaking. The separating gel 
was typically composed of 9% acrylamide (determined by the size of the 
protein of interest), 375mM Tris buffer, pH 8.8, 0.05% (w/v) ammonium 
persulphate (APS), 0.1% (w/v) SDS and 0.05% (v/v) TEMED. A thin layer of 
isopropanol was applied to remove air bubbles and ensure a level interface 
between the stacking and separating gels. The gels generally take 30-45 
minutes to polymerise; upon polymerisation the isopropanol was removed and 
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the gel washed briefly with deionised water before the stacking gel was cast 
on top. The stacking gel was composed of 4% (w/v) acrylamide; 125mM Tris 
buffer, pH 6.8, 0.05% (w/v) APS, 0.1% (w/v) SDS and 0.1% (v/v) TEMED. 
Combs were carefully placed into the stacking gel to form the wells for the 
samples to be loaded into. When polymerisation was complete the combs 
were removed and the gels were fastened into the gel tank, which was then 
filled with electrode running buffer (1 x ERB) (20mM Tris, 160mM glycine and 
0.08% (w/v) SDS, pH 8.3). 
 
2.7.5 Sample preparation and electrophoresis 
 
Protein samples were quantified as outlined in 2.7.3 prior to dilution to 1-
2µg/ml in reducing loading buffer (62.5mM Tris buffer, pH 6.8, 10% (v/v) 
glycerol, 2% (w/v) SDS, 100mM DTT and 0.02% (w/v) bromophenol blue). 
Samples were denatured by heating at 90 oC for 5 minutes, routinely 10-20µg 
total protein was loaded per well (governed by the relative expression of the 
protein of interest). Electrophoresis was carried out at 100V initially till the dye 
front had crossed the interface of the stacking and separating gel, then at 
150V until the dye front had reached the end of the gel. At this point the gels 
were removed and either stained using coomassie blue (2.7.6) or the proteins 
transferred onto a nitrocellulose membrane to detect specific proteins (2.7.7). 
 
2.7.6 Coomassie blue gel staining 
 
Once removed from the electrophoresis tank the gels were briefly washed in 
distilled water, prior to staining with coomassie blue (0.5% (w/v) coomassie 
blue in 25% (v/v) isopropanol / 10% (v/v) acetic acid) for one hour. The gel 
was then destained in 10% (v/v) methanol and 10% (v/v) acetic acid in 
deionised water, (the length of destaining was governed by the frequency of 
washes). The gel was imaged using white light on an Alpha Innotech 
fluorescent imaging system and image processed using Fluorchem software. 
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2.7.7 Western blotting 
 
Following removal from the gel tank the gels were removed from between the 
plates and the stacking gel was discarded whilst the separating gel was 
placed in chilled transfer buffer (25mM Tris, 192mM glycine and 20% (v/v) 
methanol, pH 8.3) to equilibrate for 10 minutes. Gels were loaded into the 
Western transfer cassettes overlaid with the nitrocellulose membrane 
between both filter paper and pads, and placed in the tanks with an ice pack 
before being submerged in chilled transfer buffer. The negatively charged 
proteins were transferred onto the positively charged nitrocellulose membrane 
by running the tank at 100V for an hour. Afterwards the nitrocellulose 
membrane was removed and washed in 1 x TBS-T (0.2M NaCl, 20mM Tris 
and 0.05% (v/v) Tween 20, pH 7.4) to remove any traces of methanol. The 
nitrocellulose membrane was then blocked in 3% (w/v) marvel milk powder in 
1 x TBS-T buffer for one hour at room temperature to prevent non-specific 
protein binding. The nitrocellulose membrane was then washed three times in 
1 x TBS-T, prior to incubation with the primary antibody for a further hour at 
room temperature or overnight at 4 oC. Both primary and secondary 
antibodies were diluted in incubation buffer (0.3% (w/v) milk powder in 1 x 
TBS-T). Following another three 1 x TBS-T washes the membrane was 
incubated in the appropriate secondary (horse radish peroxidise (HRP) 
conjugated) antibody for an hour at room temperature (see Table 2.5 for 
specific antibody dilutions). Finally the membrane was washed for a minimum 
of 30 minutes with multiple TBS-T changes prior to chemiluminescent 
detection. 
Pierce ECL reagent (Thermo Scientific) was used for chemiluminescent 
detection of the HRP activity of the intended protein. Following the guidelines 
provided equal volumes of reagents 1 and 2 (~750µl) were mixed and 
pipetted onto the membrane, ensuring that it was covered equally for one 
minute. Excess ECL reagent was removed by blotting with tissue paper and 
then the membrane was wrapped in saran wrap and all air bubbles were 
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removed. The membrane was fixed into a cassette and exposed to x-ray film 
(CL-Xposure Film, Thermo Scientific) in a dark room followed by development 
of x-ray film with an X-omat developer (Kodak). 
 
2.8 Immunohistochemistry (IHC) and immunocytochemistry (ICC) 
 
2.8.1 Immunohistochemistry (IHC) 
 
Tissue sections (typically liver or pancreas) fixed in 10% formalin (in 1 x PBS) 
for a minimum of 24 hours were processed (sequential ethanol washes) 
before embedding in paraffin blocks. Sequential 5µM sections were cut and 
subsequently mounted onto superfrost plus slides (Thermo, UK). Before 
individual staining procedures were undertaken, the slides were dewaxed in 
xylene for 10 minutes and washed in 100% and 95% ethanol for one minute 
before a final wash in deionised water. Tissue sections were then incubated in 
3% (v/v) hydrogen peroxide in methanol for 15 minutes to quench 
endogenous peroxidase activity. 3 x 5 minute 1 x PBS washes were 
performed prior to antigen retrieval. The predominant methods used for 
antigen retrieval were sodium citrate incubation (2.8.2) or by digestion with 
10µg/ml proteinase K (2.8.3). Non specific binding of the antibody was 
blocked by performing a 20 minute incubation with 15% (v/v) FCS in 1 x PBS 
at room temperature. The primary antibody (diluted in 0.05% (v/v) FCS in 1 x 
PBS) was incubated for a minimum of an hour at room temperature or 
overnight at 4 oC, see table 2.5 for individual antibody dilutions. The sections 
were then washed 3 x 5 minute in 1 x PBS to remove any residual primary 
antibody, before incubation with the desired secondary (HRP conjugated) 
antibody; again for an hour at room temperature. Following the 3 x 5 minute 1 
x PBS washes, HRP activity was determined using diaminobenzidine (DAB) 
chromogen (Dako), which develops a dark brown colour when oxidized by 
bound HRP. The length of the DAB incubation was optimised for each 
individual antibody; following this step the sections were briefly washed in 
deionised water before the nuclei were counterstained with haematoxylin for 
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15 seconds. Finally the sections were dehydrated sequentially through a 
number of ethanol washes (50%, 75%, 90%, and 2 x 100% ethanol) before 
two xylene washes and mounting in Depex. 
Antigen (raised in) Dilution 
 
Molecular 
weight (kDa) 
 
Supplier (product 
code) 
 
Firefly-luciferase (goat) WB - 1/100  
IHC  - 1/50 - 
1/500 
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Abcam (AB81823) 
 
Firefly-luciferase 
(chicken) 
WB - 1/400  
IHC - 1/500 
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Abcam (AB18595) 
 
β-actin (mouse) WB - 1/3000 44 Sigma (A1978) 
Synaptophysin (mouse) WB - 1/1000 37 Dako (M0776) 
Synaptophysin (rabbit) IHC - 1/200  
ICC - 1/200 
34 Millipore (AB9272) 
 
Amylase (goat) WB – 1/1000 52 Abcam (AB21156) 
αSMA-FITC (mouse) IHC - 1/200  
ICC - 1/200 
42 Sigma (F3777) 
 
NIMP (rat) IHC - 1/200 40 Serotec (MCA771G) 
anti-FITC-HRP 2
o
 
(rabbit) 
IHC - 1/200 N/A Dako (P5100) 
anti-chicken-HRP 2
o
 
(rabbit) 
WB - 1/5000  
IHC - 1/200 
N/A Abcam (AB6753) 
 
anti-rabbit-FITC 2
o
 
(sheep) 
ICC - 1/160 N/A Sigma (F7512) 
anti-rabbit-TRITC 2
o
 
(swine) 
ICC - 1/400 N/A Dako (R0156) 
anti-rabbit-HRP 2
o
 
(goat) 
WB - 1/3000  
IHC - 1/200 
N/A Dako (P0448) 
 
anti-goat-HRP 2
o
 
(rabbit) 
WB - 1/6000  
IHC - 1/300 
N/A Sigma (A5420) 
 
anti-mouse-HRP 2
o
 
(goat) 
WB - 1/6000 N/A Dako (P0447) 
anti-rat-HRP 2
o
 
(chicken) 
IHC - 1/300 N/A Abcam (AB6836) 
Table 2.5 – Antibody dilutions (IHC – immunohistochemistry, ICC – immunocytochemistry, WB 
– western blot)  
 
2.8.2 Sodium citrate antigen retrieval 
 
Tissue sections were placed in a microwaveable rack and submerged in 
0.01M sodium citrate buffer, pH 6. The lid of the rack was placed loosely on 
top and the sections were heated at full power for 20 minutes in a microwave. 
Chapter 2.0 – Materials and Methods 
66 
 
It was necessary to regularly keep topping up the level of citrate buffer to 
prevent the sections from drying out; the sections were then allowed to cool 
down at room temperature before recommencing the IHC protocol. 
 
2.8.3 Proteinase K antigen retrieval 
 
Tissue sections were digested for 25 minutes at 37 oC in 10µg/ml proteinase 
K (diluted in 1 x PBS) before continuing with the IHC protocol. 
 
2.8.4 Haematoxylin and eosin staining (H&E) 
 
H&E is one of the most common stains performed in IHC, staining the nucleus 
and cytoplasm respectively. The sections were dewaxed and rehydrated as 
outlined in 2.8.1, before staining in haematoxylin for 1 minute and subsequent 
washing in deionised water. This was followed by a thirty second incubation in 
Scott’s water before further washing in deionised water. Sections were finally 
counterstained in eosin for 30 seconds before deionised water washing and 
dehydration and mounting as outlined in 2.8.1. 
 
2.8.5 Picro-sirius red staining 
 
Picro-sirius red stain is known to specifically bind to collagens due to its 
sulphonic groups reacting strongly with the basic groups present in collagen 
molecules [214]. This makes it an ideal stain for determining fibrosis severity 
as collagen is deposited by hepatic myofibroblasts. Slides were dewaxed and 
rehydrated as outlined in 2.8.1 before incubation in picro-sirius red stain 
(0.036mM in saturated picric acid) for two hours at room temperature. Any 
excess stain was removed by three brief washes in acidified water (0.5% (v/v) 
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acetic acid in deionised water). As previously slides were dehydrated and 
mounted in depex as outlined in 2.8.1. 
 
2.8.6 Fluorescent immunocytochemistry  
 
Typically all ICC analyses were performed with cells seeded in chamber 
slides (Merck) or 6 and 24 well plates. Plates were removed from the 
incubator and media aspirated off before three washes in HBSS/ Hepes, pH 
7.4 (0.14M NaCl, 5.4mM KCl, 0.34mM Na2HPO412H2O, 0.44mM KH2PO4, 
5.6mM glucose, 1mM CaCl2, 6mM Hepes and 4mM NaHCO3), they were left 
coated in 1ml of HBSS/ Hepes before addition of 60µg/ml fluorescent C1-3 
scAb. The cells and scAb were wrapped in foil and incubated for two hours at 
37 oC and 5% CO2. Following two brief washes in 1 x PBS the cells were fixed 
by incubation with 1ml of fixative per well (2% (v/v) formaldehyde and 0.2% 
(v/v) glutaraldehyde in 1 x PBS, pH 7.4) for 15 minutes at room temperature. 
Fixative was removed and the cells subsequently washed three times in 1 x 
PBS, at this point a 20 minute blocking step was performed by incubating with 
20% (v/v) FCS in 1 x PBS. Primary and secondary antibodies were added and 
incubated in turn for an hour at room temperature (see Table 2.5 for dilutions). 
After a further three 1 x PBS washes the cells were coated in 500µl of DAPI 
(4', 6-diamidino-2-phenylindole) (6µg/ml in 1 x PBS) and incubated for 10 
minutes at room temperature. DAPI is a cell permeable fluorescent dye that 
binds specifically to AT rich regions of double stranded DNA and is therefore 
ideal for visualizing cell nuclei. The DAPI was removed and the cells washed 
a further three times in 1 x PBS (five minutes each wash) before mounting in 
vectashield anti fade (Vector Labs) and storage (protected from light) at 4 oC 
prior to fluorescent microscopy analysis. 
 
2.9 C1-3 production 
 
Chapter 2.0 – Materials and Methods 
68 
 
2.9.1 Bacterial culture and C1-3 protein expression  
 
E-coli XL-1 blue cells were transfected with the pIMS147-C1-3 plasmid and 
cultured in baffled flasks containing LB media, with the addition of glucose 
(1% (w/v)) and selective antibiotics (50µg/ml ampicillin and 50µg/ml 
tetracycline) to select cells that had be successfully transfected. Following 
culture of the cells initially in LB and then TB media (24% (w/v) yeast, 12% 
(w/v) tryptone and 5% (v/v) glycerol) over a few days to encourage bacterial 
growth at 37 oC and 250rpm C1-3 expression was induced by the addition of 
0.5M Isopropyl β-D-1-thiogalactopyranoside (IPTG). Following culture for a 
further 4 hours the cell pellet was isolated by centrifugation at 6000g for 20 
minutes. The supernatant was discarded and cell pellet resuspended in 10ml 
of fractionation buffer (200mM Tris-HCl, 20% sucrose, 1mM EDTA, pH 7.5) 
supplemented with 50mg/L lysozyme and lysed on ice for 15 minutes. 
Afterwards an equal volume of 5mM magnesium sulphate was added to the 
solution and incubated on ice for a further 15 minutes. The cells were pelleted 
by centrifugation at 6000g for 30 minutes at 4 oC, but the supernatant was 
retained as it now contains the C1-3 scAb. 
 
2.9.2 Protein isolation 
 
C1-3 was isolated from the supernatant by Ni2+ charged immobilised metal ion 
affinity chromatography (IMAC), using a fast flow sepharose resin (Amersham 
Biosciences). IMAC exploits the interaction between the side chains located 
on histidine amino acids found on the C-terminal tag of C1-3 and the chelated 
transition metal ions within the column resin. The ethanol was removed from 
the sepharose resin and washed in deionised water prior to resuspension in 
binding buffer (10mM imidazole), 1ml of binding buffer was added for every 
40ml of supernatant, the nickel sepharose was resuspended in supernatant 
and added to the rest of the supernatant and incubated overnight at 4 oC. The 
following morning the whole mixture was passed through the column twice, 
before a wash in binding buffer to remove any non-specifically bound proteins. 
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Two 10ml washes of elution buffer (400mM imidazole) were performed to 
remove the bound C1-3 scAb from the column, then the solution was dialyzed 
with 1 x PBS overnight (approximately 1L of 1 x PBS per mg of C1-3 
produced) to remove any imidazole. 
If C1-3 was being used in animal studies it was also necessary to remove all 
traces of endotoxin (ETX), which was accomplished using Q maxi H columns 
(Sartorius Vivascience). The column was prepared by sequential washes with: 
(each time the column was centrifuged at 2200rpm for 5 minutes before 
discarding the flowthrough): - 
 17ml Pharmacy water 
 17ml 0.5M NaOH 
 17ml Pharmacy water 
 17ml Pharmacy water 
 17ml Pharmacy water 
 17ml 1x sterile PBS 
Finally the C1-3 scAb was loaded onto the column and centrifuged at 
2200rpm for 10 minutes. The flowthrough containing C1-3 was collected and 
sterile filtered through a 0.45µM syringe filter (VWR International) prior to 
storage at - 20 oC. 
 
2.9.3 C1-3 quantification and specificity 
 
Enzyme linked immunosorbant assays (ELISAs) are utilised to determine the 
binding of a protein to specific antibody or antigen when coated on plastic. A 
binding ELISA was performed using synaptophysin peptide sequences 1 and 
2 (see figure 1.4.1) to display C1-3’s specificity to peptide sequence 2. 
Secondly a capture ELISA was performed alongside IgG controls to 
determine the C1-3 protein concentration. 
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2.9.4 Binding ELISA 
 
Initially flat bottomed 96 well microtitre plates (Dynex, Sussex) were coated 
with 100µl BSA as a negative control, or synaptophysin peptide 1 or 2 
conjugated to BSA (all 20µg/ml) and incubated at room temperature for 2 
hours (all steps were performed at 300rpm on a rocker to ensure 
homogenous coating of the wells). Afterwards 3 x PBS-T washes (1 x PBS + 
0.05% (v/v) Tween) were carried out, non specific binding was blocked by 
incubation with blocking buffer (2% (w/v) marvel milk protein in 1 x PBS) 
overnight at 4 oC. Following a further 3 x PBS-T washes both C1-3 and 
human IgG (Sigma) (negative control) samples were serially diluted across 
the plate before incubation for an hour at room temperature. After 5 x PBS-T 
washes the secondary antibody (goat anti human Cĸ light chain-HRP (diluted 
1:1000 in 2% (w/v) marvel milk protein in 1 x PBS)) was added, this was 
incubated for an hour at room temperature before a final set of PBS-T washes 
prior to detection as outlined in 2.9.6. 
 
2.9.5 Capture ELISA 
 
Flat bottomed 96 well microtitre plates were coated with goat anti-human Cĸ 
light chain (bound and free) for two hours at room temperature, prior to 2 x 
PBS-T washes and blocking of non specific protein binding by overnight 
incubation with 2% (w/v) BSA in  1 x PBS. The next morning after 3 x PBS-T 
washes, human IgG was serially diluted across the plate (from an initial 
concentration of 1250ng/ml to a final concentration of 0.61ng/ml) as 
calibration standards. Alongside this, C1-3 of unknown concentration was 
diluted 1 in 10 prior to serial dilution across the plate and both were incubated 
at room temperature for 90 minutes. The plate was then washed five times 
with PBS-T before addition of the secondary antibody goat anti human Cĸ 
light chain-HRP (diluted 1/1000 in 1 x PBS). Following the final set of PBS-T 
washes, the plate was ready for detection (2.9.6). 
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2.9.6 Detection of bound C1-3 
 
The amount of bound antibody was determined by incubation for 10 minutes 
with 100µl 3, 3’, 5, 5’-Tetramethylbenzidine dihydrochloride monohydrate 
(TMB) per well, 1 tablet of TMB was dissolved in 10ml of 0.05M phosphate 
citrate buffer, pH 5 and 2µl of 30% (v/v) hydrogen peroxide. The reaction was 
ended by the addition of 50µl of 1M sulphuric acid, which results in a colour 
change from yellow to blue that can be detected spectrophotmetically at 
450nm. 
 
2.9.7 Conjugation of C1-3 to Fluorescein isothiocyanate (FITC) 
 
C1-3 was conjugated to FITC using a kit purchased from Molecular probes, 
briefly 200µl of C1-3 (~ 1mg/ml) was added to 20µl of 1M bicarbonate 
solution. 12.6µl of FITC dye solution (10mg/ml diluted in DMSO) was added 
and the reaction stirred for an hour at room temperature, protected from light. 
The C1-3-FITC conjugate was separated from free dye by centrifugation with 
sepharose gel columns equilibrated with 1 x PBS. The fluorescently labelled 
C1-3 was stored in aliquots at 4 oC short term or – 20 oC long term (protected 
from light). 
 
2.9.8 Conjugation of C1-3 to Alexa-594 fluorophore 
 
C1-3 was conjugated to Alexa-594 using a kit purchased from Molecular 
probes, briefly 50µl of 1M bicarbonate solution was added to 500µl of C1-3 (~ 
1mg/ml). This C1-3 solution was then added to a vial of Alexa-594 dye and 
vortexed briefly to mix completely, before it was stirred for an hour at room 
temperature, protected from light. The C1-3-594 conjugate was separated 
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from free dye by centrifugation with sepharose gel columns equilibrated with 1 
x PBS. The fluorescently labelled C1-3 was stored as aliquots at 4 oC short 
term or – 20 oC long term (protected from light). 
 
2.9.9 Conjugation of C1-3 to Xenolight™ XF750 
 
C1-3 was conjugated to the XF750 fluorophore following the guidelines 
provided by the manufacturer (Caliper biosciences), initially 100µl of 1M 
sodium bicarbonate, pH 8.3 was added to 900µl of C1-3 (~ 1mg/ml). 1 vial of 
XF750 dye was resuspended in 25µl of DMSO and 12µl of this was added to 
the C1-3-bicarbonate solution and mixed at room temperature for 1 hour 
protected from light. The free dye was removed by centrifugation using a 
Nanosep® exclusion vial (MW 10,000) (Pall), so free dye will be lost in the 
flowthrough and the fluorescently conjugated C1-3 retained in the vial. After 
three washes with 1 x PBS the C1-3-750 was resuspended in 1ml of 1 x PBS 
to give approximately 1mg/ml of C1-3-750, which was stored at 4 oC short 
term or – 20 oC long term (protected from light). 
 
2.9.10 Conjugation of C1-3 to gliotoxin (GTX) 
 
The conjugation of C1-3 and GTX was optimized previously within this 
laboratory (see Figure 2.2) based on the method described by Fox et al [215]. 
Briefly, 750nmoles of C1-3 was reacted with 22µmoles of S-acetyl thioglycolic 
acid N-hydroxysuccinimide (SATA) and 1mM EDTA for an hour at room 
temperature. The GTX was prepared as a 2mg/ml stock in DMSO; 12µmoles 
was activated by reaction for an hour with 60µmoles of N-p-maleimidophenyl 
isocyanate (PMPI) at room temperature. Afterwards the GTX-PMPI was 
added to the C1-3-SATA and incubated for a further 2 hours, the unreacted 
components were removed by gel filtration using a PD-10 column and 1 x 
PBS washes. C1-3-GTX was aliquoted out and stored at – 20 oC until 
required. 
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Figure 2.2 Schematic of C1-3-GTX conjugation reaction (taken from [116]). Initially the primary 
amine groups on C1-3 were thiolated by reaction with SATA for 1 hour at room temperature (RTP), at 
the same time GTX was conjugated for 1 hour with PMPI at RTP. Excess reagents were removed from 
each reaction by PD-10 filtration. Upon completion C1-3-SATA was reacted with GTX-PMPI for 2 
hours at RTP, excess compounds were once again removed by PD-10 filtration. Successful conjugation 
was confirmed by SDS-PAGE and western blotting with a GTX specific antibody. 
 
2.10 Animal imaging  
 
An in vivo imaging system (IVIS) ultrasensitive camera (Xenogen) was used 
to image the mice and determine luminescent and fluorescent levels. Prior to 
imaging mice were anaesthetized with isoflurane and the fur was removed 
from their abdominal region by shaving. 
 
2.10.1 Luminescence imaging 
 
Mice were placed in the IVIS imaging chamber under anaethesia before i.p. 
injection of 200µl D-Luciferin (15 mg/kg) purchased from Caliper (Hopkinton, 
MA, United States) diluted in 1 x PBS, pH 7.8. A background luminescence 
reading over 60 seconds was recorded just prior to injection; following D-
Luciferin injection luminescence readings were taken every 5 minutes for a 
total of 15 minutes (each lasting 60 seconds). Mice were either placed back in 
Chapter 2.0 – Materials and Methods 
74 
 
their housing prior to future studies or at the culmination of a study mice were 
terminated by cervical dislocation, and blood was collected for serum analysis 
by cardiac puncture. The major organs (liver, brain, kidney, stomach, spleen, 
lung and heart) were excised and placed in the IVIS imaging chamber and 
imaged using identical settings. 
 
2.10.2 Fluorescent imaging 
 
Mice were placed in the IVIS imaging chamber under isoflurane anesthesia, 
before a fluorescence background scan was performed using the auto 
exposure settings at the desired wavelengths (λabs/λem = 755/775nm). The C1-
3-750 fluorophore was administered by either an intravenous (i.v.) or i.p. 
injection (10mg/kg bodyweight) as outlined the in individual protocols. 
Fluorescent scans were performed at designated timepoints. On completion 
of the study, the mice were culled by cervical dislocation and the major organs 
excised and scanned by an identical method. 
All images taken were analyzed using Image-Pro plus 4.0 (Media 
Cybernetics, Silver Spring, MD) software integrated with the HPD-LIS module 
as developed by Hamamatsu. 
 
2.11 Serum and tissue storage 
 
The blood samples harvested were allowed to clot before centrifuging at 
13,000rpm for at least 20 minutes. The serum layer was pipetted off into 
individual eppendorfs and stored at – 20 oC until analysis by the Clinical 
Biochemistry Department at the Royal Victoria Infirmary, Newcastle. 
Following imaging the liver tissue samples were dissected and either fixed in 
10% formalin solution in 1 x PBS, snap frozen in TRIzol or snap frozen 
directly in LqN2 prior to RNA and protein isolation at a later date. All the other 
major organs collected were snap frozen in LqN2 and stored at – 20 oC prior 
to future analysis where required. 
Chapter 2.0 – Materials and Methods 
75 
 
 
2.12 Tissue homogenisation  
 
A small sample was removed from each snap frozen liver section and 
weighed before resuspension in five times that volume of homogenisation 
buffer (20mM Tris, 100mM KCl, pH 7.4). For example a sample weighing 
100mg was resuspended in 500µl of homogenisation buffer, the sample was 
then homogenised using a small pestle and where necessary sonicated in 
short bursts to further disrupt the tissue. This ensured that all samples 
contained approximately the same amount of liver tissue. 
 
2.13 Luciferase assay 
 
The same general protocol was followed for both luciferase assays involving 
the U937-NF-κB cells and the homogenised tissue from the PXR animal study 
using a Dual-glo luciferase assay kit (Promega). A fixed volume (typically 
100µl) of 1 x PLB was mixed 1:1 with 100µl liver homogenate or the U937-
NF-κB cell pellet was resuspended in 100µl of 1 x PLB. 50µl of this was then 
added to an equal volume of the supplied Dual-glo luciferin substrate 
(Promega), and mixed vigorously before a 10 second luminescent detection 
was performed using a Junior LB 9509 benchtop luminoter detector (Berthold 
technologies). 
 
2.14 Griess assay. 
 
The levels of nitric oxide (NO) produced by cells (both U937-NF-κB cells on 
their own and in co-culture with LX-2 cells and hHSCs) could be determined 
by the nitrite (NO2-) levels present in the culture media. NO2- is one of the 
major stable and non-volatile breakdown products of NO present in the media. 
Culture media was removed at designated time points (0, 2, 4, 8, 24, 48 and 
72 hours) and if necessary centrifuged to remove U937s, before 100µl 
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aliquots were reacted with 100µl of Griess reagent (1% sulfanilamide in 0.1 
mol/l HCl and 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride) in 
triplicate. The reaction of nitrite present in the culture media with sulfinamide 
results in the formation of diazonium salts. When this is coupled with N-(1-
naphthyl)ethylenediamine an azo dye forms, and the resultant colour change 
can be detected spectrohotometrically at 540nm (Figure 2.3). Therefore the 
level of NO2- produced can be determined when the samples are extrapolated 
against a plot generated from sodium nitrite standards of known 
concentrations [216]. 
 
Figure 2.3 Griess assay chemical reaction. The level of NO can be detected by measuring the nitrite 
(NO2
-
) formation in the culture media. When Griess reagent is added the sulfinamide it contains leads 
to the formation of a diazonium salt, which in turn reacts with N-(1-naphthyl)ethylenediamine present 
in the Griess reagent leading to the formation of an azo dye that can detected spectrophotometrically at 
540nm. The nitrite concentration is determined against a standard curve of known sodium nitrite 
concentrations. 
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Chapter 3.0 - The use of C1-3-750 as a non-invasive 
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3.1 Introduction 
 
The continuing escalation in the incidence of liver fibrosis and its endpoint 
cirrhosis [24], coupled with the lack of a recognised treatment regimen explain 
why liver disease is an ever increasing healthcare issue and major burden on 
the National Health Service (NHS). Despite the significant advances in our 
understanding of the pathogenesis of liver fibrosis over the past thirty years, 
principally the ‘activation’ of HSCs to hepatic myofibroblasts - the primary 
fibrogenic cell in the liver, relatively little progress has been made in 
developing an effective anti-fibrotic treatment regimen [32, 186, 217]. 
Accurate diagnosis and staging of hepatic fibrosis at all stages of disease 
progression is critical to the development and assessment of the functioning 
of new potential anti-fibrotic agents. The methods currently available to 
diagnose liver fibrosis including the ‘gold standard’ percutaneous liver biopsy 
are listed in section 1.5, which outlines some of the major problems of the 
liver biopsy (e.g. sampling errors) [122]. Sections 1.5.2 and 1.5.3 highlight the 
limitations when using alternative diagnosis techniques such as serum 
biomarker panels and non invasive imaging modalities. Primarily these 
difficulties are differentiating between the various stages of fibrosis severity, 
and detecting early developmental fibrosis [132, 142]. 
The development of a non-invasive imaging modality to accurately quantify 
liver fibrosis severity at all stages of fibrosis development would aid the 
discovery of novel anti-fibrotic agents because it would allow rapid diagnosis 
and could be used to determine the effect of treatment outcome for individual 
patients. Obviously there would also be a significant reduction in the number 
of side effects associated with the liver biopsy. With that in mind we intend to 
utilize the hepatic myofibroblast specific properties of the scAb C1-3 as an 
imaging agent, when conjugated with a long wavelength flurophore 
(approximately 780 nm peak emission). Previous work within this laboratory 
[115] highlighted C1-3’s ability in vitro to target hepatic myofibroblasts. In vivo 
it was predominantly used as a potential anti-fibrotic agent when conjugated 
with GTX, inducing hepatic myofibroblast apoptosis and a significant reduction 
in liver fibrosis severity in vivo [116]. 
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We hypothesised that there was a relationship between the number of hepatic 
myofibroblasts and the severity of hepatic fibrosis (i.e. level of collagen scar 
deposition). Using an in vivo model of liver fibrosis (CCl4 treated mice) we 
aimed to test this hypothesis, specifically if the C1-3-750  signal is an indicator 
of fibrosis severity there should be an increase in liver fluorescence. Both 
whole body scans and ex vivo organ scans will be performed to determine if 
C1-3-750 liver fluorescence was an appropriate indicator of fibrosis severity, 
and can be used to quantify and differentiate between different stages of liver 
fibrosis non invasively. 
 
3.2 Conjugation of C1-3-750 and its functioning in vitro 
 
C1-3 was conjugated with the XF750 dye as outlined in methods 2.9.8. 
Successful conjugation was confirmed by SDS-PAGE analysis alongside 
unconjugated C1-3. The SDS-PAGE gel in figure 3.1 indicates an increase in 
molecular weight (MW) seen when XF750 was conjugated. C1-3 has a MW of 
approximately 37 kDa (lane 2 figure 3.1); the C1-3-750 scAb (lane 3 figure 
3.1) has not migrated as far along the SDS gel, indicative of its increased 
MW. The blurry appearance of the band was due to the variation in the 
number of dye molecules bound to the scAb, which cannot be controlled 
during the conjugation process. 
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Figure 3.1 SDS-PAGE analysis of C1-3 before and after conjugation with XF750 and comparison 
vs. BSA standards. C1-3 and C1-3-750 were diluted 1:1 in loading buffer, whilst BSA standards were 
diluted directly into loading buffer from a 20mg/ml stock; following electrophoresis the gel was stained 
with coomassie blue for one hour and destained with multiple washes in 10% (v/v) acetic acid and 
methanol in deionised water. The gel was imaged using a Syngene GBox gel imaging system; C1-3 has 
a MW of approximately 37 kDa, presence of XF750 is shown by the increased MW and reduced 
migration along the gel. The size of each band is directly proportional to the concentration of the 
protein sample. Therefore comparing the unknown C1-3 & C1-3-750 bands with the BSA standards 
(68 kDa) we can estimate their protein concentration – C1-3 = ~ 1mg/ml, C1-3-750 = ~ 1mg/ml. 
 
Successful conjugation of XF750 was also confirmed by MALDI-TOF analysis 
of the C1-3-750 conjugated scAb versus unconjugated C1-3 and also C1-3-
FITC. The results of these analyses are shown in figure 3.2, the findings 
confirm the SDS-PAGE results (Figure 3.1); firstly unconjugated C1-3 has a 
MW of 37.5 kDa [116] shown by the single distinct peak. There was an 
increase in C1-3’s MW when conjugated to either XF750 or FITC. There was 
also a difference in binding efficiency between the XF750 and FITC binding 
reactions, shown by the presence of multiple peaks in the C1-3-750 MALDI-
TOF (peaks of approximately 37.5, 37.6, 40.5 and 43.4kDa). This indicates 
that there was a variation in the number of XF750 dye molecules bound to the 
scAb, in contrast there was 100% binding efficiency in the C1-3-FITC reaction 
shown by the presence of a single peak, larger than that seen in the 
unlabelled C1-3 sample (37.9kDa versus 37.5kDa). The presence of an 
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identical peak at 37.5kDa in the C1-3-750 sample suggests that there was still 
unbound C1-3 present that was not conjugated during the labelling reaction. 
 
Figure 3.2 MALDI-TOF analyses of C1-3 and its conjugates. C1-3 run out confirms the SDS-PAGE 
findings (Figure 3.1) as C1-3 has a MW of 37.5 kDa shown by the single clear peak. C1-3-750 
reinforces the SDS-PAGE further as there are multiple peaks around 37 kDa as a result of varying 
numbers of dye molecules being conjugated to the C1-3 scAb. C1-3-FITC is conjugated via an 
identical protocol to C1-3-750, however it’s MALDI-TOF has a single slightly larger peak than C1-3, 
indicating that the labelling procedure is 100% successful, unlike the C1-3-750. 
 
The C1-3-750 concentration was estimated by SDS-PAGE analysis; in this 
instance the conjugated scAb was compared against BSA standards of known 
concentration (Figure 3.1). The concentration of the protein was directly 
proportional to the intensity of the band it produces on the SDS gel. Therefore 
it was possible to estimate the concentration of C1-3 or C1-3-750 when it was 
compared to the BSA standards, C1-3-750 was at a concentration of 
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approximately 1mg/ml, when corrected for the 1:1 dilution in loading buffer 
(i.e. multiply by 2). 
The C1-3-750 concentration was also quantified by a capture ELISA using 
human IgG as standards; the freshly conjugated C1-3-750 was serially diluted 
(1:2) across a 96 well plate (initial dilution 1 in 10) alongside the IgG samples 
(initial concentration 1250ng/µl). Figure 3.3A is a typical plot of the 
absorbance versus protein concentration generated for both C1-3-750 and the 
IgG standards; the unknown C1-3-750 protein concentration was calculated 
from the linear segment of the curve. It was necessary to correct for both the 
initial dilution and the presence of a second human kappa light chain domain 
on the human IgG antibody; this calculation is shown in figure 3.3B. A second 
binding ELISA using 96 well plates coated in both synaptophysin peptide 
sequences 1 and 2 (Figure 1.6) was performed to confirm that the conjugation 
process had not adversely affected C1-3’s affinity for synaptophysin peptide 
sequence 2. Figure 3.4 shows that C1-3-750 retains the unique binding 
characteristics of unconjugated C1-3, only binding to synaptophysin peptide 
sequence 2. This was also reaffirmed by BIACORE analysis (Figure 3.5) 
when synaptophysin peptide sequence 2 was immobilised onto a CM5 
BIACORE chip (synaptophysin peptide 1 was also immobilised separately as 
a negative control – Figure 3.5C). Varying concentrations of both C1-3 and 
C1-3-750 (50, 25, 12.5 and 6.25µM) were passed across the CM5 BIACORE 
chip in turn and the affinity of the antibody for the peptide sequence 
determined by surface plasmon resonance. It is clear in figures 3.5A and 3.5B 
that the association and dissociation characteristics of C1-3 and C1-3-750 are 
almost identical for synaptophysin peptide 2 following the PBS washes. This 
was confirmed when you compare the affinity (binding constant) values 
calculated from the dissociation and association rate values in figure 3.5D. 
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Figure 3.3 Quantification of C1-3-750 concentration by capture ELISA versus human IgG 
standards. A 96 well plates were coated with cκ light chain, prior to serial dilution of C1-3-750 and 
human IgG across the plate. Following incubation with the secondary antibody (cκ light chain-HRP), 
the level of bound antibody was detected by spectrophotometric analysis at 450nm after TMB addition. 
A standard curve was then produced of protein concentration versus absorbance. B Using the standard 
curve the unknown C1-3-750 concentration is calculated by extrapolating against an IgG dilution of 
similar absorbance in the linear phase of the curve. C1-3-750 concentration was corrected for the 
dilutions factor and for the presence of an extra human kappa light chain domain on the human IgG 
antibody by multiplying by 2. In this instance dilution 9 of C1-3-750 is equal to dilution 6 of IgG with 
a concentration of 39.06ng/ml. To correct for dilution this number is multiplied by 27 and finally by 10 
to account for the initial 1:10 dilution.  
 
Fluorescent spectroscopy was performed to determine the flurophores peak 
absorbance at approximately 750nm, and also its emission/ excitation 
characteristics. Figure 3.6 highlights the fluorescence spectra of C1-3-750, 
with peak absorption at 755nm and peak emission at approximately 780nm. 
These findings correlate with the manufacturers’ predicted absorption peak at 
755nm and emission peak at 777nm. When performing the in vivo studies and 
imaging mice following C1-3-750 injection, the XF750 filter settings 
programmed into the IVIS software will ensure maximum fluorescence 
detection of the C1-3-750 scAb. 
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Figure 3.4 Specificity ELISA of C1-3 and C1-3-750 to BSA synaptophysin peptide sequences 1 & 
2. 96 well plates were coated with BSA conjugated synaptophysin peptide 1 and 2 (see figure 1.6) or 
BSA (negative control). C1-3 and C1-3-750 were serially diluted across the plate and the level of 
bound antibody was detected as outlined in section 2.9.6. Dilution 5 (1/160) is shown above; 
highlighting that conjugation of XF750 to the C1-3 scAb has not altered its binding to synaptophysin 
peptide sequence 2. 
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Figure 3.5 BIACORE analyses of C1-3 and C1-3-750. In the BIACORE flow hood synaptophysin 
peptide 2 was immobilised onto a CM5 BIACORE chip. A C1-3 and B C1-3-750 were separately 
flowed across the chip at a constant rate for 1 hour. After 1 hour PBS washes were performed to 
remove the bound scAb from the peptide, the level of bound scAb was detected by surface plasmon 
resonance. C C1-3-750 was also flowed across a chip with synaptophysin peptide 1 immobilised onto it, 
to highlight it is binding specifically to the peptide coated onto the chip. D The Kd and relative affinity 
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of the scAb for the peptide sequence were calculated, revealing that conjugation of XF750 onto the C1-
3 scAb does not alter its binding kinetics with synaptophysin peptide sequence 2. 
 
3.6 Fluorescence spectra of C1-3-750. C1-3-750 (diluted 1:10 in 1 x PBS) was exposed to a range of 
excitation wavelengths to determine firstly its optimum absorbance at approximately 755nm. Secondly 
its excitation and emission characteristics were confirmed peaking at 755nm and 777nm respectively as 
outlined in the manufacturers’ predicted values. 
 
Prior to in vivo experimentation utilising C1-3-750, ICC was performed in vitro 
using both mouse and human hepatic myofibroblasts to confirm C1-3-750’s 
affinity for them. 60µg/ml C1-3-750 (C1-3-594 and C1-3-FITC were also 
incubated separately as controls) was incubated with hepatic myofibroblasts 
as outlined in 2.8.6. To confirm the cells myofibroblast phenotype αSMA dual 
staining was included. Typical fluorescent microscopy images from both the 
human and mouse hepatic myofibroblasts performed upon completion of the 
ICC protocol are shown in figure 3.7. It was clear from the representative 
images that whilst there was co-localization of both the C1-3-FITC and C1-3-
594 conjugates with the αSMA positive cells, there was no C1-3-750 signal 
detected. This could be due to the large MW of the 750 dye molecules altering 
its kinetics or a result of competitive inhibition due to the presence of unbound 
C1-3 (Figure 3.2). These findings are in contrast to the positive findings of the 
binding ELISA and BIACORE analyses (Figures 3.4 and 3.5) that indicated 
the XF750 labelled scAb still functions. Due to these positive findings a pilot 
study utilising an in vivo model of liver fibrosis was designed to determine 
whether the C1-3-750 scAb functioned in vivo. 
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Figure 3.7 ICC of C1-3 conjugates in vitro with mHSCs and hHSCs. Both activated A mHSCs and 
B hHSCs isolated from C57B1/6 mice and human resected liver tissue respectively were cultured in 
chamber slides. Briefly the media was aspirated off and replaced with HBSS/ Hepes, 60µg/ml C1-3-
FITC/ 594/ 750 was added and incubated for 2 hours at 37 
o
C and 5% CO2. The HSCs were fixed with 
2% formaldehyde/ 0.2% glutaraldehyde in 1 x PBS prior to co-staining with αSMA for a further hour; 
after PBS washes a complementary secondary fluorescent antibody was used FITC conjugated for C1-
3-750 and C1-3-594, but TRITC conjugated for C1-3-FITC incubations. Finally a 10 minute incubation 
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with DAPI was performed to stain the cell nuclei and were visualised using a Zeiss fluorescent 
microscope (all images shown are x40 magnification). 
 
Figure 3.7 ICC of C1-3 conjugates in vitro with mHSCs and hHSCs. Both activated A mHSCs and 
B hHSCs isolated from C57B1/6 mice and human resected liver tissue respectively were cultured in 
chamber slides. Briefly the media was aspirated off and replaced with HBSS/ Hepes, 60µg/ml C1-3-
FITC/ 594/ 750 was added and incubated for 2 hours at 37 
o
C and 5% CO2. The HSCs were fixed with 
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2% formaldehyde/ 0.2% glutaraldehyde in 1 x PBS prior to co-staining with αSMA for a further hour; 
after PBS washes a complementary secondary fluorescent antibody was used FITC conjugated for C1-
3-750 and C1-3-594, but TRITC conjugated for C1-3-FITC incubations. Finally a 10 minute incubation 
with DAPI was performed to stain the cell nuclei and were visualised using a Zeiss fluorescent 
microscope (all images shown are x40 magnification). 
 
3.3 Pilot study of C1-3-750 functioning in an in vivo model of liver 
fibrosis 
 
In the initial pilot study to minimise the number of mice used a single C57B1/6 
mouse was administered with CCl4 twice weekly (see Table 2.1) for a total of 
3 weeks, together with a control mouse which received olive oil. Upon 
completion of these treatments the mice were anaesthetised with isoflurane 
and had their ventral side shaved before being placed in the IVIS imaging 
chamber. Prior to injection of C1-3-750, background fluorescent scans were 
performed (Figure 3.8A), using the XF750 filter settings and both the auto 
exposure and a manual 5 second exposure setting. 10 mg/kg C1-3-750 was 
injected by i.v. injection and fluorescence scans using the same exposure 
settings were performed at regular time intervals; the final 4 hour time point 
whole body scan is shown in figure 3.8B. Upon completion of the final 4 hour 
time point the mice were terminated by a schedule I method and the major 
organs excised. 
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Figure 3.8 A Whole body fluorescent background scan prior to i.v. injection of C1-3-750 into a 
control and CCl4 treated mouse. Mice were anaesthetised with isoflurane and shaved ventrally prior 
to placing in the IVIS chamber. All scans were performed using the XF750 filter settings and initially 
performed with both the auto and a manual 5 second exposure settings separately. B Whole body 
fluorescent scan 4 hours post C1-3-750 injection. The scan was performed as outlined in figure 3.8A 
using both the auto and 5 second exposure setting following i.v. injection of 10mg/kg bodyweight C1-
3-750. (All following IVIS images utilised the auto settings, as the 5 second exposure resulted in 
saturated pixels). 
 
The organs were placed inside the IVIS imaging chamber and ex vivo 
fluorescent scans were performed to determine the fluorescence signal of 
each individual organ (Figure 3.9). The successful targeting of C1-3-750 to 
the liver was displayed by the high fluorescent signal from the liver of the 
fibrotic mouse. There was no signal from any other organ and there was only 
a weak signal from the liver of the control mouse, this was due to the 
presence of quiescent HSCs in the liver that also express synaptophysin 
[108]. 
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Figure 3.9 Ex vivo organ scan 4 hours after C1-3-750 administration. Mice were terminated by a 
schedule I method and the major organs excised and placed in the IVIS imaging chamber prior to IVIS 
imaging. 
 
All images measured on the IVIS were analysed using the accompanying 
Living Image 4.0 software; regions of interest (ROI) could be overlaid onto 
images as shown in figure 3.10. It was possible to detect the total 
fluorescence within these ROIs and therefore the total fluorescence of 
individual body regions and specific organs when they had been excised. The 
Total Radiant Efficiency ([p/s] / [µW/cm²]) (Total fluorescence) is shown in 
figure 3.11 for both the liver ROI and excised livers (Figure 3.10) of the CCl4 
and control mice 4 hours after C1-3-750 administration.  The total 
fluorescence calculations (Figure 3.11) support the initial images, indicating 
that there was approximately a two fold increase in the level of fluorescence 
seen in both the whole body liver ROI and excised liver of the CCl4 fibrotic 
mouse when compared to the control mouse. These initial findings suggest 
that C1-3-750 was a viable route to image liver fibrosis non invasively, 
although larger scale studies are required to confirm this. 
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Figure 3.10 Whole body (4 hour time point) and ex vivo organ scan + example ROIs used for total 
fluorescence calculations. ROIs could be overlaid onto images with the Image Pro Plus 4.0 software, 
allowing the calculation of total fluorescence values for specific regions and excised organs. 
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Figure 3.11 Total fluorescence values calculated for both the whole body and ex vivo organ scans. 
Numerical fluorescence values (total fluorescence) calculated from the individual ROIs shown in figure 
3.10, allowing quantification of the difference in C1-3-750 binding between the control and CCl4 
treated mice (n=1). 
 
 3.4 The effect of C1-3-750 injection route upon imaging outcome in vivo 
 
Another area of concern before undertaking the larger study was determining 
the best route to inject C1-3-750; an i.v. injection route was used in the initial 
study upon consultation with the IVIS technicians, as this is the route used in 
clinical imaging settings. However, all previous in vivo work with C1-3 and its 
conjugates (e.g. C1-3-GTX) was performed using an i.p. injection route. This 
was an essential consideration as the planned future study will involve 
multiple imaging time points and repeated injections of C1-3-750. To 
determine if i.p. was a suitable route to administer C1-3-750 the initial pilot 
study was repeated with an i.p injection route alongside the recommended i.v. 
injection route. In particular we wished to ascertain whether this had any 
detrimental effects on the imaging outcome, such as retention of the dose in 
the tail sheath. 
Three C57B1/6 mice received CCl4 twice weekly for 4 weeks before 
commencement of the imaging aspect of the study; following a background 
scan (Figure 3.12) one received C1-3-750 by an i.p. injection, one via an i.v. 
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injection and a control mouse received no C1-3-750 injection. The mice were 
subsequently imaged at regular intervals for 2 hours prior to termination by a 
schedule I method and ex vivo imaging of the major organs. Figure 3.12 
shows the variation in fluorescence detected over the 2 hour time course 
between the i.p., i.v. and non inject mice. When ROIs were overlaid (Figure 
3.13A) the level of fluorescence was quantified for specific body regions, such 
as the upper abdominal (liver) region and the bladder region (Figure 3.13B). 
The bladder region was measured as it also emits a strong fluorescent signal 
as there will be continual excretion of C1-3-750 from the body. Figure 3.14A is 
the ex vivo organ scan 2 hours after C1-3-750 administration highlighting the 
variation in fluorescence resulting from the route of C1-3-750 injection. Total 
fluorescence calculations (Figure 3.14B) from the ROI surrounding the 
individual organs suggest that both i.p. and i.v. injection routes are suitable to 
dose C1-3-750. 
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Figure 3.12 Whole body fluorescent scans over two hour time course for i.p., i.v. and non inject 
C1-3-750 administered mice. Individual fluorescent scans at designated time points from before and 
after C1-3-750 administration, highlighting the variation in fluorescent signal dependent upon the route 
of C1-3-750 injection. (Bkg – background scan prior to C1-3-750 administration, T0 – Time zero 
immediately after C1-3-750 administration, and the rest are hourly (h) time points). 
 
 
The initial whole body scan (Figure 3.12) highlights the major problem 
associated with i.v. injection, displayed by the high fluorescent signal emitted 
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from the tail (injection site) of the i.v. mouse due to the retention of the C1-3-
750 dose in the tail sheath. This was counteracted in the initial pilot work by 
covering the tails (injection site) of the mice, although this will just mask the 
fluorescence signal and does not impact upon the amount of C1-3-750 dosed. 
Therefore doubts about the success of injection and potential variations in the 
dose of C1-3-750 administered by i.v. injection will always persist. Secondly 
there was a strong signal emitted from the upper abdominal/ liver region of the 
i.p. mouse when compared to the i.v. mouse throughout the 2 hour time 
course (Figure 3.12), these findings were reinforced by the total fluorescence 
calculations in figure 3.13B. However the ex vivo organs scan (Figure 3.14A) 
and the total fluorescence calculations (Figure 3.14B) generated from the ROI 
reveal that there was a greater fluorescence from the liver of the i.v. injected 
mouse than the i.p. injected mouse. However there was still a significantly 
higher level of fluorescence from the liver of the i.p. mouse when compared to 
the non inject mouse. 
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Figure 3.13 Whole body fluorescent scan + ROIs for the upper abdominal and bladder regions, 
and the total fluorescence values. A Example image post scanning with ROIs overlaid using the 
Image Pro Plus 4.0 software. B Total fluorescence values calculated for each individual mouse (n=1). 
 
Figure 3.14 Ex vivo organ scan (with ROIs) and total fluorescence calculations for the individual 
organs from the i.p., i.v. and non inject C1-3-750 administered mice. A The ex vivo organ scan 
performed upon completion of the final (2 hour) whole body scans and schedule I termination of the 
mice. B The total fluorescence data generated shows both i.p. and i.v. are viable routes to administer 
C1-3-750 demonstrated by the high fluorescent signals emitted from the liver. There was also a high 
non specific signal emitted from the kidney (data not shown) as the scAb was being excreted from the 
body, there is also a strong pancreas signal especially in the i.p. injected mouse due to the presence of 
the target synaptophysin in the Islet cells (n=1). 
 
Considering the size of the planned study and the findings in section 3.1.4, in 
particular the need for repeated dosing and imaging of the same mice with 
C1-3-750, it was concluded that administering C1-3-750 by i.p. injection would 
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be the most easily reproduced and effective way of dosing C1-3-750 in the 
chronic study. There was no evidence of fluorescent antibodies previously 
being administered by an i.p. route in the literature; the general consensus is 
that i.v. gives a better distribution of the imaging agent [218] and is obviously 
more applicable clinically. However as the major aim of this study was the 
development of a non invasive imaging agent, an i.v. injection route cannot be 
used after the poor whole body findings in the pilot study (Figures 3.12 and 
3.13). This was reinforced by the need for repeated C1-3-750 injections, 
which can result in scarring of the injection site and subsequent problems 
when performing later injections. 
Another point of interest from this study was the high level of fluorescent 
signal emitted from the pancreas, particularly of the i.p. injected but also the 
i.v. injected mouse. This was not a result of non specific binding of the C1-3 
scAb, but due to the expression of high levels of synaptophysin in the Islet 
cells of the pancreas [219]. 
 
3.5 Using C1-3-750 in vivo to distinguish between different fibrosis 
severities 
 
To determine C1-3-750’s potential to differentiate between the various stages 
of hepatic fibrosis and to provide a quantitative value of fibrosis, a final in vivo 
study was performed with increased numbers of C57B1/6 mice with varying 
degrees of CCl4 induced liver fibrosis. Figure 3.15 is a schematic diagram 
illustrating the different treatment groups, alongside the dosing and imaging 
schedule. 
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Figure 3.15 Schematic diagram outlining the dosing and imaging regimens for the animal study 
trying to differentiate fibrosis severity. Each mouse received CCl4 twice weekly to induce 
centrilobular fibrosis (whilst controls received olive oil); the groups were staggered so the final CCl4 
doses were administered on the same day. Each group was imaged in the IVIS at 4 week intervals 
following anaesthetic and i.p. injection of 10mg/kg C1-3-750. After the final dose of CCl4 and 
subsequent IVIS imaging the following day all mice were terminated by a schedule I method.  The 
major organs were excised and placed in the IVIS chamber and imaged using the same settings, prior to 
retention for subsequent IHC and biochemical analysis. 
 
Briefly, group 1 received CCl4 for 12 weeks whilst group 2 received olive oil, 
and they were imaged at 4, 8 and 12 weeks following C1-3-750 injection. 
Group 3 received CCl4 for 8 weeks, whilst group 4 received olive oil for the 
same time period (and were imaged at 4 and 8 weeks of treatment); finally 
Chapter 3.0 – Results 
100 
 
group 5 received CCl4 for 4 weeks and group 6 received olive oil for the same 
period and both were imaged after 4 weeks of treatment. Whole body 
fluorescence scans following C1-3-750 i.p injection were performed and the 
12 weeks of CCl4 and olive oil treatment group scan is shown as an example 
in figure 3.16 (all images shown are from the two hour time point). The final 
imaging point for all treatment groups coincided on the same day and at this 
point all the mice were terminated by a schedule I method prior to ex vivo 
imaging of the major organs (Figure 3.17, 12 week treatment group example). 
The i.p. injection route is not infallible though as highlighted in figures 3.16 
and 3.17, where the final 12 week olive oil mouse does not emit any C1-3-750 
fluorescent signal from any excised organ. This was due to a poor i.p. 
injection, with the dose being accidentally administered subcutaneously and 
being trapped under the skin and unable to distribute to any of the major 
organs as seen in the other animals. 
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Figure 3.16 Whole body scan from the 12 week CCl4 treated and control mice. Image shown is the 
4 hour time point after C1-3-750 i.p. injection, all images were analysed using the Image Pro Plus 4.0 
software and the same total fluorescence scale was applied so they can be directly compared to each 
other. 
 
 
Figure 3.17 Ex vivo organ scan from the 12 week CCl4 treated and control mice. Upon completion 
of the 4 hour time point the mice were culled by a schedule I method and the major organs excised and 
imaged using the same settings. All images were analysed using the Image Pro Plus 4.0 software and 
the same total fluorescence scale was applied so they can be directly compared to each other. 
 
Using ROIs (Figure 3.18) as described in section 3.1.3 the total fluorescence 
could be calculated for both the upper abdominal and bladder regions as 
displayed in figure 3.19. The values shown are the mean for each treatment 
group (each group had a minimum of 3 animals). There was no difference in 
the total fluorescence values for the upper abdominal (liver) region of all the 
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CCl4 treatment groups and the olive oil control groups. These findings indicate 
that C1-3-750 cannot be used non-invasively as intended. The reason for the 
high upper abdominal fluorescence signals in the whole body scans of both 
the CCl4 and olive oil mice (Figure 3.16) and total fluorescence calculations 
(Figure 3.19) was a result of the C1-3-750 i.p. injection route. It appears that 
C1-3-750 pools in the peritoneal cavity for the duration of the time course and 
cannot distribute evenly throughout the body. It was saturating the upper 
abdominal region and masking any potential liver region signal, making it 
impossible to non invasively image liver fibrosis. 
 
Figure 3.18 Example whole body and ex vivo organ images annotated with ROIs. When analysing 
images with Image Pro Plus 4.0 software ROIs could be overlaid the images to allow quantification of 
total fluorescence values for specific body regions – (upper abdominal/ liver region and bladder/ C1-3-
750 excretion) and organs. 
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Figure 3.19 Total fluorescence values calculated for the upper abdominal and bladder regions of 
each treatment group. A upper abdominal and B bladder total fluorescence values calculated from the 
ROIs used during analysis of each individual treatment group. Data shown is the mean for each 
treatment group (Data are the mean, n=3 for each treatment group, Bkg – background scan prior to C1-
3-750 administration, T0 – Time zero immediately after C1-3-750 administration.) 
 
Total fluorescence calculations were also performed for the ex vivo organ 
scans (Figure 3.17) and the data generated is shown in figure 3.20A. Figure 
3.20B shows the mean total organ fluorescence of the brain, lung and liver 
when all the olive oil control animals have been combined, making it easier to 
distinguish between the treatment groups. The brain and lung have been 
included as they show very little fluorescence regardless of the treatment 
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group and help highlight the variation in liver signal between the treatment 
groups. Figure 3.21 shows the mean total fluorescence values for the excised 
livers of each treatment group, highlighting that there was no significant 
difference in fluorescence between the 12, 8 and 4 week CCl4 treatment 
groups. However there was a statistically significant (increased) level of liver 
fluorescence between the CCl4 treatment groups when compared to the 
controls and analysed using an ANOVA (p < 0.009). In this instance C1-3-750 
can distinguish between ex vivo fibrotic and non fibrotic livers, but was not 
sensitive enough to distinguish between the varying degrees of fibrosis. 
 
Figure 3.20 Total fluorescence values for the major organs of each treatment group following 
their excision. A all excised organs B brain, lung and liver fluorescence only. Individual organ total 
fluorescence values calculated from ROIs drawn around each organ, the data shown is the mean and 
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standard deviation (SD) for each treatment group (Mean and SD n=3 for non inject and CCl4 treatment 
groups, n=9 olive oil controls). 
 
 
Figure 3.21 Total fluorescence of excised liver from each treatment group. The individual total 
liver fluorescence values calculated for each treatment group from the ROIs drawn using the Image Pro 
Plus 4.0 software. (Mean and SD n=3 for non inject and CCl4 treatment groups, n=9 olive oil controls)), 
* denotes that a group is significantly different to the olive oil control when analysed using an ANOVA 
(p < 0.009). 
 
To confirm that the level of liver fluorescence coincided with liver damage and 
fibrosis development, a range of IHC analyses were performed to confirm 
both fibrosis development and the presence of hepatic myofibroblasts. Firstly, 
IHC analysis of the formalin fixed liver sections was performed to determine if 
there was, as hypothesised, a correlation between the number of hepatic 
myofibroblasts and the level of liver fluorescence. αSMA IHC was performed 
as this is a direct marker of hepatic myofibroblasts following HSC activation 
[220]. Typical images taken on the light microscope from each individual 
treatment group are shown in figure 3.22, showing the increased number of 
αSMA positive cells with CCl4 treatment. The number of αSMA positive cells 
was quantified blindly using Qwin software (Leica Microsystems) with a 
minimum of 10 random fields of view per image and 9 images per treatment 
group. As expected there was a statistically significant increase (p < 0.0001, 
analysed using an ANOVA) in the number of αSMA positive cells with CCl4 
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treatment, when compared to the olive oil and non inject control mice (Figure 
3.24A). 
 
Figure 3.22 αSMA IHC analysis of liver tissue from each treatment group. Liver tissue was fixed 
in 10% formalin prior to paraffin embedding, 5µM sections were cut from each animal. Sections were 
dewaxed prior to blocking of endogenous peroxidise activity and heat induced antigen retrieval. 
Followed by serum blocking and incubation for an hour at RTP with αSMA primary antibody, after 
PBS washing and addition of the complementary secondary antibody the level of bound antibody was 
detected by DAB incubation. The sections were counterstained with haematoxylin and dehydrated prior 
to mounting and analysis with a Leica upright microscope. (All images shown are x20 magnification). 
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Figure 3.23 Sirius red IHC analysis of liver tissue from each treatment group. Liver tissue was 
fixed in 10% formalin prior to paraffin embedding, 5µM sections were cut from each animal. Sections 
were dewaxed prior to incubation in sirius red stain (0.036mM in saturated picric acid) for 2 hours, 
after 3 brief washes in acidified H2O the sections were dehydrated prior to mounting and analysis with 
a Leica upright microscope. (All images shown are x20 magnification). 
 
Picro-sirius red IHC staining was performed, as sirius red binds strongly to 
collagens, and therefore it is an excellent indicator of fibrosis severity [214]. 
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As with the αSMA images there was an increase in collagen deposition with 
increased CCl4 administration (Figure 3.23). Quantification using the Qwin 
software (minimum of 10 random fields of view per image and 9 images per 
treatment group) confirmed that there was a statistically significant increase in 
collagen deposition proportional to the level of liver damage when compared 
to the olive oil and non inject control groups (p < 0.0001, analysed using an 
ANOVA) (Figure 3.24B). 
 
Figure 3.24 αSMA and sirius red IHC quantification. A αSMA and B sirius red positive staining 
was quantified using Qwin software (Leica), briefly 10 random images were captured for each section 
and blindly quantified to determine the positive αSMA and sirius red stain per field of view. (Mean and 
SD n=30) of percentage area of the stain for each treatment group and were tested for statistical 
significance using an ANOVA. (* denotes significance p < 0.0001 when compared to the olive oil and 
non inject control). 
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3.6 C1-3-750 signal quenching by liver tissue – limitations of optical 
imaging 
 
The long wavelength flurophore XF750 was chosen for these imaging studies 
as the major issue with optical imaging techniques is the penetration of light to 
deep tissue locations and the high auto fluorescence associated with mouse 
tissue. Tissue depth issues are due to absorption by haemoglobin at lower 
wavelengths (below 650nm) and the absorption by water at higher 
wavelengths (above 900nm) [221, 222]. Auto fluorescence is predominantly 
due to the presence of chlorophyll and other natural flavins in the mice’s diet, 
which absorbs at approximately 640nm and fluoresces at approximately 
675nm [218, 222]. Therefore by selecting XF750 as our flurophore the amount 
of background fluorescence will be reduced. The effect of tissue penetration 
on imaging outcome was another limitation I wished to determine. To assess 
this, a simple experiment was performed where a single dose of C1-3-750 in 
an eppendorf was imaged, and this was repeated when a mouse liver was 
placed over the C1-3-750 containing eppendorf (Figure 3.25A). Total 
fluorescence values were calculated with the aid of ROIs (Figure 3.25B) and 
the level of C1-3-750 fluorescence that was quenched by the liver tissue was 
calculated. In this instance 75% of the fluorescent signal had been lost, 
highlighting a major issue associated with optical imaging techniques [218, 
223]. This loss of signal will be increased when having to penetrate other 
tissues/ organs and the skin. Previous imaging work utilising C1-3 conjugated 
to an Alexa Fluor 594 dye (Molecular Probes) had signal quenching values of 
up to 99% by the liver tissue, showing the use of the long wavelength 
fluorophore XF750 improves tissue imaging. 
These findings confirm that poor tissue penetration and signal loss (Figure 
3.25) may explain the earlier results of the i.p. versus i.v. injection route pilot 
study, with improved ex vivo liver signal from the i.v. injected mouse, but very 
little upper abdominal (liver) signal detected in the whole body scans. In 
contrast the i.p. injected mouse exhibited a much higher upper abdominal 
(liver) fluorescent signal and still a relatively strong ex vivo liver signal, 
however this upper abdominal (liver) fluorescent signal was due to pooling of 
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the C1-3-750 dose in the i.p. cavity. This was confirmed in the later study 
when there was no difference in liver fluorescence detected between the CCl4 
treated and control mice in the whole body scans (Figure 3.16), whilst a 
statistically significant difference (p < 0.009, ANOVA) was detected in the ex 
vivo liver scans (Figure 3.21). 
 
Figure 3.25 Quenching of C1-3-750 fluorescence by liver tissue. A Single C1-3-750 dose and a 
single C1-3-750 covered by an ex vivo liver scans B Total fluorescence calculations for single C1-3-
750 dose and liver covered C1-3-750 dose. The arrows highlight the background fluorescence of the 
liver tissue and the degree of quenching (loss of fluorescence) of the C1-3-750 signal when covered 
with the mouse liver (n=1).  
 
3.7 C1-3-750 functioning in an in vivo rat model of liver fibrosis 
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To build upon the initial findings of the mouse study (Section 3.1.3), an 
identical study was performed in two Sprague-Dawley rats, where one 
received CCl4 twice weekly for four weeks (Table 2.1) whilst a control received 
olive oil. Upon completion of the CCl4 dosing regimen, both rats were 
anaesthetised using isoflurane and had their ventral side shaved. A 
background fluorescence scan was performed (Figure 3.26), prior to the i.p. 
injection of 10mg/kg C1-3-750. Whole body fluorescence scans were 
performed at regular time intervals as shown in figure 3.26. These initial whole 
body images coupled with the total fluorescence calculations for the upper 
abdominal/ liver region (Figure 3.27) suggest that the C1-3-750 conjugate was 
not functioning as seen previously in the mouse model. The signal appears to 
be originating more from the bladder region than the upper abdominal region, 
although it was greater in the CCl4 treated rat than the control rat. The ex vivo 
organ scans (Figure 3.28A) showed little fluorescence from both the control 
and CCl4 treated livers, and the total fluorescence calculations (Figure 3.28B) 
from the ex vivo organ scan confirm this. 
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Figure 3.26 Whole body fluorescent scans over two hour time course for 4 week CCl4 treated and 
control C1-3-750 rats. Individual fluorescent scans at designated time points from before and after 
C1-3-750 administration, highlighting the variation in fluorescent signal between the control and 
fibrotic rats. ( Bkg – background scan prior to C1-3-750 administration, T0 – Time zero immediately 
after C1-3-750 administration, and the rest are hourly (h) time points). 
 
There was negligible difference in the fluorescent signal emitted from the 
control and fibrotic rat livers, suggesting that C1-3-750 was not able to bind to 
synaptophysin present in the rat liver. The reason for this lack of binding is 
unknown, but could involve the presence of splice variants of synaptophysin 
or a variation in post translational modifications between species. This was 
particularly interesting as C1-3-750 was still binding strongly to the 
synaptophysin positive Islet cells in the rat pancreas (Figure 3.28). These 
findings are not totally unexpected, as previous unpublished in vitro work 
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within the laboratory found that C1-3-FITC does not bind rHSCs with the 
same affinity as it does mHSCs and hHSCs. 
 
Figure 3.27 Total fluorescence values calculated for the upper abdominal and bladder regions. 
Upper abdominal and bladder total fluorescence values calculated from the ROIs used during the 
analysis of each rat (n=1). 
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Figure 3.28 Ex vivo organ scan from the 4 week CCl4 treated and control rat and total 
fluorescence values calculated for individual organs. A Upon completion of the 2 hour time point 
the rats were culled by a schedule I method and the major organs excised and imaged using the same 
settings. B Total fluorescence values for individual organs calculated following analysis using ROIs 
available in the Living Image 4.0 software (n=1). 
 
3.8 Chapter discussion 
 
Liver fibrosis is caused by a wide variety of aetiologies (viral infections, 
autoimmune conditions and genetic disorders) and the current lack of a 
recognised anti-fibrotic treatment regimen, with the exception of 
transplantation, means its incidence is only expected to increase [24]. 
Commonly liver fibrosis is not diagnosed until its later stages (i.e. cirrhosis) 
[224]; this is primarily due to the compensatory ability of the hepatocytes to 
replace damaged liver tissue and the overcapacity of the liver. Despite recent 
advances in our knowledge of the fundamental steps involved in the 
pathogenesis of liver fibrosis [32, 186], we are still without a recognised anti-
fibrotic treatment regimen. 
Critical to the development of the novel anti-fibrotic regimes is the accurate 
diagnosis and quantification of fibrosis during therapeutic testing. At present 
the percutaneous liver biopsy remains the ‘gold standard’ and first choice in 
the diagnosis of liver fibrosis, despite its widely recognised limitations. These 
include issues of sample size and subsequent sampling errors [122], as well 
as medical complications associated with the procedure itself [121] and finally 
problems associated with the scoring of fibrosis/ interobserver variation. Other 
non invasive techniques, such as serum marker panels and transient 
elastography have been developed to diagnose liver fibrosis but are only able 
to successfully diagnose later stages of fibrosis [126, 139]. 
The C1-3 scAb developed by the Wright group in 2005 [115], was shown to 
be specific to synaptophysin peptide sequence 2, expressed on the surface of 
hepatic myofibroblasts. As hepatic myofibroblasts are the major fibrogenic cell 
type in the liver, the ability of C1-3 to target them is of great use. C1-3 has 
been previously conjugated with GTX as a potential anti-fibrotic agent 
inducing the apoptosis of hepatic myofibroblasts and significantly reducing the 
severity of fibrosis [116]. In this chapter we hypothesised that the number of 
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hepatic myofibroblasts was an indicator of fibrosis severity and therefore C1-3 
when conjugated with a long wavelength flurophore (XF750) could act as an 
effective imaging agent to quantify fibrosis severity in an in vivo model of liver 
fibrosis. 
Firstly the C1-3 scAb was successfully conjugated with the XF750 fluorescent 
dye, which was confirmed by SDS-PAGE analysis and its functioning 
confirmed by an ELISA to its target peptide (synaptophysin peptide sequence 
2). However, unlike the controls (C1-3-FITC and C1-3-594) C1-3-750 could 
not be detected in vitro co-localising with αSMA positive hepatic 
myofibroblasts. It was most likely this was a result of the large MW of the 
XF750 dye molecules, despite the fact all the other analyses suggested the 
C1-3-750 scAb retained C1-3’s unique properties. The functioning of the long 
wavelength filter on the microscope was confirmed as it could detect C1-3-
750 when a drop was placed directly under a coverslip. Potentially unbound 
C1-3 from the conjugation process detected in the MALDI-TOF analysis may 
have been competing with the C1-3-750 and inhibiting its binding to hepatic 
myofibroblasts in vitro; this was unavoidable as there was no effective viable 
way to separate the two samples. The size of the peaks also revealed how 
large the XF750 dye was, with an increase in MW from 37.5 kDa to 40.5 kDa. 
3 kDa is a large increase in MW and may sterically hinder C1-3’s interaction 
with its target antigen, whilst in contrast conjugation of FITC only increased 
the MW by less than 0.5 kDa. 
In vivo a single CCl4 and a single control mouse were administered C1-3-750 
by i.v. injection (as used in clinical settings) and optically imaged utilising the 
IVIS. The initial findings from the whole body scans were encouraging, with a 
clear increase in fluorescent signal from the upper abdominal (liver) region of 
the fibrotic mouse. This was reinforced by the ex vivo organ scan and total 
fluorescence calculations that confirmed there was an approximate two fold 
increase in fluorescent signal in the fibrotic mouse liver when compared to the 
control mouse. These results indicate that C1-3-750 was an effective method 
to non invasively image liver fibrosis, although a larger study with varying 
degrees of fibrosis severity was needed to confirm this. 
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Prior to undertaking this study a second pilot study was performed to 
determine whether C1-3-750 could be injected via an i.p. injection route 
without any significant detrimental effects on the imaging outcome. To assess 
this CCl4 treated mice were administered C1-3-750 by an i.p. and i.v. injection 
route together; the initial whole body scans suggested that i.p. injection would 
be an acceptable route. There was a much higher level of fluorescent signal 
from the upper abdominal (liver) region of the i.p. mouse when compared to 
the i.v. mouse on the whole body scans. Another point of interest is the high 
fluorescent signal emitted from the tail of the i.v. injected mouse, indicating 
that the C1-3-750 dose was retained in the tail sheath. Therefore the exact 
amount of the C1-3-750 dose administered cannot be known and could vary 
significantly between individual animals influencing the imaging outcome. 
However, the ex vivo organ scans revealed that there was a greater 
fluorescent signal from the liver of the i.v. mouse than the i.p. mouse, 
suggesting dosing via this route was more effective at reaching the liver. 
Potentially this could be due to the increased supply of venous blood to the 
liver from the portal vein, coupled with the slower distribution from the i.p. 
injection route [218]. There was also a strong fluorescent signal emitted from 
the liver of the i.p. mouse when compared to the other major organs indicating 
that this was also a viable route to dose C1-3-750. Due to the high numbers of 
mice and the need for repeated C1-3-750 dosing of the same mice, an i.p. 
injection route was chosen for the chronic study with varying degrees of 
fibrosis severity (12, 8 and 4 week CCl4 dosing). This decision was 
predominantly due to the difficulty associated with consistently performing 
effective i.v. injections (ensuring identical dosing) as there was the need for 
repeated injections to the same mice (issues with scarring via the i.v. route). 
Also the lack of detection of upper abdominal fluorescence in the liver region 
of i.v. pilot mouse in the whole body images suggests C1-3-750 administration 
by this route does not generate a signal that can be detected non invasively 
as desired unlike following i.p. injection. 
The whole body scans from the chronic study revealed the major limitation of 
employing an i.p. injection route, which was not encountered in the 
preliminary pilot studies. There was no difference in the fluorescent signal 
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between the upper abdominal (liver) and bladder regions of the CCl4 and olive 
oil groups; this was confirmed by the total fluorescence calculations. This was 
unavoidable especially when during the injection route pilot study; the i.v. 
injected mouse exhibited very little fluorescent signal until the liver was 
excised from the body, therefore this injection route could not be used non 
invasively. In hindsight it was a major oversight when performing the injection 
route pilot to not administer C1-3-750 to control mice. Alternatively taking into 
account the short biological half life of scAbs [225] the severity of the C1-3-
750 pooling/ signal from the i.p. cavity may have dropped significantly after a 
longer time period (e.g. 24 or 48 hours) to allow the diagnosis of the liver 
specific signals and determine any difference between the fibrotic and control 
animals. 
The ex vivo organ scans show that there was a statistically significant 
increase in  liver fluorescence of all the CCl4 treatment groups when 
compared to olive oil and non inject controls (p < 0.009, ANOVA). These 
findings were reinforced by the IHC analysis, in particular the number of 
αSMA positive myofibroblasts and sirius red positive collagen scars being 
significantly higher in all CCl4 treatment groups when compared to the olive oil 
and non inject controls (p < 0.0001, ANOVA). Another point of interest is the 
increase in fluorescence of the olive oil livers, when compared against the non 
inject controls. This increase may be due to the expression of synaptophysin 
on the surface of quiescent HSCs that are also present in the liver as well as 
the hepatic myofibroblasts (activated HSCs) [108]. 
The potential of C1-3 as a diagnostic imaging agent for liver fibrosis is clear, 
highlighted by the significant increase in liver fluorescence between the 
excised livers of the CCl4 treated and olive oil control groups. However there 
are major limitations to its use that need to be addressed, primarily the route 
of C1-3-750 injection. The findings from these pilot studies suggest that 
administration of C1-3-750 by i.p. injection results in pooling of the scAb in the 
peritoneal cavity. When coupled with C1-3’s short biological half-life this 
makes it impossible to diagnose fibrosis severity non invasively, which was 
the intended benefit of this novel technique. Secondly the deep tissue location 
of the liver and high level of fluorescence quenching (75% of the signal) by 
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the liver tissue result in a high loss of signal, illustrated when a free C1-3-750 
dose was covered by an uninjected mouse liver. 
The lack of functioning of C1-3-750 in a rat model of CCl4 induced liver 
fibrosis whilst still binding to the rat pancreas as seen in the mouse model 
indicates there is some variation in synaptophysin expression between 
species, which need to be investigated further. These pancreas findings 
suggest that C1-3-750 may be of benefit in measuring Islet cell numbers in 
pancreatic conditions such as pancreatitis, and the relative Islet mass in 
conditions including type II diabetes [226]. Although the significance of the 
pancreas signal upon the level detected in whole body scans is unclear due to 
the pooling of the C1-3-750 dose in the i.p. cavity. If a repeat study is 
performed in the future employing an i.v. injection route it is possible to 
generate a 3D composite image of the mice using the IVIS software, which 
may reveal the contribution of the pancreas fluorescence on that detected in 
the upper abdominal (liver) region of the whole body scans. 
C1-3-750 provides proof of concept findings that the C1-3 scAb can be used 
to target hepatic myofibroblasts in vivo and that their number is an indicator of 
fibrosis severity. Although in this instance C1-3 could not determine fibrosis 
severity non invasively, predominantly due to the issues with the injection 
route of C1-3-750 and the high quenching of the fluorescent signal by the liver 
tissue. The combination of C1-3 with a high power technique such as PET 
scanning is a future route to investigate. The conjugation of C1-3 with a 
radioisotope, such as 18F-SFB and PET scanning will remove the issues of 
tissue penetration and signal loss associated with optical imaging. PET 
centres on the beta decay of the radioisotope, generating a positron which 
upon collision with an electron releases two gamma rays that can be detected 
by a scanner and reconstructed into a 3D image [227]. 
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Chapter 4.0 - C1-3 binding to synaptophysin and its’ 
expression on hepatic myofibroblasts 
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4.1 Introduction 
 
The expression of synaptophysin by quiescent HSCs and activated hepatic 
myofibroblasts was first reported by Cassiman et al [108], its use as a target 
for anti-fibrotics was pioneered within this research laboratory with the 
development of the C1-3 scAb (Section 1.4). The results in chapter 3 highlight 
C1-3’s ability to bind to fibrotic livers in vivo when conjugated with a long 
wavelength flurophore. There was a statistically significant increase in the ex 
vivo liver fluorescence of fibrotic mice when compared to the control mice (p < 
0.009, analysed using an ANOVA). Interestingly there was also an increase in 
fluorescent signal emitted from the non-fibrotic mice livers when administered 
C1-3-750, supporting Cassiman’s initial work that synaptophysin is also 
expressed by quiescent HSCs. The presence of quiescent HSCs in the non-
fibrotic mice livers explaining this signal detected. 
There was also a disparity in C1-3’s functioning between species highlighted 
by its lack of functioning in a rat model of liver fibrosis (Section 3.7), in 
contrast to the positive findings when employing a mouse model of liver 
fibrosis (Sections 3.3 - 3.6). Surprisingly C1-3 was still able to bind to the Islet 
cells in the rat pancreas with high affinity, suggesting there was also a 
variation in synaptophysin expression between cells from different organs. 
Since the binding of synaptophysin in cells had not been formally tested, this 
was examined. Secondly ICC analysis was performed to investigate C1-3’s 
binding to quiescent as well as activated HSCs in vitro and to uncover more 
about the variation in synaptophysin expression of both quiescent and 
activated HSCs. 
 
4.2 Confirmation of C1-3’s binding to synaptophysin  
 
Following successful transfection of Cos7 cells with plasmids encoding either 
mouse or human synaptophysin under the control of tetracycline, C1-3-594 
and a commercially available C-terminal synaptophysin specific primary 
antibody (Dako, see Table 2.5) were individually added to the culture media, 
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as outlined in the ICC protocol (Section 2.8.6) prior to fluorescent microscopy. 
The fluorescent microscopy images shown in figure 4.1 firstly highlight the 
successful transfection of the synaptophysin plasmids into the Cos7 cells by 
the binding of the synaptophysin specific antibody. Secondly the co-
localisation of C1-3-594 only to the Cos7 cells transfected with the 
synaptophysin plasmids confirm its affinity for synaptophysin, their target 
present on the surface of hepatic myofibroblasts. 
 
Figure 4.1 C1-3-594 and synaptophysin ICC staining of transfected Cos7 cells. Cos7 cells grown in 
chamber slides (Merck) were transfected with either mouse or human synaptophysin plasmids 
overnight at 37 
o
C and 5% CO2. C1-3-594 or a synaptophysin primary antibody was added to the cells 
for 2 hours at 37 
o
C and 5% CO2 before subsequent 1 x PBS washing and addition of complementary 
fluorescent secondary antibody. The nuclei were visualised by a 10 minute DAPI incubation and 
subsequent fluorescent microscopy. Images shown are at x40 magnification. 
 
Western blotting analysis of protein samples isolated from these cell types 
(using mouse brain protein as a positive control) only detected the presence 
of synaptophysin protein in the transfected Cos7 protein samples (Figure 4.2). 
These findings prove that C1-3 specifically targets synaptophysin and the 
binding seen was not a property of the Cos7 cells. 
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Figure 4.2 Western blotting analysis of transfected Cos7 synaptophysin expression. Protein 
samples were isolated from the transfected cells and diluted to 2µg/µl in loading buffer, 20µg protein 
per sample was loaded onto a 9% acrylamide SDS gel. Following electrophoresis the protein was 
transferred onto a nitrocellulose membrane, blocked with 3% marvel protein prior to detection of C-
terminal synaptophysin and β-actin protein levels. 
 
4.3 Variation in synaptophysin expression between species 
 
 4.3.1 Whole tissue synaptophysin expression 
 
To investigate the variation in synaptophysin expression between individual 
species further, three sets of primers were designed to conserved regions of 
synaptophysin cDNA (human, mouse and rat sequences) (Figure 4.3 and 
Table 2.4). 
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Figure 4.3 Alignment of mouse, rat and human synaptophysin DNA sequences and 
synaptophysin primer locations. Synaptophysin DNA sequences were obtained from the NCBI 
database (www.ncbi.nlm.nih.gov) and were aligned using ClustalW software (found on 
http://www.ebi.ac.uk/). Primers (shown by the underlined coloured sequences) were subsequently 
designed using the Primer-BLAST programme on the NCBI database to conserved regions present in 
all species. 
 
As discussed in section 3.8 when utilising C1-3-750 as an in vivo imaging 
agent there was a variation in C1-3-750’s ability to bind to synaptophysin 
present in both the rat and mouse liver, with minimal efficacy seen in a rat 
fibrotic liver (Figure 3.28). 
Total RNA was isolated from the liver, pancreas and brain tissue of rats, mice 
and human (no human brain sample was available, so the SY5Y 
neuroblastoma cell line was used) and cDNA generated. Identical PCRs were 
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carried out using the three separate synaptophysin primer sets (1 upstream 
primer and 3 downstream primers (Table 2.4)) to detect the presence of 
synaptophysin in each tissue sample. 
Figure 4.4 shows that both mouse, rat brain and the SY5Y cell line express 
high levels of synaptophysin with all primer sets, however no synaptophysin 
could be detected in any tissue samples using the SYN1 and SYN3 primer set 
(which amplifies the whole translated cDNA sequence). When using SYN1 
and SYN2 a weak band of the correct size (347bp) was detected in the mouse 
olive oil liver but not in the mouse CCl4 liver. There are no visible bands in the 
rat liver samples, however the opposite is found when using the SYN1 and 
SYN4 primer set (DS4 is part of the synaptophysin peptide 2 cDNA sequence, 
Figure 1.6) as there were bands of the correct size in both the rat fibrotic and 
control liver samples, whilst there was only a very weak band in the fibrotic 
liver from the mouse samples. GAPDH was included as a housekeeping gene 
to confirm the integrity of the cDNA. Synaptophysin was only detected in the 
SY5Y positive control and could not be detected in any of the human tissue 
samples or the pancreas in all species. 
 
 
Figure 4.4 Synaptophysin expression of mouse, rat and human whole tissue samples. Total RNA 
was isolated from tissue samples using Trizol and quantified prior to reverse transcription to produce 
40ng/µl cDNA. 40ng was added to the PCR mastermix (see section 2.6.6). Following completion of the 
PCR cycle the products were run out on a 1.5% agarose gel (containing EtBr) to separate them 
according to their size and visualised by UV light exposure.  
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Figure 4.5 is an identical Western blot analysis on all tissue samples using a 
C-terminal synaptophysin specific primary antibody. Synaptophysin protein 
was only detected in the mouse and rat brain samples, suggesting that the 
level of synaptophysin protein expression was not high enough to be detected 
in any of the liver and pancreas samples by this method unlike the earlier 
PCR (Figure 4.4). β-actin is an internal housekeeping gene like GAPDH in the 
PCRs and serves as a loading control for Western blots, although its 
expression is minimal in the pancreas samples. Therefore the level of 
amylase was also detected as it is a pancreatic marker, simply confirming the 
presence of protein in the pancreas samples. 
 
 
Figure 4.5 Western blotting analysis of mouse, rat and human whole tissue samples 
synaptophysin protein expression. Protein samples were isolated from the tissue samples and diluted 
to 2µg/µl in loading buffer, 20µg protein per sample was loaded onto a 9% acrylamide SDS gel. 
Following electrophoresis the protein was transferred onto a nitrocellulose membrane, blocked with 3% 
marvel milk protein prior to detection of C-terminal synaptophysin, amylase and β-actin protein levels. 
 
Dual ICC analysis using αSMA and synaptophysin specific primary antibodies 
was also performed on fixed tissue samples to confirm the variation in 
synaptophysin expression between the organs of various species (Figure 4.6). 
αSMA was probed to confirm the presence of hepatic myofibroblasts in the 
CCl4 damaged rodent liver samples. Once again no synaptophysin was 
detected in any of the liver samples irrespective of the presence of hepatic 
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myofibroblasts. The presence of synaptophysin positive Islet cells in the 
pancreas samples firstly confirm the functioning of the synaptophysin 
antibody, although again only low levels of synaptophysin could be detected. 
Secondly it highlights the variation in synaptophysin expression between the 
organ samples. 
The variation in synaptophysin expression between the liver samples detected 
when utilising PCR, Western blotting and ICC analysis techniques suggest 
that synaptophysin may potentially be modified post-transcriptionally in the 
liver (e.g. glycosylation) preventing successful antibody detection by these 
methods. 
 
 
Figure 4.6 C1-3-594, αSMA and synaptophysin ICC staining of individual mouse, rat and human 
whole tissue samples. Tissue samples were fixed in 10% formalin prior to paraffin embedding, 5µM 
sections were cut from each animal. Sections were dewaxed prior to serum blocking and incubation for 
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an hour at room temperature with either C1-3-594, or the αSMA and synaptophysin primary antibodies, 
after PBS washing and addition of the complementary fluorescent secondary antibody. The sections 
were counterstained with DAPI prior to mounting and analysis with a Zeiss fluorescent microscope. 
(All images shown are x20 magnification). 
 
4.3.2 HSC synaptophysin expression 
 
The level of synaptophysin was also examined in cDNA isolated from 
activated mouse, rat and human HSCs utilising the same synaptophysin 
primer sets. Figure 4.7 highlights that synaptophysin can be detected in all 
HSC samples, with every primer set. Although the levels of synaptophysin 
detected are very low in comparison to the level detected in the mouse brain 
cDNA sample (positive control). 
 
Figure 4.7 Synaptophysin expression of mouse, rat and human HSCs. Total RNA was isolated 
from cultured HSCs using Trizol and quantified prior to reverse transcription to produce 40ng/µl 
cDNA. 40ng was added to the PCR mastermix (see section 2.6.6). Following completion of the PCR 
cycle the products were run out on a 1.5% agarose gel (containing ethidium bromide) to separate them 
according to their size and visualised by UV light exposure.  
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Figure 4.8 is an identical Western blot on HSC protein samples using the 
same C-terminal synaptophysin primary antibody (Table 2.5). Once again full 
length synaptophysin protein was only detected in the mouse brain sample, 
suggesting that the level of synaptophysin protein expression was not high 
enough to be detected using this method. These data reaffirms our earlier 
observation (found when analysing the tissue samples) that there was a post-
transcriptional modification of synaptophysin preventing its detection by this 
method. 
 
Figure 4.8 Western blotting analysis of mouse, rat and human HSCs synaptophysin protein 
expression. Protein samples were isolated from HSCs and diluted to 2µg/µl in loading buffer, 20µg 
protein per sample was loaded onto a 9% acrylamide SDS gel. Following electrophoresis the protein 
was transferred onto a nitrocellulose membrane, blocked with 3% marvel protein prior to detection of 
C-terminal synaptophysin and β-actin protein levels. 
 
4.4 Variation in relative synaptophysin expression between quiescent 
and activated HSCs 
 
As highlighted in chapter 3, there was increased liver fluorescence in the 
control mice when compared to the non inject controls, suggesting that C1-3-
750 targets quiescent HSCs as well as the intended hepatic myofibroblasts 
(activated HSCs) present in the CCl4 treated mice. Despite its use previously, 
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little work has been carried out to determine the relative synaptophysin 
expression of both quiescent and activated HSCs, and C1-3’s affinity to both. 
qRT-PCR utilising SYBR Green and the SYN1 (US) and SYN4 (DS) primer 
set was performed to determine synaptophysin expression in both mice and 
human quiescent and activated HSCs. All data was calculated relative to the 
endogenous control 18s and the fold change calculated against the level of 
mouse brain synaptophysin expression. Figure 4.9A shows that both (mouse 
and human) quiescent and activated HSCs express synaptophysin at a level 
similar to that detected in the neuroblastoma SY5Y cell line. Activated HSCs 
express more synaptophysin than quiescent HSCs although both were 
approximately 100 fold lower than that detected in the mouse brain sample. 
The average ΔCT values calculated for each cell type are shown in figure 
4.9B, highlighting the lower ΔCT value in comparison to the mouse brain 
sample. Secondly it shows the similarity in ΔCT between the various HSC cell 
types and SY5Y cell line. 
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Figure 4.9 A Quantitative real-time PCR analysis of quiescent and activated HSCs synaptophysin 
expression. B Average cT values for each cell type. Total RNA was isolated from quiescent HSCs 
(48 hours after isolation) and activated HSCs (after one passage) using Trizol and quantified prior to 
reverse transcription to produce 40ng/µl cDNA. 10ng was added to the PCR mastermix in triplicate 
(see section 2.6.9). Quantitation of synaptophysin gene expression was calculated relative to the 
endogenous control 18s; the fold change was calculated against the mouse brain cDNA (high 
synaptophysin expression). (Data plotted is the mean and SD, minimum n=3 for each cell type). B 
Average ΔCT values for each cell type following subtraction of equivalent 18s cT value.  
 
To confirm C1-3’s affinity for both cell types C1-3-594 was added to both 
quiescent (48 hours after isolation) and activated (after one passage) mouse 
and human HSCs, antibodies specific to both synaptophysin and αSMA were 
also detected (Table 2.5). Figure 4.10 is a typical image from both the ICC 
stained mouse and human quiescent HSCs, the binding of C1-3-594 (red) to 
some of the DAPI stained quiescent HSCs is apparent. As expected no αSMA 
could be detected whilst the cells were still in their quiescent state and 
synaptophysin was also undetectable. 
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Figure 4.10 C1-3-594, αSMA and synaptophysin ICC staining of quiescent mouse and human 
HSCs. 48 hours after isolation quiescent mouse and human HSCs were serum blocked with 20% FCS 
in 1 x PBS before incubation for an hour at room temperature with either C1-3-594, or the αSMA and 
synaptophysin primary antibodies, after PBS washing and addition of the complementary FITC 
secondary antibody. The cells were counterstained with DAPI prior to analysis with a Leica fluorescent 
microscope. (All images shown are x20 magnification). 
 
Figure 4.11 is a typical image from both the mouse and human activated 
HSCs following C1-3-594 incubation. There is strong binding of C1-3-594 
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(red) to some of the DAPI stained HSCs and co-localisation with αSMA. 
Synaptophysin was also detected, although the level of synaptophysin and 
number of synaptophysin positive myofibroblasts was very low in comparison 
to αSMA levels detected. The co-localisation of C1-3-594 with synaptophysin 
supports our initial hypothesis that C1-3 is binding to synaptophysin on the 
surface of hepatic myofibroblasts. 
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Figure 4.11 C1-3-594, αSMA and synaptophysin ICC staining of activated mouse and human 
HSCs. Activated mouse and human HSCs (following one passage) were serum blocked with 20% FCS 
in 1 x PBS before incubation for an hour at room temperature with either C1-3-594, or the αSMA and 
synaptophysin primary antibodies, after PBS washing and addition of the complementary FITC 
secondary antibody. The cells were counterstained with DAPI prior to analysis with a Leica fluorescent 
microscope. (All images shown are x20 magnification). 
 
4.5 Chapter discussion 
 
The data presented in this chapter confirm our previous findings that C1-3 is 
specific to hepatic myofibroblasts, due to the presence of synaptophysin on 
their surface (Figure 1.6). This was confirmed by fluorescent microscopy 
when fluorescently labelled C1-3 (C1-3-594)  was shown to bind specifically to 
Cos7 cells in vitro (transfected with plasmids encoding the over expression of 
mouse or human synaptophysin). C1-3-594  displayed no affinity for 
untransfected Cos7 cells, indicating that it was binding as a result of their 
synaptophysin expression (Figure 4.1). Western analysis of protein samples 
isolated from these transfected cells confirmed the successful transfection of 
synaptophysin plasmids into the cells (Figure 4.2). 
In the future further confirmation of C1-3’s binding to synaptophysin positive 
Cos7 cells could be performed by Western blotting following C1-3 culture with 
synaptophysin transfected Cos7s. Using a Cκ light chain specific primary 
antibody that will bind any C1-3 present, any bands detected will confirm C1-
3’s binding to synaptophysin positive Cos7 cells. 
The variation in synaptophysin expression between species and the various 
organs (i.e. liver and pancreas) was investigated employing PCR, Western 
blotting and ICC techniques. These findings (Figures 4.4 and 4.5) highlight the 
difficulty of detecting synaptophysin protein in the liver using commercially 
available antibodies with only very low levels detected by fluorescent ICC and 
none by a Western blotting method. The detection of synaptophysin by PCR 
but not by Western blotting suggests that the protein is post-transcriptionally 
modified, and the transcript may be truncated in myofibroblasts as the 
antibody was unable to detect it. The synaptophysin PCR products could be 
purified from the agarose gels and cloned into a plasmid vector for 
sequencing analysis (e.g. Zero Blunt TOPO vector, Invitrogen). The 
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sequencing data would highlight any variations in synaptophysin expression 
between the rat and mouse livers and also between quiescent and activated 
HSCs. 
It was also shown by qRT-PCR that quiescent HSCs express a similar level of 
synaptophysin to hepatic myofibroblasts (Figure 4.9), as initially reported by 
Cassiman et al [108] and suspected from the data presented in chapter 3. The 
binding of C1-3 to both quiescent HSCs and hepatic myofibroblasts was 
confirmed in vitro (Figures 4.10 and 4.11). A future study is required to 
determine the significance of C1-3 binding to quiescent HSCs upon the 
imaging outcome in vivo. Initially addition of both free GTX and C1-3-GTX to 
quiescent HSCs in vitro could shed light on their susceptibility to its toxicity 
and give an indication of what may occur when C1-3-GTX is administered in 
vivo to deplete hepatic myofibroblasts. If C1-3-GTX induces quiescent HSC 
apoptosis in vitro it could be possible to treat non-fibrotic mice with C1-3-GTX 
to determine the effect of qHSC loss in a normal healthy liver setting. This 
could in turn be repeated prior to administration of CCl4 and see the 
downstream effects of quiescent HSC loss upon liver fibrosis development. 
The data presented in this chapter confirms that C1-3 is able to target both 
quiescent and activated HSCs (hepatic myofibroblasts), and that both express 
similar levels of synaptophysin. Performing these future studies will reveal the 
impact of C1-3 targeting quiescent HSCs when it is used as either an imaging 
or anti-fibrotic agent. Finally the difficulties encountered in detecting 
synaptophysin expression by both Western blotting, IHC and ICC analysis 
techniques, indicates there may be post-transcriptional modification of the 
protein that also requires further investigation. 
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Chapter 5.0 - The anti-inflammatory potential of PXR 
activators in an in vivo model of liver fibrosis 
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5.1 Introduction 
 
The correlation between decreased CYP450 activity and increased levels of 
inflammation is well documented, although initially the mechanism of this 
CYP450 down regulation was unknown [167]. The glucocorticoid receptor 
(GR) (another major member of the NRS) has been shown to inhibit NF-ĸB 
activity and inflammation [169]. A number of groups then highlighted the 
beneficial anti-inflammatory properties of pregnane X receptor (PXR) 
agonists, most notably in gastrointestinal inflammatory disorders (e.g. IBD) 
[166, 170]. With the knowledge that the inflammatory cascade is central in 
liver fibrosis development and that the PXR is constitutively expressed in the 
liver [154], the potential benefits of employing PXR activators are clear. 
Previous work within this laboratory (both in vitro and in vivo) demonstrated 
the anti-fibrotic properties of PXR agonists in combating liver fibrosis 
development [172, 173]. 
The importance of NF-ĸB in the maintenance and development of liver fibrosis 
has been shown; it is expressed in hepatic myofibroblasts [91, 92, 183]. Novel 
anti-fibrotic agents such as C1-3-GTX and sulfasalazine, which are known to 
target NF-κB, have been used in vivo to induce hepatic myofibroblast 
apoptosis and reduce fibrosis severity [90, 91]. In vitro work, utilising the 
monocytic U937-NF-ĸB cell line (stably transfected with the luciferase gene 
under the control of a concatemer of NF-κB response elements) also showed 
that PXR activators inhibit NF-ĸB activity. Addition of PXR agonists (e.g. 
rifampicin, hyperforin and metyrapone) inhibited the luciferase response 
normally seen after addition of pro-inflammatory mediators including TNFα 
and LPS [175]. 
The generation of transgenic mice (NF-κB luciferase mice) that contain the 
firefly-luciferase gene under the control of NF-κB response elements [187], 
provide a live animal model for examining inflammation in vivo. 
Using both an acute and chronic in vivo model of liver fibrosis (CCl4 treated 
NF-κB luciferase mice) we hypothesised that administration of the rodent 
specific PXR activator PCN would have beneficial anti-inflammatory 
properties. Upon completion of the designated CCl4 treatment regimen, PCN 
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was administered prior to D-luciferin injection and IVIS imaging to generate 
both whole body and ex vivo organ images. The level of luciferase activity and 
luminescence detected is directly related to the level of inflammation, 
governed by NF-κB induction. It will be possible to locate and quantify the 
level of NF-κB activity (and inflammation) from both the whole body and ex 
vivo luminescent scans. If PXR activators exhibit beneficial anti-inflammatory 
properties as hypothesised, there would be a reduction in the level of 
luminescence (i.e. NF-κB activity) in the upper abdominal (liver) region of CCl4 
treated mice and ex vivo liver when also administered with PCN. 
 
5.2 Anti-inflammatory properties of PCN in an in vivo (chronic and acute) 
model of liver fibrosis  
 
Figure 5.1 is a schematic diagram illustrating the different treatment groups, 
alongside the dosing and imaging schedule. Briefly the chronic groups were 
treated for four weeks with CCl4 (see table 2.1 for dosing solutions), whilst 
controls received olive oil for four weeks. The acute groups received a single 
dose of CCl4 when the chronic groups received their final dose of CCl4 (the 
day before imaging). PCN was administered with these final doses where 
designated, dissolved in the olive oil vehicle solution. 
 
Figure 5.1 Schematic diagram outlining the dosing and imaging regimen. Chronic CCl4 mice 
received CCl4 twice weekly to induce centrilobular fibrosis (whilst controls received olive oil); acute 
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CCl4 mice received a single dose on the same day of the chronic groups’ final dose. Where required 
PCN was co-administered in the vehicle solution (olive oil) with the final dose, at this point mice were 
returned to their cages prior to IVIS imaging at the desired timepoints. 
 
The mice were anaesthetised with isoflurane and had their ventral side 
shaved before being placed in the IVIS imaging chamber. Whole body 
bioluminescent scans were performed before the acute dose of CCl4 to 
confirm firstly that every mouse in the study contained the luciferase 
transgene and also to demonstrate basal levels of luciferase activity. Figure 
5.2 is an example basal whole body scan performed 10 minutes after i.p. 
injection of 200µl D-luciferin (15mg/kg) using a 2 minute exposure setting 
(these settings were retained for each subsequent scan performed). 
 
Figure 5.2 Whole body luminescent background scan prior to PCN administration. Control mice 
were anaesthetised with isoflurane and had their ventral side shaved, prior to placement in the IVIS 
chamber and i.p. injection of 15mg/kg D-luciferin. All scans were performed using the same 
luminescent filter settings and a manual 2 minute exposure settings. The images were analysed using 
the Image Pro Plus 4.0 software and the total luminescence scale bar set to the same levels so they 
could be directly compared. 
 
Figure 5.3 is an example individual whole body scan, as performed for each 
treatment group 6 hours after the final CCl4/ PCN administration using the 
same imaging settings as outlined for the background scan. 
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Figure 5.3 Acute CCl4 & acute CCl4 + PCN whole body luminescent scans 6 hours after PCN 
administration. Image shown was captured 10 minutes after D-luciferin injection using the same filter 
and exposure settings. All images were analysed using the Image Pro Plus 4.0 software and the same 
total luminescence scale applied so they can be directly compared to each other. 
 
It was difficult to discern much from the images themselves, however using 
ROIs as shown earlier in section 3.3, and it was possible to quantify the level 
of luminescence of specific body regions seen in the whole body scans 
(Figure 5.4A). Figure 5.4B is the mean and SD total luminescence calculated 
for the upper abdominal (liver) region of each treatment group, the findings 
reinforce the observations from the whole body scans. The chronic CCl4 group 
was the only group where PCN appeared to act as hypothesised, with a 
decrease in luminescence of the liver region although this decrease was not 
statistically significant (p < 0.056, ANOVA). PCN administration has had no 
effect on the level of luminescence in the liver region of either the control or 
acute CCl4 treatment groups. In this instance PCN appears to be pro-
inflammatory demonstrated by the increased levels of luminescence detected 
in the acute and control groups when they also received PCN. 
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Figure 5.4 Example whole body image annotated with ROIs and accompanying 6 hour total 
luminescence values. A When analysing images with Image Pro Plus 4.0 software ROIs could be 
overlaid onto the images to allow quantification of total luminescence values for specific body regions 
e.g. upper abdominal/ liver region. B upper abdominal/ liver total luminescence values calculated for 
each individual treatment group. (Data shown is the mean and SD n=3 for each treatment group). Data 
was analysed for any statistically significant differences between treatment groups although none were 
found. 
 
Figure 5.5 is an example individual whole body scan performed for each 
treatment group performed 24 hours after the final CCl4/ PCN dose, using the 
same exposure settings and captured 10 minutes after D-luciferin injection. 
There was a much greater level of luminescence in all CCl4 treatment groups 
when compared to the control groups, and PCN administration had reduced 
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the level of luminescence in both CCl4 treatment groups. Figure 5.6A is an 
example of the ROI used to calculate the mean total luminescence counts for 
the upper abdominal (liver) region of each treatment group. The data shown in 
figure 5.6B confirm the initial observations from the whole body scans (Figure 
5.5), firstly all CCl4 treatment groups (except acute CCl4 only, due to one 
anomalous reading) exhibited significantly higher levels of upper abdominal 
(liver) luminescence when compared to the control groups (p < 0.016, 
ANOVA). More importantly there was a reduction in the level of upper 
abdominal (liver) region luminescence in both the chronic and acute CCl4 mice 
when also treated with PCN, with the greatest effect seen in the chronic CCl4 
mice treated with PCN. Analysis of the chronic CCl4 mean total luminescence 
using an ANOVA revealed this difference was statistically significant (p < 
0.0087). Therefore it is highly plausible that PCN does have beneficial anti-
inflammatory properties mediated via NF-ĸB, especially when taken together 
with the previous findings of this laboratory [172, 173]. 
 
Figure 5.5 Chronic CCl4 & Chronic CCl4 + PCN whole body luminescent scans 24 hours after 
PCN administration. Image shown was captured 10 minutes after D-luciferin injection using the same 
filter and exposure settings (these were retained for all subsequent images). All images were analysed 
using the Image Pro Plus 4.0 software and the same total luminescence scale applied so they can be 
directly compared to each other.  
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Figure 5.6 Example whole body image annotated with ROIs and accompanying 24 hour total 
luminescence values. A When analysing images with Image Pro Plus 4.0 software ROIs could be 
overlaid onto the images to allow quantification of total luminescence values for specific body regions 
e.g. upper abdominal/ liver region. B upper abdominal/ liver total luminescence values calculated for 
each individual treatment group. (Data shown is the mean and SD n=3 for each treatment group, * 
denotes a statistically significant difference between CCl4 treatment group and controls, analysed by 
ANOVA (p < 0.016) and $ denotes a significant decrease in upper abdominal luminescence following 
PCN treatment, analysed using an ANOVA (p < 0.0087). 
 
Upon completion of whole body scans 24 hours after PCN administration the 
mice were terminated by cervical dislocation and the major organs excised 
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and placed in the IVIS imaging chamber prior to detection of their individual 
luminescence. Figure  5.7 is an example ex vivo organ scan from the chronic 
CCl4 treatment group; it was clear from all the scans that there was a marked 
increase in luminescence of the liver compared to the other excised organs 
(kidney, spleen and stomach). This indicates that CCl4 treatment has resulted 
in liver damage/ inflammation as expected; the other organs exhibit minimal 
luminescence with the exception of a single anomalous stomach signal in the 
acute CCl4 + PCN treatment group (data not shown). 
 
 
Figure 5.7 Chronic CCl4 & Chronic CCl4 + PCN ex vivo organ luminescent scans 24 hours after 
PCN administration. Upon completion of the 24 hour whole body scans mice were culled by a 
schedule I method the major organs were excised (liver, kidney, spleen and stomach) and placed in the 
IVIS imaging chamber. The same filter and exposure settings were used and all images were analysed 
using the Image Pro Plus 4.0 software and the same total luminescence scale applied so they can be 
directly compared to each other. 
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As found in the 24 hour whole body scans the livers of chronic and acute CCl4 
mice display significantly higher luminescence than the control groups. This 
difference in luminescence was statistically significant in the 24 hour whole 
body scans for the liver regions of chronic CCl4 mice versus those that also 
received PCN (p < 0.0087, ANOVA), whilst no difference was detected in the 
acute CCl4 treatment groups. To determine the accuracy of these 
observations ROIs were overlaid onto the images around each individual 
organ, as shown in figure 5.8A. The mean total luminescence for each organ 
of a treatment group was calculated and is shown in figure 5.8B. As reported 
earlier there was no luminescence detected from the kidney or spleen in all 
the treatment groups and the stomach was only detected at low levels in a 
couple of groups, which could be a result of localised inflammation unrelated 
to CCl4 administration. 
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Figure 5.8 A Example ex vivo organ scan annotated with ROIs and B total luminescence values 
calculated for each treatment group. When analysing images with Image Pro Plus 4.0 software ROIs 
could be overlaid to allow quantification of total luminescence values for specific organs. The data 
shown is the mean and SD n=3 for each treatment group.  
 
Figure 5.9 is the mean and SD total liver luminescence calculated for each 
treatment group. As expected there was a statistically significant increase in 
the total liver luminescence of both the chronic and acute CCl4 treated mice 
when compared to the control mice (p < 0.019, ANOVA). More importantly the 
treatment of chronic CCl4 mice with PCN has reduced the level of 
luminescence to a level similar to that of the control mice; when analysed 
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employing an ANOVA these findings were statistically significant (p < 0.012). 
In contrast there was negligible difference in total liver luminescence between 
the acute CCl4 mice regardless of PCN administration, suggesting that PCN 
has no effect in an acute model of liver damage. This could be due to the lack 
of hepatic myofibroblasts, as they take longer than 24 hours to develop 
following CCl4 administration. 
These data confirms that PCN has beneficial anti-inflammatory properties 
mediated via NF-ĸB, and may be a potential route to alleviate inflammation in 
chronic liver disease and form part of a treatment regimen to combat liver 
fibrosis. 
 
Figure 5.9 Mean total luminescence of excised liver from each treatment group. The individual 
total liver luminescence values calculated for each treatment group from the ROIs drawn using the 
Image Pro Plus 4.0 software. The data shown is the mean and SD n=3 for each treatment group, * 
denotes a statistically significant increase in total liver luminescence in comparison to the olive oil 
control when analysed using an ANOVA (p < 0.019). $ denotes that there was a significant difference 
in liver luminescence following PCN treatment, analysed using an ANOVA (p < 0.012). 
 
Following completion of the ex vivo organ scans the liver tissue was both 
snap frozen in LqN2 for further biochemical analyses and fixed in 10% 
formalin for IHC analysis. Luciferase assays were performed on liver tissue 
homogenates (see methods 2.12 and 2.13), providing another route to 
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ascertain whether PCN treatment had reduced the level of inflammation 
induced by CCl4 administration. Figure 5.10 shows the mean and SD 
luciferase activity of each treatment group. The data mirrors the total 
luminescence calculations from the whole body scans and ex vivo liver scans 
as PCN administration has reduced the level of transgene expression (i.e. 
inflammation). In this instance PCN administration has had a greater effect in 
the acute CCl4 treated mice when compared to the chronic CCl4 treated mice 
as found previously. There was a statistically significant increase in the 
luciferase activity of the liver homogenate of both the chronic and acute CCl4 
treatment groups in comparison to the control groups (p < 0.043). However 
the difference between the chronic CCl4 treatment group and those that also 
received PCN was outside the range of significance (p < 0.16) when analysed 
employing an ANOVA. 
 
Figure 5.10 Mean luciferase activity of liver homogenates from each treatment group. Individual 
liver samples from each mouse were homogenised and mixed 1:1 with an equal volume of luciferase 
substrate prior to determination of luciferase activity using a bench top luminometer. The data shown is 
the mean and SD n=3 for each treatment group, * denotes a significant increase in luciferase activity in 
comparison to the controls when analysed using an ANOVA (p < 0.043). $ denotes that there was a 
significant difference in liver luminescence following PCN treatment, analysed using an ANOVA (p < 
0.0068). 
 
Interestingly in this instance there was a significant reduction in the luciferase 
activity of the acute CCl4 treatment group following PCN administration (p < 
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0.0068, ANOVA). The findings of the liver homogenate luciferase assays are 
in contrast to the earlier IVIS scans and total luminescence calculations, with 
a statistically significant reduction in liver luminescence in the acute CCl4  
treatment group as opposed to the chronic CCl4  treatment group as 
previously found. 
 
5.3 PCN administration does not influence CCl4 hepatotoxicity and 
severity of fibrosis development 
 
To confirm previous findings that PXR activators had no effect upon CCl4 
hepatotoxicity but reduced the level of hepatic fibrosis that occurred [172], a 
range of biochemical and IHC analyses were also performed. Firstly whole 
blood was collected by cardiac puncture and the serum fraction was isolated 
as outlined in section 2.11. The samples were analysed for both serum ALT 
and ALP levels and the mean and SD for each treatment group is shown in 
figure 5.11. The findings are consistent with previous work as there are 
significantly elevated ALT levels in all the CCl4 treatment groups regardless of 
PCN dosing, when compared to the control groups that are at normal 
physiological levels (p < 0.0001, ANOVA). ALT is an important enzyme in 
amino acid synthesis expressed at high levels in hepatocytes, and is generally 
only found at elevated levels in the serum when centrilobular hepatocyte 
necrosis has been induced [2]. ALP was measured as a negative control to 
show serum levels are unaffected, demonstrated by the low levels of ALP in 
all treatment groups. Elevated ALP levels are associated with biliary/ 
cholestatic liver injuries and are only affected by extremely severe 
centrilobular CCl4 induced liver damage [2]. 
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Figure 5.11 Serum ALT and ALP concentrations. Mice were schedule 1 killed and whole blood was 
removed and allowed to clot at room temperature for 1 hour. Serum was removed following 
centrifugation and diluted in 0.9% sodium chloride. All serum samples were analysed by Newcastle 
Clinical Biochemistry Department. Data are the mean and SD n=3 for each treatment group. * denotes 
there was a statistically significant increase in ALT serum levels, when analysed by an ANOVA (p < 
0.0001). 
 
IHC analysis was also performed to confirm the development of liver damage/ 
fibrosis consistent with 4 weeks and a single dose of CCl4 administration. 
Figure 5.12 is a typical H&E stained section from each treatment group 
highlighting the CCl4 induced liver damage and that co-administration of PCN 
has no influence on its severity. There was an increased number of infiltrating 
inflammatory cells around the regions of damage (the central veins) in both 
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the chronic and acute CCl4 treated mice; the damage was also shown by the 
lighter shade of pink and the loss of the clear regular repetitive/ patterned 
appearance of the hepatocyte nuclei as seen in the controls. 
 
Figure 5.12 H&E IHC analysis of all treatment groups. Liver tissue was fixed in 10% formalin prior 
to paraffin embedding, 5µM sections were cut from each animal. Sections were dewaxed prior to 
haematoxylin incubation for 1 minute and extensive washing in deionised water. This was followed by 
a second incubation in Scott’s water for thirty seconds before further washing. Sections were finally 
counterstained in eosin for 30 seconds before deionised water washing and dehydration and mounting. 
It is clear there is only liver damage in the CCl4 treated livers regardless of PCN treatment and that it is 
located primarily in hepatocytes surrounding the central vein. 
 
αSMA IHC staining was also performed as hepatic myofibroblasts are the 
central cell involved in liver fibrosis development, and αSMA is the most 
prominent marker used to detect them. Figure 5.13 shows there was an 
increased number of αSMA positive hepatic myofibroblasts in the chronic CCl4 
treated groups irrespective of PCN treatment. The number of αSMA positive 
hepatic myofibroblasts was quantified and the mean cell counts and SD for 
each treatment group are shown in figure 5.14. There was no difference in 
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their number regardless of PCN treatment in all groups, however it is 
important to note that there are no αSMA positive hepatic myofibroblasts in 
the control groups to be detected and there are very few if any following the 
single dose of CCl4 in the acute groups. 
 
Figure 5.13 αSMA IHC analysis of liver tissue from each treatment group. Liver tissue was fixed 
in 10% formalin prior to paraffin embedding, 5µM sections were cut for each animal. Sections were 
dewaxed prior to blocking of endogenous peroxidise activity and heat induced antigen retrieval. 
Followed by serum blocking and incubation for an hour at room temperature with αSMA primary 
antibody, after PBS washing and addition of the complementary secondary antibody the level of bound 
antibody was detected by DAB incubation. The sections were counterstained with haematoxylin and 
dehydrated prior to mounting and analysis with a Leica upright microscope. (All images shown are x20 
magnification).  
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Figure 5.14 αSMA IHC quantification. αSMA positive staining was quantified using Qwin software 
(Leica); briefly 10 random images were captured for each section and blindly quantified to determine 
the positive αSMA stain per field of view. The data are the mean and SD n=30 percentage area of the 
stain for each treatment group and were tested for statistical significance using an ANOVA, * denotes 
there was a statistically significant increase in αSMA positive cells (p < 0.0001). 
 
Another prominent marker used to quantify hepatic fibrosis development is the 
deposition of collagens, and they can be detected by sirius red staining. 
Figure 5.15 is a typical image taken from each treatment group. The 
percentage of sirius red positive areas could also be quantified and the mean 
values for each treatment group are shown in figure 5.16. The values 
calculated reinforce the images with no discernible difference between the 
chronic CCl4 treatment groups regardless of PCN administration. There was 
no obvious difference between the acute CCl4 and control groups, as identical 
to the αSMA images there was very little positive sirius red to be detected as 
collagen deposition and build up is a result of chronic liver damage. 
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Figure 5.15 Sirius red IHC analysis of liver tissue from each treatment group. Liver tissue was 
fixed in 10% formalin prior to paraffin embedding, 5µM sections were cut for each animal. Sections 
were dewaxed prior to incubation in sirius red stain (0.036mM in saturated picric acid) for 2 hours, 
after 3 brief washes in acidified H2O the sections were dehydrated prior to mounting and analysis with 
a Leica upright microscope. (All images shown are x20 magnification).  
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Figure 5.16 Sirius red IHC quantification. Sirius red positive staining was quantified using Qwin 
software (Leica); briefly 10 random images were captured for each section and blindly quantified to 
determine the positive sirius red stain per field of view. The data are the mean and SD n=30 of 
percentage area of the stain for each treatment group and were tested for statistical significance using 
an ANOVA. * denotes there was a statistically significant increase in sirius red positive cells in 
comparison to the control groups (p < 0.0001). 
 
NIMP IHC staining was also performed to detect the presence of neutrophils 
in the liver tissue; neutrophils are the hallmark inflammatory cell recruited to 
the liver during the innate immune/ inflammatory response after liver injury 
[34, 228]. If PCN has had an anti-inflammatory effect this could be displayed 
by a reduction in the number of NIMP positive cells present in the CCl4 treated 
livers after PCN treatment. Figure 5.17 is a typical image from each treatment 
group; it was clear there were an increased number of NIMP positive cells in 
all the CCl4 treatment groups when compared to the control groups. The 
mean number of NIMP positive cells was quantified per field of view for each 
treatment group and these counts are shown in figure 5.18. There was a 
statistically significant increase in the number of NIMP positive cells in all CCl4 
treatment groups when compared to the controls (p < 0.0001, ANOVA). There 
was no difference in the level of NIMP positive cells in the chronic CCl4 
treatment group following PCN treatment, however there was a statistically 
significant reduction in the number of NIMP positive cells in the acute CCl4 
treatment group when also dosed with PCN (p < 0.001, ANOVA). 
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Figure 5.17 NIMP IHC analysis of liver tissue from each treatment group. Liver tissue was fixed 
in 10% formalin prior to paraffin embedding, 5µM sections were cut for each animal. Sections were 
dewaxed prior to blocking of endogenous peroxidise activity and heat induced antigen retrieval. 
Followed by serum blocking and incubation for an hour at room temperature with NIMP primary 
antibody, after PBS washing and addition of the complementary secondary antibody the level of bound 
antibody was detected by DAB incubation. The sections were counterstained with haematoxylin and 
dehydrated prior to mounting and analysis with a Leica upright microscope. (All images shown are x20 
magnification). NIMP positive neutrophils were detected in all treatment groups, although at increased 
levels in all CCl4 treatment groups.  
Chapter 5.0 – Results 
156 
 
 
Figure 5.18 NIMP IHC quantification. NIMP positive staining was quantified using Qwin software 
(Leica); briefly 10 random images were captured for each section and blindly quantified to determine 
the positive NIMP stain per field of view. The data are the mean and SD n=30 of percentage area of the 
stain for each treatment group and were tested for statistical significance using an ANOVA, * denotes a 
significant increase in NIMP positive cells when compared to the control groups (p < 0.0001) and 
$ denotes a statistically significant decrease in NIMP positive cells following PCN administration using 
an ANOVA (p < 0.001). 
 
These findings (5.18) further support the whole body ex vivo organ scans, and 
specifically the liver homogenate findings. Indicating further that PCN is anti-
inflammatory and may be of use in combating liver fibrosis, shown by the 
statistically significant decrease in the number of NIMP positive inflammatory 
cells in the acute CCl4 treated livers following PCN treatment (p < 0.001, 
ANOVA). 
Finally an antibody specific to firefly-luciferase was purchased, as its detection 
in the liver tissue would correlate directly to the level of transgene activity (i.e. 
NF-κB activity). Following the manufacturers’ guidelines the antibody was 
trialled at a range of dilutions (1/50 – 1/500). The images in figure 5.19A 
display the high level of non-specific binding encountered, and also that 
transgene levels are abnormally low. Tissue sections from CCl4 treated mice 
of a separate study that did not contain the luciferase transgene were also 
stained (Figure 5.19B). It was clear from the high level of background signal 
encountered in these images that the antibody was not specific to firefly-
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luciferase. A replacement antibody was obtained but the same issues were 
encountered, therefore the antibody was trialled in a Western blotting method 
to see if variations in the level of luciferase protein expressed in individual 
liver protein samples from each treatment group could be detected. 
 
 
Figure 5.19 A Optimisation of luciferase IHC analysis of liver tissue from each treatment group. 
B Repetition of 1/250 primary antibody dilution in non transgenic mice. Liver tissue was fixed in 
10% formalin prior to paraffin embedding, 5µM sections were cut for each animal. Sections were 
dewaxed prior to blocking of endogenous peroxidise activity and heat induced antigen retrieval. 
Followed by serum blocking and incubation for an hour at room temperature with luciferase primary 
antibody at multiple dilutions, after PBS washing and addition of the complementary secondary 
antibody the level of bound antibody was detected by DAB incubation. The sections were 
counterstained with haematoxylin and dehydrated prior to mounting and analysis with a Leica upright 
microscope. (All images shown are x20 magnification). It is clear that the antibody is not specific to 
firefly-luciferase as there are high background signals at all initial dilutions and it binds to a protein 
present in the non-transgenic mice as well.  
 
Protein samples were isolated and quantified as outlined in methods 2.7, 
before performing the SDS-PAGE and Western blotting steps. The final 
developed membrane is shown in figure 5.20A; there are multiple bands in all 
lanes, including the negative control from wildtype mice (that do not contain 
the firefly-luciferase transgene). Unfortunately none of these bands were of 
the correct size (62 kDa as outlined in the manufacturer’s guidelines). To act 
as a positive control Cos7 cells were transfected with the pGL3 control vector 
(Promega) (as this contains multiple copies of the firefly-luciferase gene). 
Transfection was confirmed by a luciferase assay of untransfected and pGL3 
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control transfected Cos7 cells (Figure 5.20B); protein was subsequently 
isolated from these cells as outlined in methods 2.7. A firefly-luciferase 
Western was performed with the Cos7 + pGL3 control protein samples 
included alongside the individual treatment groups (Figure 5.21). There was a 
weak band detected that was only present in the Cos7 + pGL3 control lane 
slightly smaller than the predicted product size (62 kDa) suggesting that the 
antibody does function and detect firefly-luciferase. There were no bands of 
the correct size or similar to that detected in the Cos7 + pGL3 control lane in 
any of the treatment group lanes; it is most likely the firefly-luciferase gene 
was not being expressed at a high enough level to be detected by the 
antibody, especially as there will be high levels of firefly-luciferase protein in 
the transfected Cos7 cells and yet only a weak protein band could be 
detected. 
 
Figure 5.20 A Firefly-luciferase western blot analysis of individual liver protein samples. B 
Firefly-luciferase activity of Cos7’s transfected with pGL3 control plasmid. Liver protein samples 
were taken diluted 1:1 with reducing loading buffer. After denaturation, 10μl of each sample was 
loaded onto a 9% acrylamide SDS-Page gel alongside and separated according to its size. Proteins were 
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transferred to a nitrocellulose membrane, blocked with 3% milk solution, and probed with anti firefly-
luciferase antibody. Following incubation with a complimentary HRP-conjugated secondary antibody 
and washing, ECL reagent was added and the protein level detected by exposure to x-ray film. B 
Following transfection with pGL3 control plasmid a small aliquot of Cos7 protein was suspended in 1 
x PLB, which was added to an equal volume of luciferase substrate prior to determination of luciferase 
activity using a bench top luminometer. The data shown is the mean and SD for 3 separate samples. 
 
Figure 5.21 Firefly-luciferase western blot analysis of individual liver protein samples and Cos7 + 
pGL3 control plasmid (positive control). Liver protein samples were taken diluted 1:1 with reducing 
loading buffer. After denaturation, 10μl of each sample was loaded onto a 9% acrylamide SDS-Page 
gel alongside and separated according to its size. Proteins were transferred to a nitrocellulose 
membrane, blocked with 3% milk solution, and probed with anti firefly-luciferase antibody. Following 
incubation with a complimentary HRP-conjugated secondary antibody and washing, ECL reagent was 
added and the protein level detected by exposure to x-ray film.  
 
5.4 Chapter discussion 
 
The continuing escalation in the incidence of liver fibrosis and its endpoint 
cirrhosis [24] highlight the need for the development of novel anti-fibrotic 
treatment regimens. At present the only recognised treatment is 
transplantation but the lack of suitable donors make this a viable treatment 
option for only a small proportion of patients. A number of potential avenues 
of treatment are being investigated at present including induction of hepatic 
myofibroblast apoptosis and increasing MMP activity (see section 1.3 for more 
information). The induction of hepatic myofibroblast apoptosis is known to be 
mediated via the inhibition of the pro-inflammatory transcription factor NF-κB, 
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which is prominent in the maintenance of the liver fibrosis by preventing 
hepatic myofibroblast apoptosis [90, 91, 229]. 
A relatively unstudied area except for previous work within this laboratory 
[172-174] highlighted the anti-fibrotic benefits of PXR activators. In other 
diseases (most notably IBD) the anti-inflammatory effects of PXR activators 
have been shown to be mediated via inhibition of NF-κB activity [166, 170]. In 
this chapter we wished to ascertain whether the mode of action of PXR 
activators in the liver was also via NF-κB inhibition. To investigate this, NF-κB 
luciferase transgenic mice were administered CCl4 both chronically and 
acutely to induce liver damage prior to administration of the rodent specific 
PXR activator PCN. If, as hypothesised, the mode of action was via NF-κB 
inhibition there will be a reduction in the level of luciferase transgene activity 
in the PCN treated mice following optical imaging when they are compared to 
the CCl4 only treated mice. 
Data presented in this chapter shows that the beneficial anti-fibrotic properties 
of PXR activators are mediated via NF-κB activity in vivo. Administration of 
PCN to both acute and chronic CCl4 treated mice did not appear to reduce the 
level of NF-κB activity in the liver detected in the  whole body scans 
performed 6 hours after PCN administration (Figure 5.3) and this was 
confirmed by the total luminescence values calculated (Figure 5.4B). The 
whole body scans and total luminescence calculations performed 24 hours 
after PCN administration (Figure 5.5) support the initial hypothesis, with a 
clear reduction in NF-κB activity of both the acute and chronic CCl4 treatment 
groups following PCN treatment. This difference was statistically significant for 
the chronic CCl4 treatment group (p < 0.0087, ANOVA), supporting our initial 
hypothesis that PCN is anti-inflammatory. The data from the ex vivo organ 
scans mirrored the 24 hour  whole body data as there was a statistically 
significant reduction in the total liver luminescence in the chronic CCl4 
treatment group following PCN treatment (Figure 5.9B) (p < 0.012, ANOVA). 
Subsequent analysis of the liver homogenates by luciferase assays to detect 
transgene activity and NF-κB induction mirrored the earlier 24 hour whole 
body data (Figure 5.10). However the statistically significant reduction in NF-
κB activity as a result of PCN administration was detected in the acute CCl4 
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treatment group (p < 0.0068, ANOVA). It was unclear why PCN only had an 
effect on the acute CCl4 treated mice and not chronic CCl4 treated liver 
homogenates as found in the earlier scans. The only reason I can postulate 
was that the small animal numbers in each treatment group may have 
influenced the findings, especially as both the acute and chronic CCl4 mice 
also administered PCN luminescence levels had been reduced to a level 
similar to that of the control groups. 
Biochemical and IHC analyses confirmed the successful induction of 
centrilobular liver damage, shown firstly by increased ALT serum levels in all 
CCl4 treatment groups (Figure 5.11B). In addition the IHC analysis performed 
confirmed this, displayed by the increased number of inflammatory cells 
present in the H&E sections of both CCl4 treatment groups (Figure 5.12). 
Increased αSMA positive hepatic myofibroblasts (Figure 5.13) and sirius red 
positive collagens (Figure 5.15) were only detected in the chronic CCl4 
treatment group as they are associated with chronic liver injury and a single 
CCl4 dose was not sufficient for either hepatic myofibroblast formation or 
collagen deposition. 
IHC analysis of the neutrophils by NIMP staining was also performed (Figure 
5.17), as neutrophil recruitment to the liver is a critical step in the initial 
inflammatory response following liver injury and will contribute to the 
perpetuation of liver injury and subsequent fibrosis development. The images 
(Figure 5.17) show that there was background inflammation displayed by the 
presence of NIMP positive neutrophils in the control groups, however there 
was an increased number of these cells in both the chronic and acute CCl4 
treatment groups. When quantified blindly using the supplied Qwin software, 
there was a statistically significant decrease in the number of NIMP positive 
neutrophils present in the acute CCl4 treatment group following PCN treatment 
(p < 0.0001, ANOVA) (Figure 5.24). These data supports the earlier whole 
body luminescent and ex vivo organ scans favouring the hypothesis that PCN 
is anti-inflammatory and this effect is mediated via NF-κB. 
Finally firefly-luciferase IHC was performed to try and establish in which cells 
the NF-κB transgene was activated; unfortunately the antibody was not 
specific to firefly-luciferase shown by the high background levels detected 
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following DAB incubation (Figure 5.19). Western blotting utilising the firefly-
luciferase antibody on liver protein samples isolated from each individual 
treatment group yielded similar results (Figure 5.20A). The antibody was 
unable to detect firefly-luciferase in any of the protein samples, but functioning 
of the antibody was confirmed by repeated Western blotting including a 
positive control sample (Cos7 protein transfected with the pGL3 control 
plasmid) (Figure 5.21). 
The majority of the data presented in this chapter confirms our initial belief 
that PXR agonists have beneficial anti-inflammatory properties mediated via 
NF-κB functioning. Although not all the findings were within the range of 
statistical significance, it was likely this was due to the nature of the in vivo 
study (requiring multiple injections of both CCl4 and D-luciferin when imaging). 
Combined with the small number of animals in each treatment group any 
variations in dosing as a result of human error will have influenced the level of 
inflammation detected. 
If the experiment was repeated in the future it may be beneficial to increase 
the dilution of CCl4 in olive oil vehicle, therefore a greater volume will be 
injected to achieve the same dose (i.e. 120µl instead of 40µl per 20g mouse) 
and will minimise any potential variation in dosing. Obviously the number of 
mice in each treatment group could also be increased to improve the power of 
any findings. 
As found previously PCN administration has not affected CCl4 hepatotoxicity, 
as determined by serum ALT levels and H&E IHC analysis [172]. The 
beneficial anti-inflammatory properties of PCN treatment are displayed by the 
reduction of luciferase transgene activity in the optical images and the 
reduction of NIMP positive neutrophils in liver tissue detected by IHC following 
PCN administration. αSMA and sirius red IHC indicated that PCN treatment 
has no beneficial anti-fibrotic properties in contrast to previous findings [172], 
although in this study PCN was only administered with the final dose of CCl4, 
whilst it was administered chronically (twice weekly) in the earlier study 
alongside CCl4 administration. Therefore fibrosis development will have 
already occurred during the initial 4 weeks of CCl4 treatment in this study 
unchecked by PXR activation. A repeat study utilising the dosing regimen of 
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the earlier study (twice weekly injection of PCN dissolved in the CCl4/ olive oil 
vehicle solution) could confirm the dual anti-fibrotic and anti-inflammatory 
properties of PCN following chronic liver injury. 
Performing these further studies to support the initial data presented in this 
chapter will further advocate the potential use of PXR agonists as an anti-
fibrotic treatment agent, and confirm that this response is mediated via the 
inhibition of NF-κB activity. 
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Chapter 6.0 - Uncovering hepatic myofibroblasts inflammatory 
potential in vitro and in vivo 
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6.1 Introduction 
 
As outlined in section 1.1.2, liver fibrosis development is due to a combination 
of the wound healing, immune and inflammatory system responses after liver 
insult [32, 217]. The transdifferentiation of quiescent HSCs to hepatic 
myofibroblasts is the crucial step in fibrosis development, as hepatic 
myofibroblasts are the major fibrogenic cell responsible for the increased 
deposition of ECM proteins (e.g. collagen type I) [230]. It is still not clear 
where the initiating signal for fibrosis development comes from, although it is 
thought to be from monocytes/ macrophages inducing inflammation and 
subsequent quiescent HSC activation [3]. It is well documented that there are 
different populations of hepatic myofibroblasts present in the liver with 
heterogeneous expression of various genes [36, 109, 231-233]. In this 
chapter we propose that a sub-set of hepatic myofibroblasts are pro-
inflammatory and may themselves stimulate the activation of circulating 
monocytes/ macrophages responsible for the amplification of the inflammatory 
cycle central in liver fibrosis development (Figure 6.1). 
 
Figure 6.1 Schematic illustration showing HSC transdifferentiation to hepatic myofibroblasts 
during chronic liver injury. Outlining the potential mechanism by which hepatic myofibroblasts may 
activate the inflammatory cycle and maintain fibrosis perpetuation. 
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To investigate whether there was communication between monocytes/ 
macrophages and hepatic myofibroblasts and specifically that hepatic 
myofibroblasts are pro-inflammatory a simple in vitro experiment was 
designed. Hepatic myofibroblasts were cultured with the monocytic U937-NF-
κB cell line; U937-NF-κB cells contain the firefly-luciferase transgene under 
the control of a concatemer of NF-κB response elements. NF-κB is a major 
pro-inflammatory transcription factor responsible for the activation of a 
number of downstream inflammatory genes/ processes (e.g.  IL-1, TRAF1).  
Following co-culture, a luciferase assay on the U937-NF-κB cell pellet will 
reveal if hepatic myofibroblasts activate NF-κB in U937-NF-κB cells. Figure 
6.2 is a typical image taken on a light microscope showing the general 
morphology of the individual cell lines and the LX-2 and U937-NF-κB cells 
together in co-culture. 
 
Figure 6.2 General morphology of quiescent and activated HSCs, LX-2 and U937-NF-κB cell 
lines. Highlighting the difference between quiescent and activated HSCs (myofibroblast phenotype) 
and also the fact U937-NF-κB cells are a suspension culture and therefore the two can be cultured 
together. 
 
Secondly utilising the NF-κB luciferase mice used earlier in chapter 5, I wish 
to determine the inflammatory properties of hepatic myofibroblasts in vivo 
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when they are injected directly into NF-κB luciferase mice. Performing 
luminescent scans following hepatic myofibroblast and D-luciferin 
administration it will be possible to detect the level of inflammation (NF-κB 
activity) in every cell of the body and determine if hepatic myofibroblasts are 
inflammatory as hypothesised. More interestingly, it will be possible to see 
whether this inflammation was located solely in the liver or if it affects other 
areas of the body as a systemic response. 
 
6.2 Generation of a NF-κB luciferase reporter construct and stable 
transfection of U937 cells 
 
The experiments reported in section 6.3 were initially performed in U937-NF-
κB cells donated by Dr Harald Carlsen [187]. However issues were 
encountered when reviving the cells and selecting for successful transfectants 
with Hygromycin B treatment, as the cells would spontaneously lose all 
luciferase activity. The Hygromycin B selection marker was transfected into 
the U937-NF-κB cells in a separate vector to the NF-ĸB response element 
and luciferase gene (Harald Carlsen, personal communication). If this was the 
case the recommended Hygromycin B treatment may not select for cells 
containing the luciferase transgene (i.e. those which did not contain both 
vectors) leading to the loss of all luciferase activity. To avoid this issue 
untransfected U937s were purchased (ECACC) and the transfection 
procedure repeated in house with a concatemer of NF-ĸB response elements 
inserted into a vector that contains the firefly-luciferase gene. 
Firstly the pGL4.28 vector was purchased from Promega, which encodes the 
firefly-luciferase reporter gene luc2CP. pGL4.28 also contains a multiple 
cloning region for insertion of DNA sequences (in this case 3xNF-κB response 
elements) upstream of the minimal promoter and luc2CP gene, and the vector 
backbone contains a mammalian selection marker for Hygromycin B 
resistance. A DNA fragment (3xNF-κB) was designed consisting of 3 repeats 
of the consensus NF-κB response element sequence (Figure 6.3A) and its 
complementary sequence. Sticky ends flanking the insert were designed 
specifically to restriction sites XhoI and BglII, which are also located within the 
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multiple cloning region of pGL4.28 at positions 34 and 47. A schematic 
diagram of the pGL4.28 vector is shown in figure 6.3B. 
 
Figure 6.3 Generation of NF-κB luciferase reporter construct. A 3xNF-κB insert was designed 
containing a concatamer of 3 x NF-κB response elements flanked by XhoI and BglII restriction enzyme 
sites. B pGL4.28 vector outline and outline of pGL4.28 vector with insertion of the 3xNF-κB insert. 
 
The two complementary NF-κB response element sequences were annealed 
together by heating at 90 oC for 5 minutes before reduction of the temperature 
by 1 oC every minute from 90 oC to 50 oC. The pGL4.28 vector was linearised 
by a double restriction digest with XhoI and BglII, the linearised vector was 
separated from the fragment between the two restriction sites by agarose gel 
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electrophoresis (Figure 6.4A) and the linearised DNA fragment was purified 
from the agarose gel as described in section 2.5.7. 
 
Figure 6.4 Restriction digests to confirm insertion of the 3xNF-κB insert. A XhoI + BglII double 
digest to linearise plasmid prior to ligation of 3xNF-κB insert into it. B EcoRV restriction digest to 
screen for correctly assembled NF-κB luciferase reporter construct (shown by loss of EcoRV restriction 
site). 
 
The 3xNF-κB DNA fragment was subsequently ligated into the linearised 
vector as outlined in section 2.5.8. Successful ligation will result in the loss of 
the EcoRV restriction site in the multiple cloning region; therefore clones were 
screened by an EcoRV restriction digest. Figure 6.4B is an agarose gel 
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showing the successful ligation of the 3xNF-κB insert into the pGL4.28 vector; 
specifically it was shown by the identical migration of the pGL4.28-NF-ĸB 
recombinant vector when treated with EcoRV to the unrestricted pGL4.28 
vector. The successful clones were subsequently sent for sequencing 
analysis to confirm the entire 3xNF-ĸB insert sequence had been ligated in 
the correct orientation (Figure 6.5). 
 
Figure 6.5 pGL4.28-3xNF-κB luciferase reporter construct DNA sequencing. Sequencing results 
from a single transformant miniprep highlighting the complete 3xNF-κB insert sequence in the correct 
orientation within the pGL4.28 plasmid.  
 
Plasmid DNA was then isolated from successful clones prior to transient 
transfection into both Cos7 and U937 cells, which were then treated with LPS 
and TNFα to induce NF-ĸB and luciferase activity. Figure 6.6 shows that 
untransfected Cos7 and U937 cells expressed no luciferase activity when 
untreated and when treated with LPS. However both cell lines expressed a 
significant increase in luciferase activity after transfection with the pGL4.28 –
NF-κB construct and treatment with LPS; indicating that the vector was 
functioning as intended. Stable transfection of U937s with the pGL4.28 –NF-
κB vector was achieved by repeated treatment with the mammalian selection 
marker Hygromycin B. 
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Figure 6.6 Confirmation of NF-κB luciferase reporter construct functioning. A U937 and B Cos7 
were both transiently transfected (using Genejuice and PEI) with the NF-κB luciferase reporter 
construct prior to treatment with LPS and TNFα. There was a significant increase in luciferase activity 
following both LPS and TNFα treatment versus the untransfected control highlighting that the 
construct is responsive to inflammatory stimuli. Data are the mean and SD n=3. 
 
6.3 LX-2 and hHSCs are pro-inflammatory when co-cultured with U937-
NF-κB cells  
 
Due to the lack of availability of hHSCs, the LX-2 cell line was used in their 
place. Initially LX-2 cells were incubated with U937-NF-κB cells to determine 
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the optimum incubation period for induction of the luciferase gene in co-
culture. Figure 6.7 shows that LX-2 cells induce NF-ĸB activity in the U937-
NF-κB cells at all time points, demonstrated by the increase in luciferase 
activity at all time points of LX-2/ U937-NF-κB cell co-culture. LPS was also 
added on its own as a positive control, as it has been previously shown to 
induce NF-ĸB and luciferase activity in U937-NF-κB cells [175]. From figure 
6.7 it was also clear that a 6 hour incubation period yields the greatest 
increase in NF-ĸB activity, therefore all subsequent experiments were 
performed over 6 hours. 
 
Figure 6.7 LX-2’s are pro-inflammatory and induce NF-κB activity in U937-NF-κB cells. Co-
culture of the hepatic myofibroblast LX-2 cell line with U937-NF-κBs induced a significant increase in 
luciferase activity when compared to the U937-NF-κB only control at all time points. The most 
significant increase was seen following six hour incubation, therefore all future experiments utilised six 
hour incubation. (* denotes a statistically significant increase (p < 0.0014) in luciferase activity when 
compared to the U937-NF-κB only incubation, analysed using an ANOVA). Data are the mean and SD 
n=3 from a single experiment, typical of three independently repeated experiments. 
 
To confirm these initial findings U937-NF-κB cells were co-cultured with 
primary hHSCs at all stages after their initial isolation, from when they were 
still quiescent (48 hours after isolation), as they were transdifferentiating (8 
days after isolation) and when they had fully transdifferentiated to a hepatic 
myofibroblast phenotype (following one passage). Figure 6.8 shows that 
hHSCs activate NF-ĸB in U937-NF-κB cells when cultured together, although 
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this inflammatory potential was only a trait of the activating (8 day old) HSCs, 
and increasing further as they develop a hepatic myofibroblast phenotype. 
There was no induction of NF-ĸB activity when U937-NF-κB cells were co-
cultured with the freshly isolated quiescent hHSCs, as their primary function in 
the liver is the storage of retinoids [38]. These findings support our initial 
hypothesis that hepatic myofibroblasts are pro-inflammatory. 
 
 
Figure 6.8 hHSC co-culture induces NF-κB activity in U937-NF-κB cells. HSCs were isolated and 
incubated with U937-NF-κB cells at various times after their initial isolation. A significant increase in 
luciferase activity was seen when the HSCs had transdifferentiated to a hepatic myofibroblast 
phenotype. (* denotes a statistically significant increase (p < 0.0008) in luciferase activity when 
compared to the U937-NF-κB only incubation, analysed using a student’s t-test, unpaired). Data are the 
mean and SD n=3 from a single experiment, typical of three independently repeated experiments. 
 
6.3.1 LX-2s and hHSCs release a pro-inflammatory soluble factor 
 
To determine whether contact between the LX-2 cells and U937-NF-κB cells 
was required for induction of NF-ĸB activity, U937-NF-κB cells were cultured 
in 48 hour LX-2 conditioned media for 6 hours as described in section 2.3.11. 
Figure 6.9A reveals that there was still activation of NF-ĸB in the U937-NF-κB 
cells when cultured in the LX-2 conditioned media suggesting a soluble factor 
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was released into the media. The level of induction by 48 hour LX-2 
conditioned media was reduced when compared to the LX-2 co-culture 
findings, suggesting that direct contact between the cells may also play a role, 
in addition to the presence of the pro-inflammatory soluble factor released. 
Further studies demonstrated that it acts in a dose-dependent manner (Figure 
6.9B); these findings were confirmed in hHSCs when identical experiments 
were performed (Figure 6.10). 
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Figure 6.9 LX-2’s release a pro-inflammatory soluble factor that induces NF-κB activity in U937-
NF-κB cells. A Culture of U937-NF-κB cells in 48 hour LX-2 conditioned media induced a 
statistically significant increase in NF-κB activity when compared to the U937-NF-κB only control. (* 
denotes a statistically significant increase (p < 0.0001) in luciferase activity when compared to the 
U937-NF-κB only incubation, analysed using an ANOVA). Data are the mean and SD n=3 from a 
single experiment, typical of three independently repeated experiments. B The pro-inflammatory 
soluble factor was shown to act in a dose dependent manner (n=1). 
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Figure 6.10 hHSCs release a pro-inflammatory soluble factor that induces NF-κB activity in 
U937-NF-κB cells. A Culture of U937-NF-κB cells in 48 hour hHSC conditioned media induced a 
statistically significant increase in NF-κB activity when compared to the U937-NF-κB only control. (* 
denotes a statistically significant increase (p < 0.0001) in luciferase activity when compared to the 
U937-NF-κB only incubation, analysed using an ANOVA). Data are the mean and SD n=3 from a 
single experiment, typical of three independently repeated experiments. B The pro-inflammatory 
soluble factor was shown to act in a dose dependent manner (n=1). 
 
Previous unpublished work (Table 6.1) by members of this laboratory 
provided useful information regarding the cytokine profiles of all the major 
hepatic cell types. Of particular interest are the high levels of the pro-
inflammatory cytokines IL-6 and IL-8 produced by hepatic myofibroblasts. 
Therefore U937-NF-κB cells were incubated with human recombinant IL-6 
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and IL-8 separately in place of LX-2 cells. IL-6 induced a statistically 
significant increase in luciferase activity when cultured with U937-NF-κB cells 
and IL-8 did not induce NF-ĸB activity in the U937-NF-κB cells as highlighted 
in figure 6.11. It was clear the induction of luciferase activity by IL-6 although 
significant was much lower when compared to LX-2 and LPS luciferase 
induction. IL-8 can be eliminated as the soluble factor released by LX-2 cells, 
but IL-6 although unlikely could be a contributing factor. 
 
 
Table 6.1 – Cytokine profiles of major hepatic cell types (unpublished work by Angela Douglass). 
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Figure 6.11 Treatment of U937-NF-κB cells with IL-6 and IL-8 does not induce NF-κB activity in 
U937- NF-κBs. Human recombinant pro-inflammatory cytokines IL-6 and IL-8 (10ng/ml) were added 
to U937-NF-κB cells as previous unpublished work from within this laboratory (Table 6.1) highlighted 
both these cytokines are found at increased levels in both hHSCs and LX-2’s during fibrosis 
development. (* denotes a statistically significant increase (p < 0.0017) in luciferase activity when 
compared to the U937-NF-κB only incubation, analysed using a student’s t-test, unpaired). Data are the 
mean and SD n=3 from a single experiment, typical of three independently repeated experiments. 
 
6.3.2 The pro-inflammatory soluble factor released by LX-2 cells is a 
small (<1kDa) non peptide  
 
To determine the identity of the pro-inflammatory soluble factor released by 
LX-2 cells, a range of treatments were performed to LX-2 conditioned media 
prior to the resuspension and culture of U937-NF-κB cells in it (see Table 2.2 
for a full description of individual treatments performed). 
Figure 6.12A shows firstly that the soluble factor was not affected by either 
heating at 90 oC or protease treatment with 10 x trypsin-EDTA, indicating that 
its activity is heat and trypsin resistant. Secondly removal of the endogenous 
steroids and other similar chemical species present in the media by charcoal/ 
dextran stripping of the conditioned media did not alter induction of NF-κB and 
luciferase activity in the U937-NF-κB cells. Separation of the organic and 
aqueous fractions of conditioned media and the resuspension of U937-NF-κB 
cells in each fraction showed that the soluble factor was located in neither the 
aqueous or organic phase. Initially it was not possible to resuspend U937-NF-
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κB cells in the organic phase as it resulted in their death (gauged by trypan 
blue viability). To counteract this, the organic phase was evaporated by 
heating and the residue was dissolved in RPMI-1640 media, prior to the 
resuspension of U937-NF-κB cells in this media. The lack of NF-κB induction 
from both the organic and aqueous phases when added to U937-NF-κB cells 
may suggest that there is more than one factor responsible for NF-κB 
induction and they both need to be present for significant NF-κB induction. 
Alteration of the pH for 10 minutes by the addition of hydrochloric acid and 
sodium hydroxide respectively to the LX-2 conditioned media prior to U937-
NF-κB cells resuspension had no effect on the soluble factors pro-
inflammatory activity. 
 
Figure 6.12 Range of treatments to uncover more about the pro-inflammatory soluble factor. A 
Variety of treatments were performed (Table 2.2) to 48 hour LX-2 conditioned media prior to its 
addition to U937-NF-κB cells. (* denotes a statistically significant difference in luciferase activity 
when compared to the 500µl LX-2 conditioned media sample, analysed using a student’s t-test, 
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unpaired (p < 0.05). $ denotes a statistically significant increase in luciferase activity when compared 
to the U937-NF-κB cells only incubation, analysed employing an ANOVA (p < 0.0001)). Data are the 
mean and SD n=3 from a single experiment, typical of three independently repeated experiments. B 
PD-10 sepharose gel filtration revealed that the soluble factor is a small molecule as NF-κB activity 
was only induced in the later wash fractions (13 – 18). 
 
Following the filtration of 2ml LX-2 conditioned media through a PD-10 
sepharose column, a 500µl volume from each wash fraction was added to 1 x 
105 U937-NF-κB cells and incubated for 6 hours.  Figure 6.12B shows both 
the SDS-PAGE run out of large proteins (i.e. BSA 66.5 kDa) present in each 
wash fraction and the luciferase activity induced by the contents of each 
wash. Smaller molecules are retained in the gel bed and eluted later, whilst 
proteins of higher MW such as BSA are eluted straight away as shown by the 
SDS-PAGE gel. The presence of the soluble factor was only detected in the 
later wash fractions (fractions 13-18) after the elution of BSA indicating that 
the pro-inflammatory mediator is a small molecule. 
 
6.4 Screening of potential inflammatory/ fibrotic agents with U937-NF-κB 
cells  
 
6.4.1 Treatment of U937-NF-κB cells with inflammatory cytokines and 
fibrotic compounds  
 
The development of liver fibrosis is a complex process with crosstalk between 
various signalling pathways; there are a plethora of molecules and pathways 
cited in the literature for being both inflammatory and fibrogenic that contribute 
to its development. In this section we wished to ascertain whether they may 
also be released by hepatic myofibroblasts and could stimulate U937-NF-κB 
cells NF-κB activity (see Table 2.2). 
Inflammatory cytokines including IL-1α and IL-1β were incubated in place of 
LX-2s with U937-NF-κB cells, figure 6.13A displays that neither of these 
cytokines induce NF-κB in the U937-NF-κB cells to the level seen when co-
cultured with LX-2s. IL-1α and IL-1β both induced a statistically significant 
increase in NF-κB but as human recombinant cytokines were added at high 
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physiological levels a much greater induction of luciferase activity would be 
expected if they were the soluble mediator released by LX-2 cells. In an 
attempt to ascertain whether these small increases in luciferase activity could 
be part of the inflammatory response seen after LX-2 co-culture U937-NF-κB 
cells were pre-treated with an IL-1 receptor antagonist (IL-1RA) for 2 hours 
prior to the addition of IL-1α and IL-1β (Figure 6.13B). Unfortunately the IL-
1RA did not have any effect on the level of luciferase activity induced 
following IL-1α and IL-1β addition and therefore although it is unlikely, IL-1α 
and IL-1β cannot be ruled out as the pro-inflammatory soluble factor released 
by LX-2 cells. 
 
Figure 6.13 Incubation of U937-NF-κB cells with the pro-inflammatory cytokines IL-1α and IL-
1β. A Addition of human recombinant IL-1α and IL-1β (10ng/µl) to U937-NF-κB cells resulted in a 
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significant increase in NF-κB activity compared to U937-NF-κB only, but this increase was much 
smaller than that seen with LX-2 co-culture. (* denotes a statistically significant increase in luciferase 
activity when compared to the U937-NF-κB cells only incubation, (p < 0.0001, analysed using an 
ANOVA). B Incubation of U937-NF-κB cells with human recombinant IL-1α and IL-1β was repeated 
following pre incubation of U937-NF-κB cells for 2 hours with an IL-1RA, although the IL-1RA did 
not appear to be functioning as it didn’t influence the amount of NF-κB activity induced by IL-1α and 
IL-1β addition. (* denotes a statistically significant increase in luciferase activity when compared to the 
U937-NF-κB cells only incubation, (p < 0.014, analysed using a student’s t-test, unpaired)). Data are 
the mean and SD n=3 from a single experiment, typical of three independently repeated experiments. 
 
 
Secondly a range of mediators that have been linked with inflammation and 
hepatic fibrosis development were investigated including angiotensin II [194, 
234], leptin [78, 196], TIMP1 [57, 193] and serotonin [192]. Figure 6.14A 
demonstrates that none of these compounds induce NF-κB activity in the 
U937-NF-κB cells and therefore if they are released by LX-2s and HSCs are 
not the soluble factor that the U937-NF-κB cells are responding to. MCP-1 
[198, 199], CXCL12 [32, 201], MIP-1α [200, 235] and IP-10 [197] are 
cytokines known to be pro-inflammatory and important in the activation of 
monocytes/ macrophages and perpetuation of liver fibrosis development. 
Following incubation with U937-NF-κB cells although some of these cytokines 
elicited a statistically significant increase in luciferase activity (Figure 6.14B), 
the size of the increase was greatly reduced when compared to those elicited 
by LPS and LX-2 cells previously. Consequently if these cytokines are 
released by LX-2 cells they are unlikely to be the soluble factor, but could 
contribute to NF-κB induction later. 
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Figure 6.14 Incubation of U937-NF-κB cells with a range of pro-fibrogenic and/ or pro-
inflammatory molecules. A Addition of a number of pro-fibrogenic compounds cited in the literature 
for their involvement in fibrosis development resulted in minimal induction of NF-κB activity. (* 
denotes a statistically significant increase in luciferase activity when compared to the U937-NF-κB 
cells only incubation, (p < 0.0002, analysed using a student’s t-test, unpaired).B Addition of a number 
of pro-inflammatory cytokines and chemokines linked with the activation of monocytes and/ or 
macrophages central in fibrosis development. MCP-1, MIP-1α and CXCL12 all induce NF-κB activity 
in U937-NF-κB cells although not to the same level as LX-2 co-culture. (* denotes a statistically 
significant increase in luciferase activity when compared to the U937-NF-κB cells only incubation, (p 
< 0.0039, analysed using a student’s t-test, unpaired). Data are the mean and SD n=3 from a single 
experiment, typical of three independently repeated experiments. 
 
6.4.2 Increased production of nitric oxide (NO) and ROS does not induce 
NF-κB activity in U937-NF-κB cells  
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Oxidative stress and the release of ROS are known to contribute to HSC 
activation [236, 237]; their concentration increases following hepatocyte 
damage further amplifying the activation of the inflammatory cycle and 
perpetuation of liver fibrosis development in chronic situations. To mimic the 
situation of high levels of ROS a variety of hydrogen peroxide (H2O2) 
concentrations and iron sulphate (Fe2SO4) were added to U937-NF-κB cells 
before determining luciferase activity; carbon monoxide (CO) was also 
separately bubbled through the U937-NF-κB cells for a short period prior to 
incubation and detection of luciferase activity. The role of NO was 
investigated firstly by the addition of sodium nitroprusside (SNP) to the culture 
media prior to the incubation of U937-NF-κB cells, SNP is broken down to 
release NO, which can be both cytoprotective and potentially cytotoxic to 
surrounding cells [238]. OxPAPC was added with and without the addition of 
LPS, as it is a TLR4 antagonist and therefore should inhibit LPS induction of 
luciferase activity in U937-NF-κB cells. Figure 6.15A shows that CO was the 
only mode of increasing ROS levels that resulted in a statistically significant 
increase in luciferase activity when compared to the U937-NF-κB cells only. 
Once again the level of this increase was greatly reduced when compared to 
the LPS and LX-2 cells NF-κB induction suggesting CO may have a 
contributory role at most to NF-κB induction. In addition there was no 
significant reduction in LPS induction of luciferase activity following OxPAPC 
(1µg/ml) treatment, suggesting that the antagonist was not functioning as 
advertised in this instance. 
Finally the level of NO released into the culture media by LX-2 cells both 
separately and in co-culture with U937-NF-κB cells was determined by 
performing a Griess assay [216]. Culture media was isolated at various time 
points over 72 hours and the level of NO produced calculated by extrapolation 
against a sodium nitrite standard curve. Figure 6.15B shows that there was no 
significant variation in the level of NO produced over the 72 hour time course 
by the LX-2 cells when cultured individually or together with U937-NF-κB 
cells. Significant increases in NO concentration could only be detected when 
SNP was added as a positive control; these findings confirm that SNP was 
broken down to form NO. Taken together with the earlier results (Figure 
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6.15A), it confirms that the release of increased NO from LX-2 cells was not 
the pro-inflammatory soluble factor. 
 
Figure 6.15 Effect of increased ROS concentration on NF-κB activity in U937-NF-κB cells. A 
Addition of H2O2 and Fe2SO4, CO and SNP to increase ROS concentration in the culture media had no 
effect on U937-NF-κB cells NF-κB activity, the same was found with the addition of OxPAPC (TLR4 
antagonist) which didn’t appear to function as its addition did not abrogate LPS induction of NF-κB in 
U937-NF-κB cells. (* denotes a statistically significant increase in luciferase activity when compared 
to the U937-NF-κB cells only incubation, (p < 0.015, analysed using a student’s t-test, unpaired)). Data 
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are the mean and SD n=3 from a single experiment, typical of three independently repeated 
experiments. 
B Gries assay was performed on LX-2’s and U937-NF-κB cells in co-culture to determine the levels of 
NO released into the culture media. A significant increase in NO concentration was only detected in the 
positive control with SNP also added, confirming NO release from LX-2’s does not responsible for 
NF-κB induction in U937-NF-κB cells.  
 
6.5 In vivo studies investigating the inflammatory properties of hepatic 
myofibroblasts  
 
6.5.1 NF-ĸB luciferase mice genotyping  
 
Firstly it was necessary to genotype the NF-ĸB luciferase mice and set up 
appropriate breeding cages to generate sufficient mice for subsequent 
experiments. DNA was isolated from the individual ear notches of each 
mouse (as described in section 2.6.2) and the presence of the luciferase 
transgene detected by PCR using primers specific to the firefly-luciferase 
gene (Table 2.4). Figure 6.16A is a typical electrophoresis agarose gel 
showing the genotype of individual mice. Figure 6.16B is the accompanying 
IVIS whole body scans performed on a wildtype and transgenic mouse as 
determined by the genotyping PCR. The IVIS images support the PCR 
genotyping with luciferase activity only detected in the transgenic mouse 
following D-luciferin administration. 
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Figure 6.16 Genotyping NF-κB luciferase mice. A Genotyping PCR using primers specific firefly-
luciferase were performed on DNA isolated from individual ear notches of each mouse, presence of the 
transgene was confirmed by a band at 221bp. B The functioning of the luciferase primers (due to the 
presence of weaker bands in some mice) was confirmed by the injection of 200µl of D-luciferin into a 
non-transgenic and transgenic mouse prior to IVIS imaging. A Luminescent signal was only detected in 
the transgenic mouse. 
 
6.5.2 Pilot study of hepatic myofibroblast injection directly into NF-κB 
luciferase mice 
 
In the first pilot study, 2 x 105 hepatic myofibroblasts suspended in 1 x PBS 
(isolated from a wildtype male NF-κB luciferase mouse as outlined in section 
2.3.2) were injected by i.v. injection into a transgenic male NF-κB luciferase 
mouse to determine if hepatic myofibroblasts migrate specifically to the liver 
and induce NF-κB activity. Figure 6.17 are the whole body images performed 
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over the 72 hour time period to determine if there was an optimum time point 
when luciferase activity could be detected. It was apparent from these images 
that there was induction of NF-κB activity in the mouse dosed with both D-
luciferin and hepatic myofibroblasts when compared to the controls and this 
signal originated in the upper abdominal (liver) region, suggesting that hepatic 
myofibroblasts are pro-inflammatory in the liver. 
 
Figure 6.17 Whole body luminescent scans over 72 hour time course following hepatic 
myofibroblast injection. Mice were anaesthetised with isoflurane and shaved ventrally prior to placing 
in the IVIS chamber. All scans were performed 10 minutes after i.p. injection of 200µl D-luciferin using 
a one minute exposure and bioluminescent filter setting, the images were analysed and scale bar set to 
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the same levels using the Image Pro Plus 4.0 software so they could be directly compared. ( Bkg – 
background scan prior to D-luciferin administration, T0 – Time zero immediately after D-luciferin 
administration, and the rest are hourly (h) time points). 
 
ROIs available in the Image Pro-Plus 4.0 software were once again overlaid 
onto the images and the total luminescence for a specific region calculated; 
an example image and the total luminescence value for the upper abdominal 
(liver) region of each mouse are shown in figure 6.18. These data confirms 
that there was a significant increase in the upper abdominal/ liver region total 
luminescence of the mouse receiving both D-luciferin and hepatic 
myofibroblasts. Finally an ex vivo organ scan and ROI calculations (Figure 
6.19) were performed to confirm that the luciferase signal originates in the 
liver. The ex vivo calculations confirm the signal was located in the liver with 
approximately a fivefold increase in liver signal detected in the mouse injected 
with hepatic myofibroblasts and D-luciferin, when compared to the D-luciferin 
only injected mouse. There was negligible luciferase activity detected in any 
of the other major organs of the control mice. 
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Figure 6.18 Example whole body scan with ROIs overlaid and the calculated total luminescence 
values. ROIs could be overlaid onto images with the Image Pro Plus 4.0 software, allowing the 
calculation of total luminescence values for specific regions. The total luminescence values reveal 
hepatic myofibroblasts induce NF-κB in the upper abdominal peaking 48 hours after injection (n=1). 
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Figure 6.19 Example ex vivo organ scan with ROIs overlaid and the calculated total luminescence 
values. ROIs could be overlaid onto images with the Image Pro Plus 4.0 software, allowing the 
calculation of total luminescence values for specific excised organs. The total luminescence values 
reveal the induction of NF-κB is specifically from the liver (n=1). 
 
These findings suggest that hepatic myofibroblasts are pro-inflammatory to 
the liver with a peak in NF-κB activity seen 48 hours after injection. The ex 
vivo organ scans (at approximately 96 hours after hepatic myofibroblast 
injection) confirm that the signal was from the liver as an increase in luciferase 
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activity was not detected in any other organs or treatments confirming the 
response seen was solely due to hepatic myofibroblast injection. 
αSMA IHC analysis performed on fixed liver samples taken from each mouse 
indicated that there were now a small number of αSMA positive cells present 
in the hepatic myofibroblast injected livers, which are not detected in the 
uninjected liver samples (Figure 6.20). 
 
Figure 6.20 αSMA IHC of liver sections from hepatic myofibroblast inecjected and control mice. 
Liver tissue was fixed in 10% formalin prior to paraffin embedding, 5µM sections were cut for each 
animal. Sections were dewaxed prior to blocking of endogenous peroxidise activity and heat induced 
antigen retrieval. Followed by serum blocking and incubation for an hour at room temperature with 
αSMA primary antibody, after PBS washing and addition of the complementary secondary antibody 
the level of bound antibody was detected by DAB incubation. The sections were counterstained with 
haematoxylin and dehydrated prior to mounting and analysis with a Leica upright microscope. (All 
images shown are x40 magnification).  
 
To verify the initial pilot findings the study was repeated with an increased 
number of mice and also including a ‘trypsin dummy’ control (to confirm that 
when the hepatic myofibroblasts were isolated by trypsinisation and 
resuspension in 1 x PBS, residual trypsin-EDTA had not given NF-κB 
Chapter 6.0 – Results 
193 
 
induction as there will still be some present despite 1 x PBS washing). 2 x 105 
hepatic myofibroblasts or the ‘trypsin dummy’ were injected by i.v. injection 
and whole body images were taken over a 48 hour time period (Figure 6.21). 
 
Figure 6.21 Whole body luminescent scans over 48 hour time course following hepatic 
myofibroblast and ‘trypsin dummy’ injection. Mice were anaesthetised with isoflurane and shaved 
ventrally prior to placing in the IVIS chamber. The scans were performed using the same settings 
described in figure 6.17. ( Bkg – background scan prior to D-luciferin administration, T0 – Time zero 
immediately after D-luciferin administration, and the rest are hourly (h) time points). 
 
Once again a liver signal was only detected in the mice that received hepatic 
myofibroblasts, peaking 6 hours after hepatic myofibroblast injection; there 
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was no signal detected in the D-luciferin or the ‘trypsin dummy’ control mice 
confirming that this NF-κB induction was a property of the hepatic 
myofibroblasts.  The ROI example scan and total luminescence calculation 
(Figure 6.22) confirm that there was no induction of NF-κB in the liver region 
of the ‘trypsin dummy’ or D-luciferin controls, whilst there was only a signal 
detected in the liver region at the T0 and 6 hour time points of the hepatic 
myofibroblast injected mice. 
 
Figure 6.22 Whole body scan with ROIs overlaid and the calculated total luminescence values. 
ROIs could be overlaid onto images with the Image Pro Plus 4.0 software, allowing the calculation of 
total luminescence values for specific regions. The total luminescence values confirm hepatic 
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myofibroblasts induce NF-κB in the upper abdominal although peaking 6 hours after injection in this 
study (n=2 controls and hepatic myofibroblasts injected, n=1 for trypsin dummy injected). 
 
The ex vivo organ scan and ROI calculations (Figure 6.23) reveal that there 
was no difference in NF-κB activity detected between the different treatments 
group and that they are all at a very low level, equivalent to the D-luciferin only 
mice in the initial pilot study (Figure 6.18B). The ex vivo organ data confirms 
that there was a variation in the retention of the hepatic myofibroblasts within 
the liver during the two studies. The upper abdominal liver signal peaked at 
the 6 hour time point in the second study and was undetectable by the 48 
hour time point. However in the initial study it peaked at approximately 48 
hours, and could still be easily detected 72 hours after hepatic myofibroblast 
injection. 
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Figure 6.23 Ex vivo organ scan with ROIs overlaid and the calculated total luminescence values. 
ROIs could be overlaid onto images with the Image Pro Plus 4.0 software, allowing the calculation of 
total luminescence values for specific excised organs. The total luminescence values suggest there is no 
variation in liver NF-κB induction in this study (n=2 controls and hepatic myofibroblasts injected, n=1 
for trypsin dummy injected). 
 
These data confirms that the induction of luciferase activity in the liver region 
of the hepatic myofibroblast injected mice was a result of the hepatic 
myofibroblasts and not an undesired result of the trypsin used in the isolation 
process. However in contrast to the earlier study NF-κB induction was 
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detected much earlier (6 hours instead of 48 hours after injection) and cannot 
be detected at later time points and in the final ex vivo organ scan. 
 
6.5.3 In vivo study to determine if hepatic myofibroblasts inflammatory 
traits are unique or a property of other cell types 
 
To determine whether these inflammatory characteristics are unique to 
hepatic myofibroblasts, kidney fibroblasts were isolated from a male wildtype 
NF-ĸB luciferase mouse, using a similar collagenase/ pronase digestion 
protocol as outlined in section 2.3.2. 2 x 105 kidney fibroblasts suspended in 1 
x PBS were injected via i.v. injection prior to performance of whole body 
scans over a 48 hour time course (Figure 6.24). The whole body images show 
there was a similar induction of NF-ĸB in the liver as a result of kidney 
fibroblast injection, although as seen before it peaks approximately 6 hours 
after injection and was not detected at 24 and 48 hours after injection. The 
total luminescence values calculated from the liver ROI confirm the 
observations from the whole body images; specifically that there was a 
significant increase in the liver ROI signal at 6 hours when compared to the D-
luciferin and non inject control mice (Figure 6.25). This increase had 
diminished by the 24 hour time point and no difference was detectable 
between the different treatment groups. 
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Figure 6.24 Whole body luminescent scans over 48 hour time course following kidney fibroblast 
injection. Mice were anaesthetised with isoflurane and shaved ventrally prior to placing in the IVIS 
chamber. The scans were performed using the same settings described in figure 6.17. (Bkg – 
background scan prior to D-luciferin administration, T0 – Time zero immediately after D-luciferin 
administration, and the rest are hourly (h) time points). 
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After the final 48 hour time point an ex vivo organ scan was performed (Figure 
6.26A). The total luminescence values calculated for each individual organ 
show there was an increase in liver signal when injected with kidney 
fibroblasts in comparison to the control mice (Figure 6.26B). However the 
level of this increase was greatly reduced when compared to the initial hepatic 
myofibroblast study (Figure 6.19B), which was approximately three fold 
higher. Also there were similar levels of luminescence detected in the lung of 
the D-luciferin control and the stomach of both the D-luciferin and D-luciferin + 
kidney fibroblasts mice (Figure 6.26B). The NF-ĸB activity detected in these 
organs could be due to areas of localised inflammation or just abnormally high 
basal levels. 
Chapter 6.0 – Results 
200 
 
 
Figure 6.25 Whole body scan with ROIs overlaid and the calculated total luminescence values. 
ROIs could be overlaid onto images with the Image Pro Plus 4.0 software, allowing the calculation of 
total luminescence values for specific regions. The total luminescence values confirm kidney 
fibroblasts induce NF-κB in the upper abdominal peaking 6 hours after injection (n=1). 
 
The induction of NF-κB in the liver region 6 hours after injection of kidney 
fibroblasts indicates that the inflammatory properties of hepatic myofibroblasts 
are not unique. As found in the previous study the inflammation peaked at 
approximately 6 hours and there was negligible luciferase activity detected 
between the treatment groups at the later time points and the ex vivo organ 
scan. 
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Figure 6.26 Ex vivo organ scan with ROIs overlaid and the calculated total luminescence values. 
ROIs could be overlaid onto images with the Image Pro Plus 4.0 software, allowing the calculation of 
total luminescence values for specific excised organs. The total luminescence values suggest there was 
no variation in liver NF-κB induction in this study (n=1). 
 
A follow up study was performed to confirm whether the migration of hepatic 
myofibroblasts to the liver and induction of NF-ĸB are specific to hepatic 
myofibroblasts or are common to kidney fibroblasts or particles of a similar 
size as well. Briefly NF-ĸB luciferase mice received D-luciferin and were 
imaged following i.v. injection of hepatic myofibroblasts, kidney fibroblasts or 
latex beads (Sigma L2778, 1µm average diameter). The mice were not culled 
so the ideal time point for detecting luciferase activity and any correlation 
between the different cell types could be determined. 
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Figure 6.27 shows the whole body luminescent images over the 48 hour 
timecourse following i.v. injection of hepatic myofibroblasts, kidney fibroblasts 
or latex beads. It was clear from these images that there was little induction in 
luciferase activity in the liver region of any of the treatments when compared 
to the previous studies. 
 
Figure 6.27 Whole body luminescent scans over 48 hour time course following hepatic 
myofibroblast, kidney fibroblast and latex bead injection. Mice were anaesthetised with isoflurane 
and shaved ventrally prior to placing in the IVIS chamber. The scans were performed using the same 
settings described in figure 6.17. (Bkg – background scan prior to D-luciferin administration, T0 – Time 
zero immediately after D-luciferin administration, and the rest are hourly (h) time points). 
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The total luminescence values calculated from the overlaid ROI (Figure 6.28) 
confirm this initial observation; there was an increase in liver region total 
luminescence following hepatic myofibroblast injection compared to the 
kidney fibroblasts and latex beads mice. However this difference was minimal, 
especially as there was an abnormally high liver luminescence in the 
background scan prior to hepatic myofibroblast injection suggesting there may 
be some underlying inflammation present. The upper abdominal total 
luminescence signal of each treatment peaked 6 hours after cell injection and 
the hepatic myofibroblast injected mouse was higher than the other two cell 
types at the later time points suggesting that they may exhibit greater liver 
specific inflammation. Although as highlighted earlier the levels of total 
luminescence detected are greatly reduced when compared to the earlier 
studies (maximum liver region luminescence of 6.5 x 104 compared to a 
maximum liver region luminescence of 3 x 105 in the initial pilot study). 
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Figure 6.28 Whole body scan with ROIs overlaid and the calculated total luminescence values. 
ROIs could be overlaid onto images with the Image Pro Plus 4.0 software, allowing the calculation of 
total luminescence values for specific regions. The total luminescence values highlight that none of the 
injected cells/ particles induced a significant increase in NF-κB activity in the upper abdominal at all 
time points (n=1). 
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The reason for this loss of inflammatory activity is unknown as prior to 
injection the cells were prepared and quantified in an identical method to 
previous experiments. The only potential variation could be the passage 
number of the hepatic myofibroblasts and kidney fibroblasts injected, although 
the difference in passage number was only a single passage so it is unlikely 
that this will have had a significant effect on the cells’ inflammatory 
characteristics. 
 
6.5.4 The effect of C1-3-GTX mediated hepatic myofibroblast depletion 
upon acute liver inflammation  
 
A subsequent study was performed to investigate the effect of C1-3-GTX 
depletion of hepatic myofibroblasts upon liver inflammation in an acute CCl4 
model of liver injury. Figure 6.29 outlines the dosing and imaging schedule. 
Briefly all mice received a single dose of CCl4 and immediately afterwards 
either C1-3 or C1-3-GTX by i.p. injection (Table 2.1). 
 
Figure 6.29 Schematic diagram outlining the dosing and imaging regimen to determine the effect 
of hepatic myofibroblast depletion on NF-κB activity. Each mouse received a single dose of CCl4 to 
mimic acute liver damage; half then received 10 mg/kg C1-3 by i.p. injection whilst the second group 
received 10 mg/kg C1-3-GTX. The mice were then IVIS imaged at the timepoints outlined. Upon 
completion of the final timepoint the mice were terminated by a schedule I method.  The major organs 
were excised and placed in the IVIS chamber and imaged using the same settings, prior to retention for 
subsequent IHC and biochemical analysis. 
 
Whole body luminescent scans were then performed at regular intervals over 
96 hours to determine any differences in upper abdominal (liver) NF-ĸB 
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activity (a 2nd dose of C1-3 or C1-3-GTX was administered 24 hours after the 
initial CCl4 injection). The whole body scans are shown for each time point in 
figure 6.30. There was little that could be deciphered between the C1-3 and 
C1-3-GTX treatment groups by eye over the time course although there was a 
strong signal in one of the C1-3 treated mice at the 36 hour time point. The 
total luminescence values were calculated for the liver ROIs for each 
individual time point and are shown in figure 6.31. The level of luminescence 
detected was similar for both C1-3 and C1-3-GTX treatment groups at the 
initial time points, although from the 12 hour time point onwards there was a 
reduction in the level of luciferase activity detected in the C1-3-GTX treated 
mice. These findings support the initial hypothesis that C1-3-GTX treatment 
depletes the number of hepatic myofibroblasts and consequently the level of 
inflammation detected. 
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Figure 6.30 Whole body luminescent scans over 96 hour time course following acute liver damage 
and C1-3 or C1-3-GTX administration. Mice were anaesthetised with isoflurane and shaved 
ventrally prior to placing in the IVIS chamber. The scans were performed using the same settings 
described in figure 6.17. (Bkg – background scan prior to D-luciferin administration, T0 – Time zero 
immediately after D-luciferin administration, and the rest are hourly (h) time points). 
 
After the final 96 hour time point an ex vivo scan was performed on the livers 
of both the C1-3 and C1-3-GTX treated mice and the mean total 
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luminescence calculated for each treatment group (Figure 6.32). The mean 
liver luminescence values support the whole body scans’ data with a reduced 
level of luciferase activity detected in the C1-3-GTX treated mice, although the 
size of the difference was not as significant as seen at the earlier time points. 
 
Figure 6.31 Whole body scan with ROIs overlaid and the calculated total luminescence values. 
ROIs could be overlaid onto images with the Image Pro Plus 4.0 software, allowing the calculation of 
total luminescence values for specific regions. The upper abdominal total luminescence values at 36 
and 48 hours highlight C1-3-GTX administration has reduced the level of NF-κB. (* denotes that C1-3-
GTX treatment resulted in a statistically significant reduction in liver NF-κB levels when compared to 
the C1-3 only treated mice when analysed using a student’s t-test, unpaired (p < 0.05). Data are the 
mean and SD n=5 for every timepoint except the 36 and 48 hour timepoints n=8, calculated from three 
independently repeated experiments. 
 
The data from this study highlight C1-3-GTX’s beneficial anti-inflammatory 
activity, shown by the reduction in NF-κB activity seen after CCl4 treatment 
when compared to the C1-3 control mice. This reduction in luciferase activity 
was statistically significant at the 36 and 48 hour time points (p < 0.029 and p 
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< 0.050 respectively, student’s t-test, unpaired). These findings support the 
earlier in vitro U937-NF-κB work and hepatic myofibroblasts in vivo work 
specifically that hepatic myofibroblasts are pro-inflammatory as their depletion 
with C1-3-GTX treatment reduced the level of NF-κB activity and liver 
inflammation detected. Also these data reinforces the targeted properties of 
the C1-3 scAb as if it wasn’t specific to the hepatic myofibroblasts, there 
should be an overall increase in liver NF-κB activity as a result of hepatocyte 
cell death due to the elevated GTX levels. Repetition of this study with an 
increased number of mice will allow statistical analysis to confirm whether 
these preliminary findings are accurate. 
 
Figure 6.32 Ex vivo organ scan with ROIs overlaid and the calculated total luminescence values. 
ROIs could be overlaid onto images with the Image Pro Plus 4.0 software, allowing the calculation of 
total luminescence values for the excised livers. The total luminescence values suggest C1-3-GTX 
administration has reduced the level of NF-κB activity in the liver although the reduction is much 
smaller than observed at the earlier time points in the whole body scans (Figure 6.30) (n=2). 
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6.6 Chapter discussion 
 
Previous work over the past thirty years has delineated the major pathways 
central in the pathophysiology of liver fibrosis, predominantly the crosstalk of 
the inflammatory and wound healing cycles [32, 217]. When the liver is 
injured, hepatic myofibroblasts proliferate and function to re-model the ECM 
as part of a coordinated multi-cellular response that leads to the regeneration 
of liver tissue [32, 230]. The transdifferentiation of HSCs is a major source of 
hepatic myofibroblasts.  However, the signal that initiates the process of trans-
differentiation is not known but has been proposed to originate from monocyte 
and/ or macrophage-derived oxidative stress and cytokines [3].  In this 
chapter we investigated firstly whether the initiating signal could derive from a 
population of hepatic myofibroblasts themselves, through the release of a 
factor(s) that activate monocytes/ macrophages, which in turn release 
oxidizing molecules and cytokines further promoting hepatic myofibroblast 
transdifferentiation and liver fibrosis development. 
To test this hypothesis in vitro, both LX-2s and primary hHSCs were cultured 
with the non-adherent human U937-NF-κB cell line (stably-transfected with a 
luciferase reporter gene under control of a concatamer of NF-κB response 
elements) [187]. NF-κB describes a series of transcription factor complexes 
that play a major role in the regulation of inflammatory gene expression (e.g. 
IL-1) [179, 239]. Secondly in vivo hepatic myofibroblasts were injected directly 
into NF-κB luciferase mice prior to optical imaging to ascertain whether they 
were pro-inflammatory by the variation in luminescence detected and also to 
determine if this inflammation was confined to the liver. 
Following issues with revival and selection of the U937-NF-κB cell line 
supplied by Dr Carlsen, a 3xNF-KB luciferase construct was designed and 
transfected into U937 cells to detect NF-KB activity (Figures 6.3 – 6.6). The 
initial co-culture of LX-2 and hHSCs with U937-NF-κB cells (Figures 6.7 and 
6.8) revealed that both are pro-inflammatory displayed by their statistically 
significant induction of luciferase activity when compared to the U937-NF-κB 
cells only. Further analysis revealed that this induction of NF-κB was mediated 
via a soluble factor released into the culture media, as addition of 48 hour LX-
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2 and hHSC conditioned media also induced luciferase expression (Figures 
6.9 and 6.10). 
There are a multitude of inflammatory pathways/ cytokines that have been 
implicated in the development/ perpetuation of liver fibrosis. A range of pro-
inflammatory cytokines including IL-6, IL-8, IL-1α and MCP-1 (see Table 2.3 
for a complete list) were incubated with U937-NF-κB cells in place of LX-2 
cells. A number of these treatments resulted in a statistically significant 
increase in luciferase activity induction, as seen following LX-2 co-culture 
(Figures 6.11, 6.13A and 6.14). The values of these increases were 
significantly lower indicating that these cytokines are not the pro-inflammatory 
mediator released by LX-2 cells. IL-1α and IL-1β both induced luciferase 
activity, so to determine if they were a contributing part of the response seen 
they were cultured with U937-NF-κB cells again in the presence of an IL-1RA. 
Although this IL-1RA did not have any effect (Figure 6.13B), so it is possible 
IL-1α and IL-1β could be a part of the soluble factor(s) released by LX-2 cells. 
The inflammatory potential of ROS has previously been highlighted [236], to 
discount them the level of NO released by LX-2 cells released into the culture 
media (alone and in co-culture with U937-NF-κB cells) was determined by a 
Griess assay (Figure 6.15B). There was no significant increase in NO 
concentration following co-culture of LX-2 cells and U937-NF-κB cells over the 
48 hour timecourse. Significant increases in NO concentration were only 
detected in the co-culture also treated with the positive control SNP. In 
addition the incubation of SNP and H2O2 with U937-NF-κB cells had no 
impact on luciferase activity; however bubbling CO through the U937-NF-κB 
cells for ten minutes prior to incubation did result in a statistically significant 
increase in U937-NF-κB cells luciferase activity (Figure 6.15A). Once again 
the size of this induction was significantly lower than that induced by LX-2 co-
culture with U937-NF-κB cells, indicating CO is unlikely to be the soluble 
factor released by LX-2 cells. Finally a range of treatments were performed to 
48 hour LX-2 conditioned media (Table 2.3) to try and uncover the 
characteristics of the pro-inflammatory soluble factor. Figure 6.11 highlights 
that the soluble factor was unlikely to be a peptide and was a molecule of 
small MW (< 1kDa). 
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Future work will be designed to characterise the soluble factor further initially 
employing neutralising antibodies against target proteins, including IL-1 as 
previously attempted with an IL-1RA. In addition it may be beneficial to 
perform a dose response analysis of IL-1α and IL-1β to determine if the 
concentration that was administered (10ng/µl) in the initial study (Figure 6.13) 
was within their optimal pro-inflammatory range. 
In parallel further biochemical analyses will be performed to uncover the 
soluble factor including silver staining of the SDS-PAGE containing the later 
fractions eluted from the PD-10 column, which are known to contain the pro-
inflammatory soluble factor. Silver staining is approximately 50 times more 
sensitive than standard Coomassie blue staining so any small protein bands 
found could be excised and sent for mass spectroscopy analysis to try and 
identify them. 
In vivo injection of hepatic myofibroblasts directly into NF-κB luciferase mice 
resulted in increased luciferase transgene activity in the upper abdominal 
(liver) region (Figures 6.18 and 6.19) peaking 48 hours after hepatic 
myofibroblast injection. In a subsequent study it was confirmed the 
inflammation induced was due to hepatic myofibroblast injection and not the 
presence of residual trypsin from the isolation process (Figure 6.22). However 
in contrast the peak induction of NF-κB activity was much earlier than in the 
initial study (6 hours versus 48 hours after hepatic myofibroblast injection), the 
reason for this variation in NF-κB induction was unknown but could be 
influenced by the passage number of the cells. Alternatively the hepatic 
myofibroblasts viability could have varied between the two studies during the 
isolation and injection of hepatic myofibroblasts, although the same protocol 
and timeframe was used. Potentially the viability of the cells could have 
allowed the engraftment of the injected hepatic myofibroblasts into the liver 
tissue as seen at 48 hours after injection in the initial study, supported by the 
αSMA IHC (Figure 6.20). Whilst the cells may have been less viable in the 
follow up studies and the inflammatory response seen at 6 hours after 
injection was a result of an increased number of dead cells, responsible  for 
the increased induction NF-κB activity. 
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Repeat experiments included a range of controls such as kidney fibroblasts 
and latex beads to determine whether these inflammatory properties were 
specific to hepatic myofibroblasts or are a property of other cell types or 
particles of a similar size. When kidney fibroblasts were injected there was a 
significant increase in liver region total luminescence 6 hours after injection 
(Figures 6.25 and 6.26), although there was no variation in the total 
luminescence detected in the ex vivo liver scan 48 hours after injection. These 
results mirror the second hepatic myofibroblast study (Figures 6.22 and 6.23), 
suggesting that the inflammatory properties of hepatic myofibroblasts are not 
unique. The final study incorporated latex beads as well beside hepatic 
myofibroblasts and kidney fibroblasts, unfortunately in this instance none of 
the injected cell types resulted in a significant induction of NF-κB activity at 
any time points (Figure 6.27 and 6.28). Once again the cells were isolated 
and prepared identically to the previous studies; the reason for lack of NF-κB 
induction in this instance can only be postulated at (i.e. passage number and 
cell viability). 
These preliminary findings are encouraging, suggesting hepatic 
myofibroblasts are also pro-inflammatory when injected in vivo, although 
further studies need to be performed to confirm the initial observations. 
Primarily the initial study alongside the kidney fibroblast and latex bead 
controls needs repeating with a minimum of three mice per treatment group 
as these initial experiments were performed with a single mouse in each 
treatment group, due to the limited number of NF-κB luciferase mice available. 
In addition all studies would be performed on the same day ensuring that 
there was no variation in the viability/ passage number of the cells injected. 
The inclusion of multiple mice in each treatment group will minimise the 
impact of human error (e.g. D-luciferin dosing at each time point), which could 
have impacted upon on the imaging outcome in the initial studies. 
The pro-inflammatory trait of hepatic myofibroblasts was also confirmed 
following a single dose of CCl4 to NF-κB luciferase mice and subsequent 
administration of either C1-3 or C1-3-GTX (Figure 6.29). Treatment with C1-3-
GTX to deplete hepatic myofibroblasts resulted in a statistically significant 
decrease (p < 0.050, students t-test, unpaired) in liver region NF-κB activity 36 
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and 48 hours after CCl4 dosing when compared to the C1-3 only treated mice 
(Figure 6.31), confirming that hepatic myofibroblasts are pro-inflammatory. 
Similarly to the earlier studies this pilot study only contained 2 mice per 
treatment group, therefore with increased numbers of mice and injection of a 
greater volume of diluted CCl4 the degree of human error will be reduced and 
the statistical significance of any findings increased. Also repetition of the 
study in a chronic situation with repeated CCl4 and C1-3-GTX dosing may 
allow greater conclusions to be drawn regarding both hepatic myofibroblasts 
pro-inflammatory characteristics and C1-3-GTX’s dual anti-fibrotic and anti-
inflammatory properties. 
A future study could be performed treating fibrotic NF-κB luciferase mice with 
C1-3-GTX and also unconjugated GTX at various concentrations. This study 
could confirm the selectivity of C1-3-GTX and also reveal the effect of its 
targeting of quiescent HSCs and other hepatic cell types. Luminescent scans 
would reveal the induction of inflammation by free GTX and supporting IHC 
analysis would indicate the amount of damage induced by GTX and C1-3-
GTX administration. The use of a GTX specific secondary antibody may also 
confirm that C1-3-GTX is specific to hepatic myofibroblasts and does not 
target Kupffer cells. 
A major limitation of all the studies performed utilising the NF-κB mice is the 
lack of the IHC analysis of the transgene activity, therefore it may be 
beneficial to revisit the optimisation of the firefly-luciferase antibody trialled in 
chapter 5. Alternatively if a chronic study is performed involving repeated 
hepatic myofibroblast injection it may be possible to detect the presence of 
αSMA positive cells that are now present in the liver. 
The data presented in this chapter demonstrates that hepatic myofibroblasts 
are pro-inflammatory; releasing a soluble factor in vitro that activates U937-
NF-κB monocyte NF-κB transcriptional activity. These findings were further 
reinforced by the in vivo results, when hepatic myofibroblast injection into NF-
κB luciferase mice resulted in increased liver luminescence. These data 
therefore suggest that myofibroblasts may regulate/ contribute to the 
inflammatory process and may release a soluble factor that could via the 
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release of pro-inflammatory molecules from monocytes/ macrophages impact 
on hepatic myofibroblast activity and fibrosis development. 
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7.1 Results summary 
 
The incidence of liver fibrosis/ cirrhosis has been steadily increasing for the 
past fifty years and as a result of increased alcoholic consumption and a more 
sedentary life style its incidence is only expected to increase further. Liver 
injury in acute cases is of little consequence, due to the livers’ high capacity 
for regeneration maintaining a constant functional capacity. However with 
chronic injury there is continual activation of the inflammatory and immune 
responses, which result in the transdifferentiation of quiescent HSCs to a pro-
fibrogenic hepatic myofibroblast phenotype as part of the wound healing 
response in an attempt to remodel the ECM and encapsulate the injured 
region. Eventually the level of ECM fibrosis deposition exceeds the level at 
which it is also degraded, leading to increased levels of fibrous ECM. As the 
severity of these fibrotic bands increases there is an increased distortion of 
the general liver architecture and consequently a reduction in liver function. 
Presently the only mode of treatment for liver fibrosis/ cirrhosis is 
transplantation, although this is only an option for a small minority of sufferers. 
Alternatively treating the underlying cause of the disease is an effective 
treatment, e.g. anti-viral treatment of hepatitis viral infections. Critical to 
development of novel anti-fibrotics is the availability of an accurate non-
invasive imaging modality to diagnose and quantitate liver fibrosis at all 
disease stages. The current ‘gold standard’ liver biopsy is a highly invasive 
procedure and also has issues associated with sampling errors and 
interobserver variation in its scoring. Available non-invasive methods including 
serum biomarker panels and transient elastography are useful but cannot 
distinguish early developmental fibrosis and fatty/ fibrotic livers respectively. 
The primary aims of this thesis were to try and develop a non-invasive method 
to diagnose and quantify hepatic fibrosis, using the hepatic myofibroblast 
specific properties of the scAb C1-3 when conjugated with a long wavelength 
fluorophore. Of equal importance despite the advances in our understanding 
of the pathways underpinning HSC activation the stimulus for their activation 
and transdifferentation is still unknown. It has been suggested the stimulus 
may arise from a subset of hepatic myofibroblasts themselves, this was 
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investigated by co-culturing hepatic myofibroblasts with the monocytic U937-
NF-κB luciferase cell line. NF-κB is a major pro-inflammatory transcription 
factor whose induction will result in luciferase activity when the D-luciferin 
substrate is added. Finally we wished to further elucidate the anti-fibrotic 
benefits of PXR activators and in particular whether their anti-inflammatory 
properties are mediated via NF-κB in an in vivo model of liver fibrosis. 
Initially it was intended in collaboration with the chemistry department to 
conjugate the C1-3 scab with a radiolabel (in this instance 18F-SFB) prior to 
injection into fibrotic and control mice. PET scans would then have been 
performed to determine if there was an increase in radiolabel detected in the 
liver region of the fibrotic mice when compared to the control mice. 
Unfortunately there were significant problems encountered in the setting up of 
the ‘hot cells’ in the chemistry laboratory central to the 18F-SFB conjugation 
process that are yet to be rectified. Therefore as an alternative it was elected 
to conjugate C1-3 with a long wavelength fluorophore (XF750) and perform 
identical experiments using optical imaging fluorescent scans in place of PET 
scans. 
C1-3 was conjugated to XF750 via its primary amine and successful 
conjugation was confirmed by an increase in MW by both SDS-PAGE and 
MALDI-TOF analyses. In addition its specificity for its target antigen 
synaptophysin was confirmed by both a binding ELISA and BIACORE 
analyses. Addition of C1-3-750 to hepatic myofibroblasts in vitro suggested 
that the scAb was unable to target synaptophysin (although C1-3-FITC and 
C1-3-594 were both functioning), whether this was a result of XF750 presence 
or competitive inhibition from unlabelled C1-3 is unclear (which was detected 
in the MALDI-TOF analysis leftover from the conjugation reaction). The initial 
pilot study illustrated firstly that C1-3-750 targeted hepatic myofibroblasts in 
vivo and was potentially an indicator of fibrosis severity. Secondly both an i.v. 
and i.p. injection route could be employed to administer C1-3-750, although it 
appeared i.p. would be more suitable for non-invasive imaging of hepatic 
fibrosis. The final study incorporated mice with varying degrees of fibrosis 
severity (12, 8 and 4 week CCl4 administration) and control mice which 
received olive oil. Measurement of the total luminescence of the upper 
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abdominal liver region revealed that C1-3-750 could not be used non-
invasively using an i.p. injection route. However the total liver luminescence 
values calculated from the ex vivo organ scans revealed all fibrotic mice had a 
statistically significant increase in liver fluorescence when compared to the 
controls. Subsequent αSMA and sirius red IHC confirmed the increased 
number of hepatic myofibroblasts and collagen deposition following CCl4 
administration. This chapter provides proof of concept for C1-3’s use as an 
imaging agent of hepatic fibrosis although further experiments need to be 
performed to optimise its use. Investigating the contribution of the pancreas 
signal (due to the synaptophysin positive Islet cells present) on the overall 
upper abdominal luminescence detected needs to be performed. 
Initial IHC work by Cassiman et al [108] indicated that synaptophysin was 
expressed by both quiescent and activated HSCs. The data from the C1-3-
750 imaging study supported this view, as there was an increase in total liver 
fluorescence of the control mice as well, suggesting that C1-3 was also 
binding to quiescent HSCs. Also of note was the loss of C1-3-750’s 
functioning in a rat model of liver fibrosis, indicating that there was some 
variation in synaptophysin expression between mouse and rat liver. Therefore 
the primary aim of the second chapter was to uncover more about 
synaptophysin expression in whole tissue and HSCs from rat, mouse and 
human samples. In addition the synaptophysin expression of quiescent and 
activated HSCs was determined by both qRT-PCR and ICC analysis. 
Firstly C1-3 binding to synaptophysin and not another target present on the 
surface of hepatic myofibroblasts was confirmed by fluorescent microscopy. 
C1-3-594 only targeted Cos7 cells transfected with either human or mouse 
synaptophysin and not untransfected Cos7 cells. The level of synaptophysin 
expression was determined by both Western blotting and by PCR utilising 
predesigned primers specific to conserved regions of mouse, rat and human 
synaptophysin cDNA sequences. Synaptophysin was undetectable in all 
protein samples (both tissue samples and those isolated from HSCs) using 
commercially available synaptophysin antibodies. It was only detected in the 
neural (mouse brain) positive control sample, whilst synaptophysin could be 
detected in all HSC samples with each primer set although at a much lower 
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level than that expressed in the positive control sample. In contrast 
synaptophysin expression could only be detected in the mouse and rat liver 
tissue samples using specific primer sets, and the full transcribed 
synaptophysin sequence could not be detected in any organ sample. These 
findings coupled with ICC staining of tissue sections indicate that there was a 
variation in synaptophysin expression potentially as a result of a post-
transcriptional modification. qRT-PCR revealed that both quiescent and 
activated HSCs express similar levels of synaptophysin (approximately 100 
fold lower than mouse brain). ICC analysis following C1-3-594 addition to 
quiescent and activated HSCs demonstrated for the first time that C1-3 was 
able to target both cell types. 
Previous work from members of this laboratory revealed the anti-fibrotic 
properties of PXR agonists, in this chapter we wished to ascertain whether 
this effect was mediated via NF-κB. A single dose of the PXR agonist PCN 
was administered to NF-κB-luciferase mice that had received chronic (4 
weeks CCl4), acute (a single dose of CCl4) or no liver injury. Bioluminescent 
scans were performed in the IVIS (6 and 24 hours after PCN administration) 
to quantify NF-κB activity and inflammation levels in the liver region. Ex vivo 
organ scans were performed following the 24 hour bioluminescent scan to 
determine individual liver NF-κB levels. There was a statistically significant 
reduction in liver luminescence of the chronic CCl4 treatment group following 
PCN treatment at the 24 hour scan and in the liver of the ex vivo organ scans. 
These findings indicate that PCN is anti-inflammatory as hypothesised; 
luciferase assays performed on homogenised liver tissue from each mouse 
indicated that PCN had an anti-inflammatory effect on the acute CCl4 treated 
mice only. Subsequent IHC analysis (H&E, αSMA and sirius red) 
demonstrated that liver damage, hepatic myofibroblast number and collagen 
deposition had all increased following CCl4 treatment and PCN administration 
had no effect on CCl4 hepatotoxicity. The number of neutrophils was also 
determined by NIMP IHC staining and there was a statistically significant 
reduction in their number following PCN administration in the acute CCl4 
treatment group reinforcing PCN’s anti-inflammatory properties. Attempts 
were also made to try and measure the luciferase transgene directly, using a 
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luciferase specific primary antibody to determine if specific cells in the liver 
were responsible for the inflammation seen. Unfortunately these attempts 
were unsuccessful when using the luciferase antibody in both IHC and 
Western blotting techniques. 
Despite major advances in our understanding of the pathogenesis of liver 
fibrosis, especially the central role of HSCs and their transdifferentiation to a 
hepatic myofibroblast phenotype the identity of the stimulus responsible for 
their activation is still unknown. In the final chapter I investigated whether a 
subset of hepatic myofibroblasts themselves are pro-inflammatory and may 
stimulate circulating monocytes/ macrophages resulting in the activation of the 
inflammatory cycle critical in fibrosis development. 
To test this hypothesis the monocytic U937-NF-κB cell line was initially 
incubated with LX-2 cells (due to the limited availability of primary hHSCs) 
and luciferase assays were performed to determine the level of inflammation 
(NF-κB transgene activity) induced. Due to the problems encountered with 
revival and functioning of the U937-NF-κB cells supplied by Dr. Harald 
Carlsen it was necessary to manufacture our own U937-NF-κB cell line. A NF-
κB responsive luciferase construct (pGL4.28-NF-κB) was generated and its 
functioning confirmed by transient transfection into U937 and Cos7 cells prior 
to LPS treatment. Stable transfection of U937-NF-κB cells with the construct 
was achieved by Hygromycin B selection, prior to further experimentation. 
Initial co-culture of U937-NF-κB cells with LX-2 cells revealed that they are 
pro-inflammatory, and this was mediated via a soluble factor released into the 
media in a dose dependent manner. These findings were subsequently 
verified in hHSCs to confirm they weren’t just a property of the LX-2 cells. 
Treatments performed on the LX-2 cultured media revealed that the soluble 
factor was a small molecule (found in the later fractions PD-10 filtration), and 
that it was unlikely to be a peptide (unaffected by 10 x trypsin-EDTA 
treatment). Incubation of a range of pro-inflammatory cytokines and fibrogenic 
mediators (e.g. IL-6, IL-1α, IL-1β, MCP-1, serotonin, leptin, ROS) resulted in a 
statistically significant increase in luciferase activity of U937-NF-κB cells in 
some cases. However the size of these increases were much smaller than 
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those seen with LX-2’s or LX-2 conditioned media co-culture suggesting that 
they are unlikely to be the soluble factor released by LX-2 cells. 
An in vivo pilot study injecting hepatic myofibroblasts directly into NF-κB-
luciferase mice revealed that they are pro-inflammatory in vivo as well and 
appeared to be specific to the liver (demonstrated by the increase upper 
abdominal liver region luminescence 48 hours after injection). Subsequent 
studies with controls (including latex beads and kidney myofibroblasts) were 
not as successful, yielding an increased liver luminescence at 6 hours after 
cell injection. The reason for this variation was unclear but could be due to a 
variation in the viability of the injected cells. A final study utilising the NF-κB-
luciferase mice highlighted the pro-inflammatory properties of hepatic 
myofibroblasts as their proliferation was induced by CCl4 injection prior to the 
administration of C1-3 or C1-3-GTX. There was a statistically significant 
decrease in liver region luminescence 36 and 48 hours following treatment 
with C1-3-GTX when compared to those treated with C1-3 only. This 
decrease indicates that hepatic myofibroblast depletion by C1-3-GTX 
treatment resulted in a reduction in liver inflammation mediated via NF-κB 
activity. 
 
7.2 Project limitations and future work 
 
There are unavoidable limitations when utilising optical imaging techniques, 
primarily issues with tissue penetration and signal loss due to non specific 
signal absorption by body fluids. By utilising the XF750 long wavelength 
flurophore the level of non specific signal absorption will have been minimised 
as it is highest below 500nm where haemoglobin absorption is high and 
above 900nm where water absorption interferes with the signal detected. The 
poor liver region fluorescence signal detected from the i.v. injected fibrotic 
mouse in contrast to the high ex vivo liver signal of the same mouse, coupled 
with the high signal loss when a C1-3-750 dose was placed beneath a control 
liver perfectly highlight these issues of tissue penetration and signal loss 
associated with optical imaging. These problems are unavoidable, especially 
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when trying to non-invasively diagnose liver fibrosis by this method. The use 
of an i.p. injection route prevented non-invasive diagnosis of hepatic fibrosis 
due to the retention of the C1-3-750 dose in the peritoneal cavity masking any 
liver specific signal. In hindsight utilising an i.v. injection route with a greater 
number of mice to avoid repeat injections, and accepting the potential 
variation in dosing as a result of that injection route would have been a more 
appropriate way to perform the final study. Another issue was the high signal 
detected from the pancreas due to the presence of synaptophysin positive 
Islet cells. Firstly this limits the use of the antibody clinically as it is not solely 
specific to the liver, and utilising optical imaging it was not possible to 
determine and quantify the contribution of the pancreas and kidney signals to 
the overall liver region fluorescence detected in the whole body scans. 
The majority of these issues could be rectified if as intended C1-3 was 
conjugated with 18F-SFB and PET scans were performed. Firstly PET is a 
much higher power technique and will improve the resolution of the signal 
detected. In addition it is normal practise in clinical settings to overlay PET 
images onto computerised tomography (CT) scans. Therefore it will be 
possible to identify the signal of specific organs and more accurately quantify 
the liver signal and fibrosis severity. Irrespective of the imaging technique 
used there is also the need to investigate the use of C1-3 in other causes of 
hepatic fibrosis, as hepatic myofibroblasts are not the only fibrogenic cell type 
present in the liver (e.g. portal fibroblasts which are prominent in portal 
fibrosis development). It would be of benefit to repeat this initial study in mice 
following BDL to determine the level of C1-3-750 binding and hepatic 
myofibroblast presence in this disease setting. 
The confirmation that quiescent HSCs express similar levels of synaptophysin 
as ‘activated’ hepatic myofibroblasts indicates suggests that more caution 
must be used when administering C1-3 as an imaging agent. This is 
especially true when it is conjugated with GTX as an anti-fibrotic agent as the 
implications of quiescent HSC loss are unknown and need researching 
further. The data in chapter 4 highlighted the difficulty involved in detecting 
synaptophysin by both Western blotting and IHC techniques with 
commercially available C-terminal synaptophysin antibodies at present. This 
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lack of detection could be the result of a post-transcriptional modification of 
synaptophysin masking its detection with antibodies. Further research needs 
to be performed to determine if there is indeed a splice variant of 
synaptophysin expressed on the surface of hepatic myofibroblasts. 
The major limitations of the in vivo study to investigate the anti-inflammatory 
effects of PCN in a mouse model of liver fibrosis only became apparent in 
hindsight. The data generated from this pilot study supported the initial 
hypothesis that PCN is anti-inflammatory and this was mediated via NF-κB 
displayed by the whole body and ex vivo liver luminescence values and NIMP 
IHC staining. Unfortunately it was not possible to determine luciferase 
transgene activity by Western blotting or IHC techniques, which would have 
given a greater insight into the cells responsible for NF-κB activity in the liver. 
Two different antibodies were trialled yet neither exhibited the specificity 
advertised for the firefly-luciferase gene. Previously PCN was shown to have 
anti-fibrotic properties as it significantly reduced the number of αSMA positive 
myofibroblasts and sirius red collagen deposition. This was not found in this 
study although PCN was only administered acutely with the final dose of CCl4, 
therefore significant hepatic myofibroblast and collagen deposition would 
already have occurred. A future repeat study administering PCN chronically 
with various CCl4 treatment groups (e.g. 12, 8 and 4 week administration) 
would allow greater conclusions to be drawn about both the anti-fibrotic and 
anti-inflammatory properties of PCN. 
As highlighted earlier, issues were encountered when reviving and culturing 
the U937-NF-κB cells, despite Hygromycin B selection. In some instances the 
cells would spontaneously lose all luciferase activity even in response to LPS. 
The reason for this was unclear; potentially it was a result of the viability of the 
cells decreasing due to increased cell death, although this was not detected 
by trypan blue counting prior to experiments being performed. As the U937-
NF-κB cells are grown as a suspension culture there was no feasible way to 
separate the viable and non-viable cells unlike trypsinisation for adherent cell 
lines. The initial co-cultures confirmed that LX-2 cells and hHSCs are pro-
inflammatory and induce NF-κB activity, releasing a pro-inflammatory soluble 
factor. Despite our best efforts (protease treatment and PD-10 filtration of LX-
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2 conditioned media and addition of pro-inflammatory cytokines to U937-NF-
κB cells) the identity of the soluble factor is still unknown. The roles of 
potential contributing cytokines could be determined with the use of 
monoclonal antibodies to these targets. In addition it may be possible to 
perform additional biochemical/ proteomic analysis (e.g. MALDI-TOF) on later 
PD-10 filtered fractions of LX-2 conditioned and normal U937-NF-κB cells 
media to try and determine the soluble factor. 
In vivo injection of hepatic myofibroblasts directly into NF-κB-luciferase mice 
resulted in induction of NF-κB specifically in the liver indicating they are pro-
inflammatory in vivo as well. However there was a significant variation in 
response in follow up experiments when hepatic myofibroblasts, kidney 
fibroblasts and latex beads were injected. Whether this was due to a 
difference in viability of the cells was unclear, in addition these initial studies 
were generally only performed with a single mouse in each treatment group. 
Repeat studies with increased NF-κB-luciferase mice will minimise the effect 
of any human errors that will have affected the imaging outcome detected 
(e.g. CCl4 and D-luciferin dosing). As discussed earlier in the PXR study the 
lack of functioning of the firefly-luciferase antibody prevents the detection of 
luciferase transgene activity and detection of NF-κB in specific hepatic cell 
types. Depletion of hepatic myofibroblasts by co-administration of C1-3-GTX 
resulted in a decrease in liver NF-κB activity further indicating the pro-
inflammatory properties of hepatic myofibroblasts. In the future performing 
repeat injections of hepatic myofibroblasts may encourage greater 
engraftment of hepatic myofibroblasts into the liver, which may also be 
detectable by αSMA IHC staining as well as the bioluminescent scans. 
 
7.3 Conclusions 
 
The data presented in this thesis firstly reveals that the number of hepatic 
myofibroblasts can be used as an indicator of fibrosis severity, suggesting the 
hepatic myofibroblast specific scAb C1-3 has the potential to be utilised as a 
non-invasive alternative to the liver biopsy. Although further work needs to be 
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performed distinguishing the effect of C1-3 also targeting the pancreas and 
trial its conjugation to 18F-SFB and PET imaging, which is more clinically 
applicable unlike optical imaging. Further in vitro analysis confirmed C1-3’s 
affinity for quiescent HSCs as well hepatic myofibroblasts and quantitative 
real-time PCR analysis indicated that they express identical levels of 
synaptophysin. 
The in vivo imaging study further advocated the use of PXR agonists as an 
anti-fibrotic agent, specifically highlighting their anti-inflammatory properties. 
Further studies could determine whether they could be beneficial when 
administered alone or as part of a combined treatment regimen. Finally in vitro 
and in vivo studies highlighted the pro-inflammatory properties of hepatic 
myofibroblasts activating NF-κB, which could contribute to initial hepatic 
fibrosis development. 
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9.1 Abstracts 
 
9.1.1 British Toxicology Society (BTS) Annual Conference 2009 
Hepatic myofibroblasts are pro-inflammatory and activate NF-κB in monocytes 
via a soluble factor.  
 
Stephen Hill
1,
, Matthew C Wright
1
  
1
Institute Cellular Medicine, Newcastle University, UK. Stephen.Hill1@ncl.ac.uk 
 
When the liver is injured, hepatic myofibroblasts proliferate and function to re-model the 
extracellular matrix as part of a coordinated multi-cellular response that leads to a 
regeneration of liver tissue (Wallace et al, 2008). The trans-differentiation of hepatic stellate 
cells is a major source of hepatic myofibroblasts.  However, the signal that initiates the 
process of trans-differentiation is not known but has been proposed to originate from 
monocyte and/or macrophage-derived oxidative stress and cytokines (Wallace et al, 2008).  
We hypothesize that the initiating signal could derive from a population of myofibroblasts 
themselves, through release of a factor(s) that activate monocytes /macrophages, which then 
release oxidizing molecules and cytokines to further promote trans-differentiation.  To test 
this hypothesis, a human liver myofibroblast (LX-2) cell line was cultured with a non-
adherent human U-937 monocyte cell line stably-transfected with a luciferase reporter gene 
under control of a concatamer of NF-κB response elements (Axon et al, 2008). 
 
LX-2 (adherent) and U-937 (non-adherent) cells were routinely cultured in Dulbecco’s 
modified eagle media (DMEM) and RPMI-1640 media respectively, both supplemented with 
10% foetal calf serum (FCS) and antibiotics.  For experiments, LX-2 cells in 6 well plates 
were cultured to 50% confluence, washed 3 times with phosphate buffered saline and cultured 
with 1 x 10
5
 U-937 cells in RPMI-1640 media and where indicated bacterial 
lipopolysaccharide (LPS).  U-937 cells were incubated for 6 hours at 37
o
C , pelleted by 
centrifugation and re-suspended in a fixed volume of lysis buffer prior to determination of 
luciferase activity using a Dual-glo kit (Promega). 
 
Table 1 shows that un-stimulated U-937 cells expressed low levels of luciferase activity.  LPS 
– an established activator of NF-κB – significantly induced luciferase activity in U-937 cells 
as expected (Axon et al, 2008).   Table 1 also shows that co-culturing U-937 cells with LX-2 
cells significantly induced luciferase expression.  Addition of LX-2-conditioned media also 
induced luciferase expression.   
 
Cultured cells   
LX-2 
(myofibroblast) 
U-937-NF-ĸB-luc 
(monocyte) 
LPS 
( 300ng/ml) 
Luciferase activity 
(u/well) 
- - - 226 ± 6.8 
+ - - 227 ± 5.6 
- + - 234 ± 6.5 
+ + - 1420 ± 235.6
*
 
+
$
 + - 804 ± 69.2
*
 
- + + 607 ± 67.9
*
 
$
U-937 cells were treated with LX-2-condition medium (cells not in co-culture).  
*
Significantly different from untreated U-937 cells using Student’s T-test (two 
tailed), P > 95%.  LPS, bacterial lipopolysaccharide. 
 
Table 1.  Activation of NF-κB/induction of luciferase expression in U-
937 cells. 
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NF-κB describes a series of transcription factor complexes that play a major role in the 
regulation of inflammatory gene expression.  These data demonstrate that human liver 
myofibroblasts release a soluble factor that activates monocyte NF-κB transcriptional activity.  
These data therefore suggest that myofibroblasts regulate the inflammatory process and may 
release a soluble factor that could – via the release of pro-inflammatory molecules from 
monocytes and macrophages - impact on myofibroblast activity.  
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9.1.2 International Society for Hepatic Sinusoidal Research (ISHSR) 
symposium 2010 
 
Hepatic myofibroblasts are pro-inflammatory and activate NF-κB in monocytes 
via a soluble factor.  
 
Stephen Hill
1,
, Matthew C Wright
1
  
1
Institute Cellular Medicine, Newcastle University, UK. Stephen.Hill1@ncl.ac.uk 
 
After liver injury hepatic myofibroblasts proliferate re-modelling the extracellular matrix as 
part of a multi-cellular response leading to regeneration of liver tissue (Wallace et al, 2008). 
The trans-differentiation of hepatic stellate cells is a major source of hepatic myofibroblasts.  
However, the signal initiating this trans-differentiation is unknown but proposed to originate 
from monocyte/macrophage-derived oxidative stress (Wallace et al, 2008).  We hypothesize 
that the signal could derive from a population of myofibroblasts themselves releasing a 
factor(s) that activates monocytes/macrophages, which then release oxidizing molecules and 
cytokines further promoting trans-differentiation.  To test this hypothesis, LX-2 (human liver 
myofibroblast) cell line was cultured with human U-937 monocyte cell line stably-transfected 
with a luciferase reporter gene controlled by NF-κB response elements. 
 
LX-2 cells were cultured in 6 well plates to 50% confluence, washed with 1xPBS before co- 
culture with 1x10
5
 U-937 cells, incubated for 6 hours at 37
o
C. U-937 cells were pelleted by 
centrifugation and re-suspended in passive lysis buffer prior to determination of luciferase 
activity. 
 
Un-stimulated U-937 cells expressed low levels of luciferase activity, bacterial 
lipopolysaccharide – an established activator of NF-κB – significantly induced luciferase 
activity as expected (Axon et al, 2008).   Co-culture of U-937 cells with LX-2 cells 
significantly induced luciferase expression, as did the addition of LX-2-conditioned media. 
 
These data demonstrate that hepatic myofibroblasts release a factor that activates monocyte 
NF-κB transcriptional activity, therefore suggesting that myofibroblasts regulate the 
inflammatory process and may release a soluble factor that could – via the release of pro-
inflammatory molecules from monocytes/macrophages - impact on myofibroblast activity.  
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9.1.3 North East Postgraduate Conference (NEPG) 2011 
 
Using the fluorescently labelled scAb C1-3 as a potential imaging agent of hepatic 
myofibroblasts and fibrosis 
 
Stephen J. Hill, Anne Lakey and Matthew C. Wright. 
 
Liver Research Group, Newcastle University, UK. Stephen.hill1@ncl.ac.uk 
 
A major obstacle limiting the discovery of novel anti-fibrotics is the lack of an effective way 
to rapidly quantify hepatic fibrosis, both in experimental and clinical studies. The aim of this 
investigation was to examine the potential of the hepatic myofibroblast-specific C1-3 scAb 
conjugated to a fluorescent dye as an imaging agent for hepatic fibrosis. 
 
The C1-3 scAb was expressed in e-coli, purified and fluorescently labelled with CF750 (a 
fluorophore that emits light at a max 777nm) to generate the conjugate C1-3-
CF750. 
C1-3-
CF750
 
was injected into both fibrotic (CCl4 induced) and control mice. Upon completion of the CCl4 
treatment regimen, both whole body and ex vivo organs fluorescent scans were performed 
using IVIS optical imaging equipment.  
 
Successful conjugation of C1-3 and CF750 was confirmed by SDS-PAGE and MALDI-TOF. 
C1-3-
CF750 
retained its affinity and specificity for its target antigen (synaptophysin) as 
determined by both a synaptophysin specific ELISA. The ex vivo organ scans of the fibrotic 
mice (at all time points) exhibit significantly higher fluorescence than both the C1-3-
CF750 
control and non-inject control mice. Sirius red and αSMA immunohistochemical analysis 
confirmed the varying degrees of liver fibrosis induced between the different CCl4 groups. 
 
Fluorescently labelled C1-3 provides an effective way to determine liver fibrosis severity, in 
this instance the scAb cannot be used non-invasively, as only the ex vivo organ scans exhibit a 
significant difference between the control and fibrotic animals. However, a radioligand (e.g. 
18F
-SFB) conjugated to the scAb, utilising the high sensitivity of positron emission topography 
would maximise the potential of C1-3 as a targeted imaging agent for liver fibrosis. 
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The PXR is a drug target for chronic inflammatory liver disease. 
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